Official Protocol Title:  
NCT number:  [STUDY_ID_REMOVED] 
Document Date:  06-Jul-2022A Phase 3, Multicenter, Randomized, Double-blind, Active 
Comparator-Controlled Study to Evaluate the Safety, Tolerability, 
and Immunogenicity of V116 in Adults Living With HIV
PRODUCT: V116  1
PROTOCOL/AMENDMENT NO.: 007-01
V116 -007-01 FINAL PROTOCOL 06-JUL-2022
Title Page
THIS PROTOCOL AMENDMENT AND ALL OF THE INFORMATION RELATING 
TO IT ARE CONFIDENTIAL AND PROPRIETARY PROPERTY OF MERCK 
SHARP & DOHME LLC, RAHWAY, NJ, [LOCATION_003] (MSD ).
Protocol Title: A Phase 3, Multicenter, Randomized, Double -blind, Active Comparator -
Controlled Study to Evaluate the Safe ty, Tolerability, and Immunogenicity of V116 in Adults 
Living With HIV
Protocol Number: 007-01
Compound Number: V116
Sponsor Name:
[CONTACT_19519] & Dohme LLC
(hereafter called the Sponsor or MSD)
Legal Registered Address:
[ADDRESS_368619], NJ [ZIP_CODE] US A
Regulatory Agency Identifying Number(s):
IND [ADDRESS_368620] 2021- 006710- 36
Approval Date: [ADDRESS_368621]: V116  2
PROTOCOL/AMENDMENT NO.: 007-01
V116 -007-01 FINAL PROTOCOL 06-JUL-2022
Sponsor Signatory
Typed Name:
[CONTACT_1641]:Date
Protocol -specific Sponsor c ontact information can be found in the Investigator Study
File Binder (or equivalent).
Investigator Signatory
I agree to conduct this clinical study in accordance with the design outlined in this protocol 
and to abide by [CONTACT_19373].
Typed Name:
[CONTACT_1641]:Date
08LGKL
PRODUCT: V116  3
PROTOCOL/AMENDMENT NO.: 007-[ADDRESS_368622]: V116  4
PROTOCOL/AMENDMENT NO.: 007-01
V116 -007-01 FINAL PROTOCOL 06-JUL-2022
PROTOCOL AMENDMENT SUMMARY OF CHANGES
Amendment: 01
Overall Rationale for the Amendments:
The primary reason for this amendment is to update the country -specific requirements for [LOCATION_009].
Summary of Changes Table:
Section # and Name [CONTACT_9353] 10.7.1 Country -
specific Requirements for 
[LOCATION_009] (Section 5.2 and 
Section 6.5)Added a [LOCATION_009] -specific version of 
exclusion criteria and restricted 
concomitant therapy.To include country- specific timeframe for prior and 
concomitant therapy.
Section 10.7.1 Country -
specific Requirements for 
[LOCATION_009] (Section 5.2)Added a [LOCATION_009] -specific version of 
exclusion criteria .To clarify the exclusion criteria for protected 
populations.
Section 10.7.1 Country -
specific Requirements for 
[LOCATION_009] (Section 10.5.2)Added a [LOCATION_009] -specific version of 
contraception requirements for female 
participants.To clarify current contraception me thods allowed 
during the study .
Section 5.[ADDRESS_368623]: V116  5
PROTOCOL/AMENDMENT NO.: 007-01
V116 -007-01 FINAL PROTOCOL 06-JUL-2022
Section # and Name [CONTACT_296500] 10.1.[ADDRESS_368624] for Clinical TrialsSponsor entity name [CONTACT_148231]. [COMPANY_006] Sharp & Dohme Corp. underwent an entity 
name [CONTACT_19520] & Dohme 
LLC, Rahway, NJ, [LOCATION_003]. This conversion resulted only 
in an entity name [CONTACT_26406].
Section 4.4 Beginning and 
End- of-Study DefinitionAdded a definition of local start of study 
for countries in the EEA.To align with the EU CTR.
Section 5 Study Population Added text related to the collection of 
demographic data.To clarify the collection, use, and c onfidentiality of 
demographic data provided by [CONTACT_3038].
Section 8.4 Adverse Events, 
Serious Adverse Events, and 
Other Reportable Safety 
Events
Section 10.3 Adverse 
Events: Definitions and 
Procedures for Recording, 
Evaluating, Follow -up, and 
Repor tingAdded the requirement for investigators to 
document if an SAE is associated with 
medication error, misuse, or abuse.
Definitions of medication error, misuse, 
and abuse were added.Per Regulation (EU) No 536/2014 of the European 
Parliament and of the Council.
Section [IP_ADDRESS] Scientific 
Advisory Committee (SAC)Scientific Advisory Committee 
responsibilities were updated .To clarify Scientific Advisory Committee 
responsibilities .
Throughout Document Minor administrative, formatting, 
grammatical, and/or typographical changes 
were made throughout the document.To ensure clarity and accurate interpretation of the 
intent of the protocol.
08LGKL
PRODUCT: V116  6
PROTOCOL/AMENDMENT NO.: 007-01
V116 -007-01 FINAL PROTOCOL 06-JUL-2022
Table of Contents
DOCUMENT HISTORY ........................................................................................................ 3
PROTOCOL AMENDMENT SUMMARY OF CHANGES ............................................... 4
1 PROTOCOL SUMMARY ............................................................................................ 13
1.1 Synopsis ................................................................................................................. 13
1.2 Schema .................................................................................................................. 18
1.3 Schedule of Activities........................................................................................... 20
1.3.1 Schedule of Activities for Part A ................................................................ .20
1.3.2 Schedule of Activities for Part B ................................................................ .24
2 INTRODUCTION .......................................................................................................... 25
2.1 Study Rationale ....................................................................................................25
2.2 Background .......................................................................................................... 26
2.2.1 Pharmaceutical and Therapeutic Background ............................................. 26
2.2.2 Information on Other Study -related Therapy .............................................. 27
[IP_ADDRESS] PCV15 ................................................................................................ 27
[IP_ADDRESS] PPSV23 .............................................................................................. 27
[IP_ADDRESS] Pneumococcal Vaccination Guidelines .............................................. 28
2.3 Benefit/Risk Assessment ...................................................................................... 28
3 HYPOTHESES, OBJECTIVES, AND ENDPOINTS ................................................ 29
4 STUDY DESIGN ............................................................................................................ 32
4.1 Overall Design ......................................................................................................32
4.2 Scientific Rationale for Study Design ................................................................ .33
4.2.1 Rationale for Endpoints ............................................................................... 34
[IP_ADDRESS] Immunogenicity Endpoints ................................................................ 34
[IP_ADDRESS] Safety Endpoints ................................................................................ 34
[IP_ADDRESS] Future Biomedical Research .............................................................. 35
4.2.2 Rationale for the Use of Comparator/Placebo ............................................. [ADDRESS_368625]: V116  7
PROTOCOL/AMENDMENT NO.: 007-01
V116 -007-01 FINAL PROTOCOL 06-JUL-2022
6 STUDY INTERVENTION ............................................................................................ 41
6.1 Study Intervention(s) Administered ...................................................................41
6.1.1 Medical Devices ........................................................................................... 44
6.2 Preparation/Handling/Storage/Accountability ................................................. 44
6.2.1 Dose Preparation .......................................................................................... 44
6.2.2 Handling, Storage, and Accountability ........................................................ 44
6.3 Measures to Minimize Bias: Randomization and Blinding .............................. [ADDRESS_368626] to Follow -up................................................................................................ .49
8 STUDY ASSESSMENTS AND PROCEDURES ........................................................ 50
8.1 Administrative and General Procedures ........................................................... 52
8.1.1 Informed Consent ......................................................................................... 52
[IP_ADDRESS] General Informed Consent ................................................................ .52
[IP_ADDRESS] Consent and Collection of Specimens for Future Biomedical 
Research ............................................................................................. 52
[IP_ADDRESS] Consent and Collection of Specimens for Optional Assay 
Development ...................................................................................... 52
8.1.2 Inclusion/Exclusion Criteria ........................................................................[ADDRESS_368627] .....................................................................53
8.1.4 Medical History ........................................................................................... 53
8.1.5 Prior and Concomitant Medications Review ............................................... 53
[IP_ADDRESS] Prior M edications ............................................................................... 53
[IP_ADDRESS] Concomitant Medications ..................................................................54
8.1.6 Assignment of S creening Number............................................................... 54
8.1.7 Assignment of Treatment/Randomization Number .....................................[ADDRESS_368628]: V116  8
PROTOCOL/AMENDMENT NO.: 007-01
V116 -007-01 FINAL PROTOCOL 06-JUL-2022
8.1.8 Study Intervention Administration .............................................................. 54
[IP_ADDRESS] Timing of Dose Administration ......................................................... [ADDRESS_368629] Questionnaire ................................................................ 55
8.1.11 Confirmation of Eligibility in Part B ........................................................... 56
8.1.12 Discontinuation and Withdrawal ................................................................ .56
[IP_ADDRESS] Withdrawal From Future Biomedical Research ................................ 56
8.1.13 Participant Blinding/Unblinding ..................................................................57
8.1.14 Calibration of Equipme nt............................................................................. 58
8.2 Immunogenicity Assessments ............................................................................. 58
8.2.1 Multiplex Opsonophagocytic Assay ............................................................ 58
8.2.2 Pneumococcal Electrochemiluminescence Assay .......................................59
8.3 Safety Assessments ............................................................................................... 59
8.3.1 Physical Examinations ................................................................................. 59
8.3.2 Pregnancy Testing ........................................................................................ 60
8.3.3 HIV Serology, CD4+ T -cell Count, and Plasma HIV RNA Testing........... 60
8.3.4 Body Temperature Measurement ................................................................ .60
8.3.5 Postvaccination Observation Period ............................................................ 60
8.3.6 Clinical Safety Laboratory Assessments ..................................................... 61
8.4 Adverse Events, Serious Adverse Events, and Other Reportable Safety 
Events .................................................................................................................... 61
8.4.1 Time Peri od and Frequency for Collecting AE, SAE, and Other 
Reportable Safety Event Information .......................................................... 62
8.4.2 Method of Detecting AEs, SAEs, and Other Reportable Safety Events ......64
8.4.3 Follow -up of AE, SAE, and Other Reportable Safety Event Information ...64
8.4.4 Regulatory Reporting Requirements for SAE ............................................. 64
8.4.5 Pregnancy and Exposure During Breastfeedi ng.......................................... 64
8.4.6 Disease -related Events and/or Disease -related Outcomes Not Qualifying 
as AEs or SAEs ............................................................................................ [ADDRESS_368630] ............................................................................ 65
8.4.8 Medical Device and Drug -device Combination Products -
PQCs/Malfunctions ...................................................................................... 65
8.4.9 Adverse Events on the VRC ........................................................................65
[IP_ADDRESS] Solicited Adverse Event .....................................................................65
[IP_ADDRESS] Unsolicited Adverse Events ............................................................... [ADDRESS_368631]: V116  9
PROTOCOL/AMENDMENT NO.: 007-01
V116 -007-01 FINAL PROTOCOL 06-JUL-2022
8.9 Future Biomedical Research Sample Collection ............................................... 66
8.10 Optional Assay Development Blood Sample Collection ...................................67
8.11 Medical Resource Utilization and Health Economics .......................................67
8.12 Visit Requirements ............................................................................................... 67
8.12.1 Screening ......................................................................................................67
8.12.2 Treatment Period/Vaccination Visit ............................................................ 67
8.12.3 Participants Discontinued From Study Intervention but Continuing to be 
Monitored in the Study ................................................................................ 67
9 STATISTICAL ANALYSIS PLAN ............................................................................. 67
9.1 Statistical Analysis Plan Summary .....................................................................68
9.2 Responsibility for Analyses/In -house Blinding ................................................. 69
9.3 Hypotheses/Estimation ........................................................................................ 69
9.4 Analysis Endpoints ............................................................................................... 69
9.4.1 Immunogenicity Endpoints .......................................................................... 69
9.4.2 Safety Endpoints .......................................................................................... 71
9.5 Analysis Populations ............................................................................................ 73
9.5.1 Immunogenicity Analysis Populations ........................................................ 73
9.5.2 Safety Analysis Populations ........................................................................74
9.6 Statistical Methods ............................................................................................... 74
9.6.1 Statistical Methods for Immunogenicity Analyses ......................................74
9.6.2 Statistical Methods for Safety Analyses ...................................................... 76
[IP_ADDRESS] Overall Safety Assessment ................................................................ 76
9.6.3 Demographic and Baseline Characteristics ................................................. 78
9.7 Interim Analyses ..................................................................................................78
9.8 Multiplicity ........................................................................................................... 78
9.9 Sample Size and Power Calculations ................................................................ .79
9.9.1 Sample Size and Power for Immunogenicity Analyses ............................... 79
9.9.2 Sample Size and Power for Safety Analyses ............................................... 79
9.10 Subgroup Analyses ............................................................................................... 80
9.11 Compliance (Medication Adherence) ................................................................ .80
9.12 Extent of Exposure ............................................................................................... 80
10 SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS .....................................................................................................81
10.1 Appendix 1: Regulatory, Ethical, and Study Oversight Considerations ........[ADDRESS_368632] for Clinical Trials ............................................................. 81
10.1.2 Financial Disclosure ..................................................................................... 83
10.1.3 Data Protection ............................................................................................. 84
[IP_ADDRESS] Confidentiality of Data ......................................................................[ADDRESS_368633]: V116  10
PROTOCOL/AMENDMENT NO.: 007-01
V116 -007-01 FINAL PROTOCOL 06-JUL-2022
[IP_ADDRESS] Confidentiality of Participant R ecords ............................................... 84
[IP_ADDRESS] Confidentiality of IRB/IEC Information ............................................ 84
10.1.4 Committees Structure ................................................................................... 85
[IP_ADDRESS] Executive Oversight Committee ........................................................ 85
[IP_ADDRESS] External Data Monitoring Committee ............................................... 85
[IP_ADDRESS] Scientific Advisory Committee (SAC) .............................................. 85
10.1.5 Publication Policy ........................................................................................ 85
10.1.6 Compliance with Study Registration and Results Posting Requirements ...86
10.1.7 Compliance w ith Law, Audit, and Debarment ............................................ 86
10.1.8 Data Quality Assurance ............................................................................... 87
10.1.9 Source Documents ....................................................................................... 87
10.1.10 Study and Site Closure ................................................................................. 88
10.2 Appendix 2: Clinical Laboratory Tests .............................................................. 89
10.3 Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting ............................................................... 90
10.3.1 Definitions of Medication Error, Misuse, and Abuse ..................................90
10.3.2 Definition of AE .......................................................................................... 90
10.3.3 Definition of SAE ........................................................................................ 92
10.3.4 Additional Events Reported ......................................................................... 93
10.3.5 Recording AE and SAE ............................................................................... 93
10.3.6 Reporting of AEs, SAEs, and Other Reportable Safety Events to the 
Sponsor ........................................................................................................98
10.4 Appendix 4: Medical Device and Drug -device Combination Products: 
Product Quality Complaints/Malfunctions: Definitions, Recording, and 
Follow -up............................................................................................................ 100
10.4.1 Definitions ..................................................................................................100
10.4.2 Recording, Assessing Causality, and Follow- up of PQCs/Malfunctions ..101
10.5 Appendix 5: Contraceptive Guidance .............................................................. 103
10.5.1 Definitions ..................................................................................................103
10.5.2 Contraception Requirements ......................................................................104
10.6 Appendix 6: Collection and Management of Specimens for Future 
Biomedical Research .......................................................................................... 105
10.7 Appendix 7: Country -specific Requirements .................................................. 110
10.7.1 Country- specific Requirements for [LOCATION_009] ................................................ 110
10.8 Appendix 8: Abbreviations ............................................................................... [ADDRESS_368634]: V116  11
PROTOCOL/AMENDMENT NO.: 007-[ADDRESS_368635] OF TABLES
Table 1 Study Interventions .......................................................................................... 42
Table 2 Approximate Blood Volumes Drawn by [CONTACT_301782] A.......................................................................................................... 51
Table 3 Approximate Blood Volumes Drawn by [CONTACT_301782] B.......................................................................................................... 51
Table 4 Reporting Time Periods and Time Frames for Adverse Events and Other 
Reportable Safety Events ................................................................................. 63
Table 5 Solicited Adverse Events ................................................................................. 66
Table 6 Analysis Strategy for Immunogenicity Variables ............................................ 76
Table 7 Analysis Strategy for Safety Parameters – Part A and Part B ......................... 77
Table 8 Within -group 95% CIs for Varying Hypothetical OPA GMTs and Varying 
Standard Deviations With [ADDRESS_368636]: V116  12
PROTOCOL/AMENDMENT NO.: 007-[ADDRESS_368637]: V116  13
PROTOCOL/AMENDMENT NO.: 007-01
V116 -007-01 FINAL PROTOCOL 06-JUL-2022
1 PROTOCOL SUMMARY
1.1 Syno psis
Protocol Title: A Phase 3, Multicenter, Randomized, Double -blind, Active Comparator -
Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Adults 
Living With HIV
Short Title: Safety and Immunogenicity of V11 6in Adults Living With HIV
Acronym: STRIDE -7
Hypotheses, Objectives ,and Endpoints :
There is no hypothesis testing in this study.
The following objectives and endpoints will be evaluated in pneumococcal vaccine -naïve or 
pneumococcal vaccine -experienced adults ≥18 years of age living with HIV.
Objecti ves Endpoints
Primary
Part A
•Objective: To evaluate the safety and 
tolerability of V116 as assessed by [CONTACT_93287] (AEs).•Solicited injection -site AEs from Day 
1 through Day 5 postvaccination
•Solicited systemic AEs from Day 1 
through Day 5 postvaccination
•Vaccine -related serious adverse events 
(SAEs) from Day 1 through the 
duration of participation in Part A
Part A
•Objective: To evaluate the serotype -
specific opsonophagocytic activity ( OPA )
geometric mean titers ( GMTs )
postvaccination with V116 ( 30 days 
postvaccination [ Day 30]) and PCV15 + 
PPSV23 ( 30 days postvaccination with 
the final dose in the regimen [ Week 12] ) 
within each vaccination group separately.•Serotype -specific OPA response s
o13 serotypes common between 
V116 and PCV15 + PPSV23
o8 serotypes unique to V116
08LGKL
PRODUCT: V116  14
PROTOCOL/AMENDMENT NO.: 007-01
V116 -007-01 FINAL PROTOCOL 06-JUL-2022
Objecti ves Endpoints
Secondary
Part A
•Objective: To evaluate the serotype -
specific Immunoglobulin G ( IgG)
geometric mean concentrations ( GMCs)
postvaccination with V116 ( Day 30 )and 
PCV15 + PPSV23 (Week 12 ) within each 
vaccination group•Serotype -specific IgG responses
o13 serotypes common between 
V116 and PCV15 + PPSV23
o8 serotypes unique to V116
Part A
•Objective: To evaluate the serotype -
specific geometric mean fold rises 
(GMFRs )and proportions of participants 
with a ≥4 -fold rise from baseline (Day 1) 
to postvaccination with V116 (Day 30) 
and PCV15 + PPSV23 (Week 12) for 
both OPA and IgG responses within each 
vaccination group separately .•Serotype -specific OPA and IgG 
responses
o13 serotypes common between 
V116 and PCV15 + PPSV23
o8 serotypes unique to V116
Part B
•Objective: To evaluate the safety and 
tolerability of PCV15 as assessed by [CONTACT_301783] V116 in Part A.•Solicited injection -site AEs from 
Day 1B through Day 5B 
postvaccination
•Solicited systemic AEs from Day 1B 
through Day 5B postvaccination
•Vaccine -related SAEs from Day 1B 
through the duration of participation in 
Part B
08LGKL
PRODUCT: V116  15
PROTOCOL/AMENDMENT NO.: 007-01
V116 -007-01 FINAL PROTOCOL 06-JUL-2022
Overall Desig n:
Study Phase Phase 3
Primary Purpose Prevention
Indication Pneumococcal disease
Population Adults ≥18 years of age living with HIV
Study Type Interventional
Intervention Model Parallel
This is a multi- sitestudy.
Type of Control Active control
Study Blinding Part A : Double -blind with in -house blinding
Part B : Unblinded Open -label
Blinding Roles Part A : 
Participants or Subjects
Investigator
Sponsor
Part B : No Blinding
Estimated Duration of Study The Sponsor estimates that the study will require 
approximately 19months from the time the first 
participant (or their legally acceptable representative) 
provides documented informed consent until the last 
participant’s last study- related contact .
For purposes of ana lysis and reporting, the overall study 
ends when the Sponsor receives the last laboratory result 
or at the time of final contact [CONTACT_26355], 
whichever comes last.
Number of Participant s:
Approximately [ADDRESS_368638]: V116  16
PROTOCOL/AMENDMENT NO.: 007-01
V116 -007-01 FINAL PROTOCOL 06-JUL-2022
Intervention Groups and Du ration :
Intervention 
Group sIntervention 
Group 
Name [CONTACT_301814] -
quencyRoute of 
Admin .Vaccination 
Regimen Use
V116V1164 µg of each PnPs
antigen (3, 6A, 
7F, 8, 9N, 10A, 
11A, 12F, 15A, 
15C, 16F, 17F, 
19A, 20, 22F, 
23A, 23B, 24F, 
31, 33F, and 35B )Single 
doseIMSingle dose 
at Visit 2 
(Day 1)Test 
Product
Placebo N/ASingle 
doseIMSingle dose 
at Visit 5
(Week 8)Placebo
PCV152 µg of each PnPs 
antigen ( 1, 3, 4, 5, 
6A, 7F, 9V, 14, 
18C, 19A, 19F, 
22F, 23F, and 
33F) and 4 µg of 
PnPs antigen 6BSingle 
doseIMSingle dose 
at Visit 9 
(Day 1B)Test 
Product
PCV15 +
PPSV23PCV152 µg of each PnPs
antigen ( 1, 3, 4, 5, 
6A, 7F, 9V, 14, 
18C, 19A, 19F, 
22F, 23F, and 
33F) and 4 µg of 
PnPs antigen 6BSingle 
doseIMSingle dose 
at Visit 2 
(Day 1)Com -
parator
PPSV2325 µg of each 
PnPs antigen (1, 2, 
3, 4, 5, 6B, 7F, 8, 
9N, 9V, 10A, 
11A, 12F, 14, 
15B, 17F, 18C, 
19A, 19F, 20, 
22F, 23F, and 
33F)Single 
doseIMSingle dose 
at Visit 5
(Week 8)Com -
parator
Admin.=administration; IM=intramuscular; N/A=not applicable; PCV15= VAXNEUVANCE™ ; 
PnPs=pneumococcal polysaccharide; PPSV23= PNEUMOVAX™23
Other current or former name(s) or alias(es) for study intervention(s) are as 
follows: V116, polyvalent pneumococcal conjugate vaccine (pPCV) .
Total 
Number of 
Intervention 
Groups/
Arms2
Duration of 
ParticipationEach participant will participate in the study for approximately [ADDRESS_368639]: V116  17
PROTOCOL/AMENDMENT NO.: 007-01
V116 -007-01 FINAL PROTOCOL 06-JUL-2022
Study Governance Committees:
Executive Oversight Committee Yes
Data Monitoring Committee Yes
Clinical Adjudication Committee No
Study governance considerations are outlined in Appendix 1.
Study Accepts Healthy Volunteers :No
A list of abbreviations is in Appendix 8.
08LGKL
PRODUCT: V116  18
PROTOCOL/AMENDMENT NO.: 007-[ADDRESS_368640]: V116  19
PROTOCOL/AMENDMENT NO.: 007-[ADDRESS_368641]: V116  20
PROTOCOL/AMENDMENT NO.: 007-01
V116 -007-01 FINAL PROTOCOL 06-JUL-2022
1.3 Schedule of Activities
1.3.1 Schedule of Activities for Part A
Study Period :Screening Intervention and Follow -up Notes
Visit Number : 1 2 3 4 5 6 7 8
Visit Type :Site VisitSite 
VisitTCSite 
VisitSite Visit TCSite 
VisitTC
Scheduled Time :ScreeningDay 1
(Vac . 1)Day 7
(after 
Vac. 1 )Day 30
(after 
Vac. 1 )Week 8
(Vac 2; Day 
56 after 
Vac. 1)Week 9
(Day 7
after 
Vac. 2)Week 12
(Day 30 
after 
Vac. 2)Day 180
(after 
Vac. 1 )The day of Vac .1 is considered 
Day 1 of the study .
Visit Window :NA≤[ADDRESS_368642] be obtained before any 
sample collection .
Assignment of Screening Number X
Inclusion/Exclusion Criteria X X
Blood Sample for HIV Serology X
Blood Sample for CD4+ T -cell Count X X X
Blood Sample for Plasma HIV RNA 
TestingX X X
Medical History X X
Participant Identification Card X X
Postrandomization Procedures
Assignment of Randomization Number X
Prior/Concomitant Medication and 
Nonstudy Vaccination ReviewX X X X X X X
V116 or PCV15 Administration 
(Blinded)X
08LGKL
PRODUCT: V116  21
PROTOCOL/AMENDMENT NO.: 007-01
V116 -007-01 FINAL PROTOCOL 06-JUL-2022
Study Period :Screening Intervention and Follow -up Notes
Visit Number : 1 2 3 4 5 6 7 8
Visit Type :Site VisitSite 
VisitTCSite 
VisitSite Visit TCSite 
VisitTC
Scheduled Time :ScreeningDay 1
(Vac . 1)Day 7
(after 
Vac. 1 )Day 30
(after 
Vac. 1 )Week 8
(Vac 2; Day 
56 after 
Vac. 1)Week 9
(Day 7
after 
Vac. 2)Week 12
(Day 30 
after 
Vac. 2)Day 180
(after 
Vac. 1 )The day of Vac .1 is considered 
Day 1 of the study .
Visit Window :NA≤30 days 
after 
Visit 1Days 7 
to 10
after 
Visit 2aDays 30 
to 44
after 
Visit 2aDays 56 to 
70after Visit 
2aDays 7 
to 10
after 
Visit 5bDays 30 
to 44
after 
Visit 5bDays 166 
to 194
after 
Visit 2a
Placebo or PPSV23 Administration 
(Blinded)X
Provide Electronic Device or 
Configure Participant’s Own 
Electronic Device for eVRC Data 
CollectionX
Review eVRC Data With Participant X X X X
Collect Electronic D evice From 
Participants Who Received an 
Electronic DeviceX
Complete the Telephone Contact 
[CONTACT_301784] X Performed by [CONTACT_301785].Directed Physical Examination X
Pregnancy Test – if applicable X XFemales of reproductive 
potential must have a negative 
urine or serum test (consistent 
with local requirements and 
sensitive to ≤25 IU hCG) result 
before vaccination.
Body Temperature Measurement X XMeasured before vaccination. 
Participants with febrile illness 
within [ADDRESS_368643]: V116  22
PROTOCOL/AMENDMENT NO.: 007-01
V116 -007-01 FINAL PROTOCOL 06-JUL-2022
Study Period :Screening Intervention and Follow -up Notes
Visit Number : 1 2 3 4 5 6 7 8
Visit Type :Site VisitSite 
VisitTCSite 
VisitSite Visit TCSite 
VisitTC
Scheduled Time :ScreeningDay 1
(Vac . 1)Day 7
(after 
Vac. 1 )Day 30
(after 
Vac. 1 )Week 8
(Vac 2; Day 
56 after 
Vac. 1)Week 9
(Day 7
after 
Vac. 2)Week 12
(Day 30 
after 
Vac. 2)Day 180
(after 
Vac. 1 )The day of Vac .1 is considered 
Day 1 of the study .
Visit Window :NA≤[ADDRESS_368644] 
30minutes postvaccination.
AE Monitoring X X X X X X X XNonserious AEs collected 
through Day 30 after each 
vaccination. SAEs and deaths 
collected through the duration 
of participation in Part A .See 
Section 8.4.1 for further 
details.
Immunogenicity Procedures
Serum for Immunogenicity Assays X X XDay 1 samples should be 
collected before vaccination.
Future Biomedical Research
Blood (DNA) for FBR XFor participants who provided 
FBR consent. Should be 
collected before vaccination at 
Visit 2, or at a later date as 
long as FBR consent is 
obtained prior to collection .
Assay Development Samples
Serum for Optional Assay 
DevelopmentX X XFor participants who provided 
consent for optional assay 
development. Visit [ADDRESS_368645]: V116  23
PROTOCOL/AMENDMENT NO.: 007-01
V116 -007-01 FINAL PROTOCOL 06-JUL-2022
Study Period :Screening Intervention and Follow -up Notes
Visit Number : 1 2 3 4 5 6 7 8
Visit Type :Site VisitSite 
VisitTCSite 
VisitSite Visit TCSite 
VisitTC
Scheduled Time :ScreeningDay 1
(Vac . 1)Day 7
(after 
Vac. 1 )Day 30
(after 
Vac. 1 )Week 8
(Vac 2; Day 
56 after 
Vac. 1)Week 9
(Day 7
after 
Vac. 2)Week 12
(Day 30 
after 
Vac. 2)Day 180
(after 
Vac. 1 )The day of Vac .1 is considered 
Day 1 of the study .
Visit Window :NA≤30 days 
after 
Visit 1Days 7 
to 10
after 
Visit 2aDays 30 
to 44
after 
Visit 2aDays 56 to 
70after Visit 
2aDays 7 
to 10
after 
Visit 5bDays 30 
to 44
after 
Visit 5bDays 166 
to 194
after 
Visit 2a
AE=adverse event; eVRC=electronic Vaccination Report Card; FBR=future biomedical research; hCG=human chorionic gonadotropin; HIV=human immunodeficiency virus; 
NA=not applicable; PCV15=VAXNEUVANCE™; PPSV23=PNEUMOVAX™23; RNA=ribonucleic acid ;SAE=serious adverse event; TC=telephone contact; 
Vac.=vaccination
aWhen scheduling Visits 3, 4, 5, and 8, “Day 1” is the date of Visit 2.
bWhen scheduling Visits 6 and 7, “Day 1” is the date of Visit 5.
08LGKL
PRODUCT: V116  24
PROTOCOL/AMENDMENT NO.: 007-01
V116 -007-01 FINAL PROTOCOL 06-JUL-2022
1.3.2 Schedule of Activities for Part B
Study Period: Intervention and Follow -up Notes
Visit Number: 9 10 11
Visit Type: Site Visit TC Site Visit
Scheduled Time: Day 1B Day 7B Day 30B
Visit Window:≤[ADDRESS_368646] 
Part A DBLDays 7B 
to 10BDays 30B 
to 44B
Administrative Procedures
Confirmation of Eligibility in Part B X
Blood Sample for CD4+ T -cell Count X X
Blood Sample for Plasma HIV RNA Testing X X
Prior/Concomitant Medication and Nonstudy 
Vaccination ReviewX X X
PCV15 Administration (Open -label) X
Provide Electronic Device or Configure 
Participant’s Own Electronic Device for 
eVRC Data CollectionX
Review eVRC Data With Participant X X
Collect Electronic Device From Participant s 
Who Received an Electronic DeviceX
Safety Procedures
Directed Physical Examination XPerformed by [CONTACT_301786].
Pregnancy Test – if applicable XFemales of reproductive potential must have a negative urine or serum test 
(consistent with local requirements and sensitive to ≤25 IU hCG) result before 
vaccination.
Body Temperature Measurement XMeasured before vaccination. Participants with febrile illness within [ADDRESS_368647] 30 minutes postvaccination.
AE Monitoring X X X Nonserious AEs and SAEs collected through the duration of Part B .
Immunogenicity Procedures
Serum for Immunogenicity Assays X X Visit 9 samples should be collected before vaccination.
Assay Development Samples
Serum for Optional Assay Development X XFor participants who provided consent for optional assay development. Visit 9
sample should be collected before vaccination.
AE=adverse event; DBL=database lock; eVRC=electronic Vaccination Report Card; hCG=human chorionic gonadotropin; HIV=human immunodeficiency virus; NA=not 
applicable; PCV15=VAXNEUVANCE™; RNA=ribonucleic acid ;SAE=serious adverse event; TC=telephone contact
08LGKL
PRODUCT: V116  25
PROTOCOL/AMENDMENT NO.: 007-01
V116 -007-01 FINAL PROTOCOL 06-JUL-2022
2 INTRODUCTION
The Sponsor is developi[INVESTIGATOR_93267] 21- valent conjugate 
vaccine ( V116) for the prevention of pneumococcal disease caused by [CONTACT_93290].
2.[ADDRESS_368648] burden seen in children 
<5years and adults > 70 years of age [Troeger, C., et al 2018] . PCV vaccination has reduced 
the incidence of disease caused by [CONTACT_93291]
(primarily children <[ADDRESS_368649] countries) and has had an indirect effect in other 
age groups.
However, an unmet me dical need exists as increases in IPD due to serotypes not included in 
licensed PCVs have been observed in several countries , especially in adults.
V116 is an investigational PCV designed to address this unmet need and includes 
Spneumoniae serotypes not included in licensed PCVs . The serotypes in V116 account for 
the majority of IPD observed in adults.
Persons living with HIV are at an increased risk of IPD compared with uninfected 
individuals . This risk remains elevated even in individuals on combined ART and with a high 
CD4+ T- cell count and suppressed viral load [Garcia Garrido, H. M., et al 2020] . Currently, 
treatment guidelines in many countries recomm end the use of a PCV as part of a sequential 
regimen with PPSV23 for persons living with HIV . Specifically, in October 2021 ,the US 
ACIP recommended pneumococcal vaccination either with a sequential regimen of PCV15 
followed by [CONTACT_93297]23 or with a single dose of PCV20 to adults 19to 64 years of age with 
chronic medical conditions or immunocompromising conditions which confer an increased 
risk of pneumococcal disease [Kobayashi, M., et al 2022] .Many countries and regions
follow similar recommendations (sequential regimen of PCV 13followed by [CONTACT_93297]23 or 
PPSV23 alone ) foradults with certain conditions at increased risk of pne umococcal disease
[Castiglia P. 2014] [Bonnave, C., et al 2019] .
Adults a t high risk for pneumococcal disease due to underlying comorbid conditions such as 
HIV,may benefit from receiving V116, which contains [ADDRESS_368650] pneumococcal disease and offer an 
advantage due to being a conjugate vaccine, which include sinduction of a memory immune
response .
This clinical study is designed to evaluate the safety, tolerability, and immunogenicity of 
V116 in persons living with HIV who are ≥18 years of age with a CD4+ T- cell count 
≥50cells/µL and a plasma HIV RNA value <50,000 copi[INVESTIGATOR_014]/mL prior to study e ntry. 
Participants with or without prior pneumococcal vaccination experience will be eligible for 
enrollment (see Section 5.1) .
08LGKL
PRODUCT: V116  26
PROTOCOL/AMENDMENT NO.: 007-01
V116 -007-01 FINAL PROTOCOL 06-JUL-2022
This study will be conducted in 2 parts (see Section 4.2) :
Part A will evaluate V116 and the comparator regimen of PCV15 followed by [CONTACT_93297]23 to 
provide safety and immunogenicity data of V116 with respect to a regimen that is 
currently recommended by [CONTACT_301787].
Part B will evaluate PCV15 in participants who received V116 in Part A to provide safety 
and immunogenicity data in a high -risk population who may also benefit from 
vaccination with serotypes that are included in PCV15.
2.2 Backgroun d
To date, a Phase 1/Phase 2 study (V116 -001) and a Phase 1 study in Japan (V116 -002) have 
been conducted with V116. Results from the Phase [ADDRESS_368651] 
the optimal vaccine formulation for subsequent development. Results from thes e studies 
showed that V116 is immunogenic and has acceptable safety and tolerability in healthy 
adults. Refer to the IB for detailed background information on V116.
2.2.1 Pharmaceutical and Therapeutic Background
Pneumococcal disease (ie, disease caused by [CONTACT_93293] ) is one of the single largest 
vaccine -preventable causes of death in children and older adults ( ≥65 years of age) 
worldwide. PCV use in children has decreased the incidence of disease caused by [CONTACT_93294]. This has resulted in decreased hospi[INVESTIGATOR_301772] ≥65 years of age, including estimated decreases of 29% and 34% in admissions due to
IPD and noninvasive pneumococcal pneumonia, respectively [Simonsen, L., et al 2014] . In 
some countries, including the US, the decrease in pneumococcal disease in children 
vaccinated with PCV has led to the recommendation to vaccinate adults with PCVs. 
However, c urrent surveillance does not definitively indicate that the use of PCVs in adults 
results in a similar reduction in pneumococcal disease [Matanock, A. 2018] . The residual 
burden of disease in the US is estimated as 24 cases of IPD per 100,000 in adults ≥65 years 
of age , and surveillance data estimates serotypes included in currently licensed PCVs account 
for approximately 23% to 50% of these case s [Centre for Disease Control and Prevention 
2016] [Centers for Disease Control and Prevention 2019] [Kobayashi, M. 2021] .
Theresidual burden of disease in adults reflects the difference in seroty pe distribution in 
adults compared with infants and children. An increasing incidence of disease due to 
serotypes not included in the licensed PCVs has been observed, particularly in adults [Miller, 
Elizabeth, et al 2011] [Moore, M. R., et al 2015] [Pi[INVESTIGATOR_63466], T. 2015] [van der Linden, M., et 
al 2015] [Golden, A. R., et al 2016] . Increases in IPD cases due to nonvaccine serotypes (3, 
7F, and 19A after implementation of PCV7 ; 22F and 3 3F following widespread usage of
PCV13 ) have been observed in both pediatric and older adult (≥65 years of age) populations 
in the US [Hicks, L. A., et al 2007] [Pi[INVESTIGATOR_63466], Tamara, et a l 2010] [Waight, P. A., et al 2015] 
[Moore, M. R., et al 2015] [Demczuk, W. H. B., et al 2013]. Similarly, due to the limited 
serotype coverage of the currently licensed vaccines in the EU , serotype replacement due to 
08LGKL
PRODUCT: V116  27
PROTOCOL/AMENDMENT NO.: 007-01
V116 -007-01 FINAL PROTOCOL 06-JUL-2022
nonvaccine serotypes is being obser ved in older adults and may decrease the potential 
additional benefit of vaccination with currently available PCVs [European Center for Disease 
Prevention and Control 2018] .
Serotypes were selected for inclusion in V116 based on available global epi[INVESTIGATOR_93269] a primary focus on data from older adults ( ≥65 years of age) in the US and EU, regions 
with an established pediatric vaccination program. Based on 2018 surveillance data in US 
adults ≥65 years of ag e, the serotypes selected for inclusion in V116 account for 
approximately 83% of all cases of IPD, 25 % to 30% of which are accounted for by [CONTACT_93295] V116 (US CDC ABC sunpublished data 2014 to 2018) [Centre for 
Disease Control and Prevention 2018] .
V116 includes serotypes not currently contained in any licensed pneumococcal vaccine. It is 
being developed to support an indication for active immunization for the prevention of 
invasive disease and pneumonia caused by S pneumoniae serotypes 3, 6A , 6C, 7F, 8, 9N, 
10A, 11A, 12F, 15A, 15B , 15C, 16F, 17F, 19A, 20, 22F, 23A, 23B, 24F, 31, 33F, and 35B in 
adults ≥ 18years of age .Note that serotype 15C represents deOAc1 5B as the molecular 
structures for deOAc15B and 15C are similar .
2.2.2 Information on Other Study -related Therapy
[IP_ADDRESS] PCV15
Refer to approved labeling for detailed background information on PCV15.
PCV15 is a pneumococcal conjugate vaccine that includes 15 serotypes (1, 3, 4, 5, 6A, 6B, 
7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F) individually conjugated to the CRM 197and 
formulated with aluminum phosphate adjuvant.
PCV15 is approved for use in the US , EU, and other countries in adults ≥18 years of age for 
the prevention of pneumococcal disease caused by [CONTACT_93296] (indication 
may vary by [CONTACT_1606]) .
[IP_ADDRESS] PPSV23
Refer to approved labeling for detailed background information on PPSV23 .
PPSV23 is comprised of the polysaccharides from 23 of the serotypes causing disease in 
adults (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 
22F, 23F, and 33F). The formulation is not adjuvanted and no carrier protein is used.
PPSV23 was first approved in the US in 1983 and is now licensed in > 50 countries 
worldwide. PPSV23 is indicated for the prevention of pneumococcal disease in adults 
≥50years of age and in individuals ≥[ADDRESS_368652]: V116  28
PROTOCOL/AMENDMENT NO.: 007-01
V116 -007-01 FINAL PROTOCOL 06-JUL-2022
[IP_ADDRESS] Pneumococcal Vaccination Guidelines
Many countries have implemented age -based and/or risk- based recommendations for 
pneumococcal vaccination. Age -based recommendations typi[INVESTIGATOR_93270] 65 years of age due 
to the increased risk of pneumococcal disea seassociated with age.
Prior to 2014, the US ACIP recommended that all adults ≥65 years of age receive a single 
dose of PPSV23. In 2014, ACIP recommended the sequential vaccination regimen of PCV13 
followed by [CONTACT_93297]23 for all adults ≥65 years of age, with the intent to reevaluate this 
recommendation. The guideline was updated in 2019 to remove the recommendation for 
routine use of PCV13 among adults ≥65 years and continued to recommend a routine single 
dose of PPSV23 for adults aged ≥65 years [Matanock, A., et al 2019]. The ACIP updated the 
guidelines in 2021 to recommend that adults ≥65 years of age should receive either PCV15 
followed by [CONTACT_93297]23, or PCV20 alone [Kobayashi, M., et al 2022] .
Risk-based recommendations generally inc lude individuals with an increased risk of 
pneumococcal disease who are categorized as immunocompetent at -riskor as high- risk.
Conditions associated with immunocompetent at- risk include, but are not limited to, chronic 
heart disease, chronic lung disease (including chronic obstructive pulmonary disease, 
emphysema, and asthma), diabetes mellitus, alcoholism, chronic liver disease (including 
cirrhosis), and cigarette smoking . Conditions associated with high-risk include , but are not 
limited to, congenital or acquired asplenia, sickle cell disease/other hemoglobinopathies, 
chronic renal failure, congenital or acquired immunodeficiencies, generalized malignancy, 
hematologic malignancy, HIV infection, nephrotic syndrome, solid organ transplant, and 
hematopoietic stem cell transplant [Kobayashi, M., et al 2022] . In the US, recommendations 
for immunocompetent at -risk individuals 19 to 64 years of age previously include da single 
dose of PPSV23, with the exception of indi viduals with cochlear implants or CSF leaks ,who 
should receive PCV13 followed by [CONTACT_93297]23. High -risk individuals were recommended to
receive 1 dose of PCV13 followed by 1 dose of PPSV23 ≥ 8 weeks later, and an additional 
dose of PPSV23 ≥5 years later [Matanock, A., et al 2019] . Similar to the age -based 
recommendations, the ACIP guidelines were updated in 2021, and now recommend that 
immunocompetent at -risk individuals and high -risk individuals 19 to 64 years of age receive 
PCV15 followed by [CONTACT_93297]23, or PCV20 alone [Kobayashi, M., et al 2022] .
2.3 Benefit/Risk Asse ssment
It cannot be guaranteed that participants in clinical studies will directly benefit from 
administration of V116, as clinical studies are designed to provide information about the 
safety and effectiveness of an investigational medicine.
Despi[INVESTIGATOR_301773], 
pneumococcal disease in adults remains a nunmet medical need. S pneumoniae is a major 
cause of vaccine -preventable disease worldwide, resulting in considerable morbidity and 
mortality [Troeger, C., et al 2018] .
Vaccination with PCVs has reduced the incidence of disease caused by [CONTACT_93298] (primarily children <[ADDRESS_368653]: V116  29
PROTOCOL/AMENDMENT NO.: 007-01
V116 -007-01 FINAL PROTOCOL 06-JUL-2022
countries) and has h ad an indirect effect in other age groups. However, in several countries, 
infant vaccination with PCVs has also led to increases in IPDdue to serotypes not included 
in the licensed PCVs, particularly in adults .
V116 is designed to provide broader pneumoco ccal disease coverage in adults compared with
currently licensed pneumococcal vaccines and is anticipated to have a generally comparable 
safety profile. No clinically important safety findings have been identified to date based on 
data from early phase cli nical studies with V116.
The benefit -riskprofile for V116 supports continued evaluation.
In this study, a pproximately 50% of participants will receive PCV15 followed by [CONTACT_93297]23. 
V116 is expected to provide comparable immune responses to PCV15 + PPSV23 for the 
serotypes in common with either PCV15 or PPSV23 while providing additional coverage for 
the serotypes unique to V116. It is unknown if V116 will have the same clinical benefit as 
PCV15 + PPSV23. Participants who received V116 in Part A may benefit from vaccination 
with serotypes that are included in PCV15 by [CONTACT_301788]15 in Part B .
Additional details re garding specific benefits and risks for participants participating in this 
clinical study may be found in the accompanying IB and informed consent documents.
3 HYPOTHESE S, OBJECTIVES ,AND ENDPOINTS
There is no hypothesis testing in this study.
The following objectives and endpoints will be evaluated in pneumococcal vaccine -naïve or 
pneumococcal vaccine -experienced adults ≥18 years of age living with HIV.
Objectives Endpoints
Primary
Part A
•Objective: To evaluate the safety and 
tolerability of V116 as assessed by [CONTACT_93287] (AEs).•Solicited injection -site AEs from Day 
1 through Day 5 postvaccination
•Solicited systemic AEs from Day 1 
through Day 5 postvaccination
•Vaccine -related serious adverse events 
(SAEs) from Day [ADDRESS_368654]: V116  30
PROTOCOL/AMENDMENT NO.: 007-01
V116 -007-01 FINAL PROTOCOL 06-JUL-2022
Objectives Endpoints
Part A
•Objective: To evaluate the serotype -
specific opsonophagocytic activity ( OPA )
geometric mean titers ( GMTs )
postvaccination with V116 ( 30 days 
postvaccination [ Day 30]) and PCV15 + 
PPSV23 ( 30 days postvaccination with 
the final dose in the regimen [ Week 12] ) 
within each vaccination group separately.•Serotype -specific OPA response s
o13 serotypes common between 
V116 and PCV15 + PPSV23
o8 sero types unique to V116
Secondary
Part A
•Objective: To evaluate the serotype -
specific Immunoglobulin G ( IgG)
geometric mean concentrations ( GMCs)
postvaccination with V116 ( Day 30 )and 
PCV15 + PPSV23 (Week 12 ) within each 
vaccination group•Serotype -specific IgG responses
o13 serotypes common between 
V116 and PCV15 + PPSV23
o8 serotypes unique to V116
Part A
•Objective: To evaluate the serotype -
specific geometric mean fold rises 
(GMFRs )and proportions of participants 
with a ≥4 -fold rise from b aseline (Day 1) 
to postvaccination with V116 (Day 30) 
and PCV15 + PPSV23 (Week 12) for 
both OPA and IgG responses within each 
vaccination group separately .•Serotype -specific OPA and IgG 
responses
o13 serotypes common between 
V116 and PCV15 + PPSV23
o8 serotypes unique to V116
Part B
•Objective: To evaluate the safety and 
tolerability of PCV15 as assessed by [CONTACT_301783] V116 in Part A.•Solicited injection -site AEs from 
Day 1B through Day 5B 
postvaccination
•Solicited systemic AEs from Day 1B 
through Day 5B postvaccination
•Vaccine -related SAEs from Day 1B 
through the duration of participation in 
Part B
08LGKL
PRODUCT: V116  31
PROTOCOL/AMENDMENT NO.: 007-01
V116 -007-01 FINAL PROTOCOL 06-JUL-2022
Objectives Endpoints
Tertiary/Exploratory
Part A
•Objective: To evaluate the serotype -
specific OPA GMTs and IgG GMCs 
postvaccination with V116 (Day 30) 
compared with PCV15 +PPSV23 (Week 
12).•Serotype -specific OPA and IgG 
responses
o13 serotypes common between 
V116 and PCV15 + PPSV23
o8 serotypes unique to V116
Part A
•Objective: To evaluate the serotype -
specific OPA GMTs and IgG GMCs 
postvaccination with V116 (Day 30) and 
PCV15 (Day 30), and evaluate serotype -
specific GMFRs and proportions of 
participants with a ≥4 -fold rise from 
baseline (Day 1) to postvaccination with 
V116 (Day 30) and PCV15 (Day 30)
within each vaccination group separately .•Serotype -specific OPA and IgG 
responses
o6 serotypes common between 
V116 and PCV15
o15 serotypes unique to V116
Part A
•Objective: To evaluate the cross- reactive 
immune responses to serotypes within a 
serogroup 30 days postvaccination.•Serotype -specific OPA and IgG 
responses
Part B
•Objective: To evaluate the serotype -
specific OPA and IgG responses 30 days 
postvaccination with PCV15 for 
participants administered V116 in Part A.•Serotype -specific OPA and IgG 
responses
o6 serotypes common between 
V116 and PCV15
o15 serotypes unique to V116
o9 serotypes included in PCV15 but 
not in V116
08LGKL
PRODUCT: V116  32
PROTOCOL/AMENDMENT NO.: 007-01
V116 -007-01 FINAL PROTOCOL 06-JUL-2022
4 S TUDY DESIGN
4.1 Overall Design
This is a 2- part study.
Part A
Part A is a randomized, active comparator -controlled , parallel -group, multisite, double -blind 
study of V116 in participants ≥18 years of age living with HIV.
Approximately 300 participants will be randomized in a 1:1 ratio to receive either V 116 on 
Day 1 followed by [CONTACT_14296] 8 weeks later, or PCV15 on Day 1 followed by [CONTACT_93297]23 8weeks 
later. Randomization will be stratified by [CONTACT_301789] ( PCV13 and 
PPSV23 naïve; prior PCV13 only; prior PPSV23 only orprior PCV13 and PP SV23) and by 
[CONTACT_398]4+ T- cell count at Screening ( ≥50 to <500 cells/µL ;≥500 cells/µL ).Approximately 50% 
of participants will be naïve to PCV13 and PPSV23 .
An eVRC will be used by [CONTACT_301790] -siteAEs, solicited 
systemic AEs , and daily body temperature from Day [ADDRESS_368655]: V116  33
PROTOCOL/AMENDMENT NO.: 007-[ADDRESS_368656] a periodic review of safety and tolerability data for the V116 
Phase 3 program. A description of the structure andfunction ofthe DMC, along with the 
timing and content of the safety reviews ,will be outlined in the DMC charter. Information 
regarding the composition of the DMC is provided in Appendix 1.
Specific procedures to be performed during the study, including prescribed times and 
associated visit windows, are outlined in Section 1.3 .1 (Part A) and Section 1.3.2 (Part B) of 
the SoA. Details of each procedure are provided in Section 8.
4.2 Scientific Rationale for Study Design
Individuals living with HIV are at an increased risk of IPD compared with HIV uninfected 
individuals. This study will be conducted inadults ≥18 years of age living with HIV, with or 
without prior pneumococcal vaccination experience , and with a documented CD4+ T -cell 
count ≥50 cells/µL as well as plasma HIV RNA <50,000 copi[INVESTIGATOR_014]/mL prior to study entry . This 
study is designed to assess saf ety, tolerability, and immunogenicity in a representative 
population whom vaccination with a pneumococcal vaccine is recommended.
This study aims to enroll participants with CD4+ T -cell counts ≥50 cells/µL. Due to early 
initiation of ART, the majority of p articipants are expected to have CD4+ T -cell counts >200 
cells/µL. Participants with CD4+ T- cell count <50 cells/µL or plasma HIV RNA ≥50,000 
copi[INVESTIGATOR_014]/mL will be excluded based on the accepted clinical practice of prioritizing ART prior 
to vaccination. HI V is considered an immunocompromising condition, in which the degree of 
immunosuppression is directly related to the CD4+ T -cell count. CD4+ T- cell count at the 
time of study vaccination may impact the immune response of the study vaccine , with lower 
CD4+ T-c ell counts having more of an impact on the ability of the immune system to 
respond to the vaccine ;thus, CD4+ T- cell counts will be used as a stratification factor ( see 
Section 6.3.2). Additionally, CD4+ T- cell counts and HIV RNA will be monitored during the 
study as indicated in Sections 1.3.1 and 1.3.2 to provide information on the immune status of 
the participants following study vaccination.
Pneumococcal vaccine -experienced participants (based on prior PCV13 and PPSV23 
vaccination history; see S ection 5.1) are included in this study to provide data on the impact 
of prior vaccination in a population that may benefit from additional vaccination with V116. 
Prior vaccination history will be included as a stratification factor ( see Section 6.3.2).
Participants who received PCV7 will be eligible for this study. PCV7 was largely approved 
and in recommendation guidelines in 2000, thus, there will be some participants who 
received PCV7 and are ≥ [ADDRESS_368657] the immunogenicity analysis of V116 serotypes as there are no 
common serotypes between PCV7 and V116 or PPSV23, and only serotypes included in 
V116 will be analyzed.
Individuals who received PCV10 as part of their pediat ricvaccination schedule will not be 
eligible for this study as these individuals will be <[ADDRESS_368658]: V116  34
PROTOCOL/AMENDMENT NO.: 007-[ADDRESS_368659] to a regimen that is currently 
recommended by [CONTACT_301791].
Part B will evaluate PCV15 in participants who receive dV116 in Part A to provide safety , 
tolerability ,and immunogenicity data in a high -risk population who may also benefit from 
vaccination with serotypes that are included in PCV15 .
4.2.1 Rationale for Endpoints
[IP_ADDRESS] Immunogenicity Endpoints
The immunogenicity endpoints are consistent with previous studies evaluating PCVs.
Sera from participants will be used to assess vaccine -induced , anti- PnPs serotype -specific 
OPA and IgG responses using the validated MOPA and Pn ECL assay, respectively.
Immunogenicity endpoints will be evaluated for all serotypes included in V116 a nd for cross -
reactive serotypes within a serogroup.
Several studies have shown a positive correlation between serotype -specific IgG antibody 
concentrations and OPA titers in children and adults [Centers for Disease Control and 
Prevention 2010] [Anttila , M., et al 1999] [Romero- Steiner, S., et al 1997] .OPA assesses 
levels of functional antibodies capable of opsonizing pneumococcal capsular polysaccharides 
for presentation to phagocytic cells for engulfment and subsequent killing, and therefore is 
considered an important immunologic surrogate for protection against IPD in adults. It is 
noted that IgG antibody concentration and OPA titer threshold values that correlate with 
protection in adults have not been defined; however, the OPA responses are consi dered 
accepted endpoint sfor the evaluation of novel pneumococcal vaccines in adults.
The OPA GMT, IgG GMC, GMFRs, and proportion of participants with 4- fold rise in OPA 
and IgG responses are acceptable assessments use dto evaluate novel PCVs.
Details on t he immunogenicity endpoints evaluated in this study can be found in 
Section 9.4.1.
[IP_ADDRESS] Safety Endpoints
Safety information will be collected from all participants on an eVRC. The eVRC used to 
record AEs during the postvaccination periods (Section 8.1.9) is str uctured as recommended 
in the final US FDA Patient- reported Outcome Guidance [U.S. Food and Drug 
Administration 2009] .
08LGKL
PRODUCT: V116  35
PROTOCOL/AMENDMENT NO.: 007-01
V116 -007-01 FINAL PROTOCOL 06-JUL-2022
The safety endpoints (ie, AEs and temperature) evaluated in this study are consistent with 
previous studies of V116 and published data from marketed PCVs. Detailed information for
the safety endpoints evaluated in this study can be found in Section 9.4.2.
Definitions and reporting requirements for AEs are provided in Appendix 3.
[IP_ADDRESS] Future Biomedical Research
The Sponsor will conduct FBR on specimens for which consent was provided during this 
study. This research may include genetic analyses (DNA), gene express ion profiling (RNA), 
proteomics, metabolomics (serum, plasma), and/or the measurement of other analytes, 
depending on whi ch specimens are consented for FBR .
Such research is for biomarker testing to address emergent questions not described elsewhere 
in the protocol and will only be conducted on specimens from appropriately consented 
participants. The objective of coll ecting/retaining specimens for FBR is to explore and 
identify biomarkers that inform the scientific understanding of diseases and/or their 
therapeutic treatments. The overarching goal is to use such information to develop safer, 
more effective drugs/vaccines, and/or to ensure that participants receive the correct dose of 
the correct drug/vaccine at the cor rect time. The details o f FBR r esearch are presented in
Appendix 6.
4.2.2 Rationale for the Use of Comparator/Placebo
Placebo -controlled clinical studies for new PCVs are no longer practical given the proven 
clinical efficacy and widespread use of licensed pneumococcal vaccines worldwide.
The s equential regimen of a PCV followed by [CONTACT_93297]23 is recommended in many countries 
for individuals at increased risk for pneumococcal disease [Nuorti, J. P. and Whitney, C. G. 
2010] [Robert Koch Institut 2017] . In Part A, the comparator regimen is PCV15 followed by 
[CONTACT_93297]23 (PCV15 +PPSV23). This comparator is supported because the regimen of PCV15 
followed by [CONTACT_93297]23 has been evaluated in the population of perso ns living with HIV and 
includes the most serotypes directed against pneumococcal disease compared with other 
licensed vaccines [Mohapi, L., et al 2021] . The sequential regimen of PCV15 + PPSV23 has 
13 serotypes in common with V116: 6 serotypes ( 3, 6A, 7F, 19A, 22F ,33F) contained in 
PCV15 and7 serotypes ( 8, 9N, 10A, 11A, 12F, 17F, 20 ) contained in PPSV23 but not 
included in PCV15. V116 contains 8 unique serotypes ( 15A, 15C, 16F, 23A, 23B, 24F, 31 ,
35B)not included in any licensed pneumococcal vaccine .Note that serotype 15C represents 
deOAc15B as the molecular structures for deOAc15B and 15C are similar.
Placebo is used in this study to maintain blinding. The placebo is sterile saline for injection.
In Part B, participants who received V116 in Part A will receive PCV15 open -label .
Participants who received PCV15 + PPSV23 will not proceed to Part B.
08LGKL
PRODUCT: V116  36
PROTOCOL/AMENDMENT NO.: 007-01
V116 -007-01 FINAL PROTOCOL 06-JUL-2022
4.3 Justification for Dose
The V116 dose of 4 µg/each PnPs was selected based on review of safety and 
immuno genicity data from the Phase 1 and Phase 2 studies. In Phase 1, 2doses of V116 were 
evaluated: a single dose containing 2 µg/each PnPs and a single dose of 4 µg/each PnPs. 
Based on the data from Phase 1, the V116 dose of 4 µg/each PnPs was selected for fu rther 
evaluation in Phase 2. Results from Phase 2 showed that the V116 dose of 4 µg/each PnPs is 
well tolerated and generates serotype -specific immune responses. These data support the 
selection of the V116 dose of 4 µg/each PnPs for further development in Phase 3.
Refer to the IB for detailed background information on V116.
The doses of PCV15 and PPSV [ADDRESS_368660] labeling of 
VAXNEUVANCE™ and PNEUM OVAX™23, respectively .
4.[ADDRESS_368661] participant (or their legally acceptable representative) 
provides documented informed consent . The overall study ends when the last participant 
completes t he last study -related contact , withdraws consent , or is lost to follow -up (ie, the 
participant is unable to be contact[CONTACT_19379]) .
For purposes of analysis and reporting, the overall study ends when the Sponsor receives the 
last laboratory result or at the time of final contact [CONTACT_26355], whichever comes 
last.
If the study includes countries in the European Economic Area (EEA), the local start of the 
study in the EAA is defined as First Site Ready (FSR) in any Mem ber State.
4.4.1 Clinical Criteria f orEarly Study Termination
The clinical study may be terminated early if the extent (incidence and/or severity) of 
emerging effects/clinical endpoints is such that the risk/benefit ratio to the study population 
as a whole is u nacceptable. In addition, further recruitment in the study or at (a)particular 
study site(s) may be stopped due to insufficient compliance with the protocol, GCP, and/or 
other applicable regulatory requirements, procedure -related problems or the number of
discontinuations for administrative reasons is too high .
[ADDRESS_368662] for Clinical Trials (Appendix 1.1), this study include s
participants of varying age (as applicable) , race, ethnicity, and sex (as applicable) . The 
collection and use of these demographic data will follow all local laws and participant 
confidentiality guidelines while supporting the study of the disease, its related factors, and 
the IMP under investigation .
08LGKL
PRODUCT: V116  37
PROTOCOL/AMENDMENT NO.: 007-01
V116 -007-01 FINAL PROTOCOL 06-JUL-2022
Prospective approval of protocol deviations to recruitment and enrollment criteria, also 
known as protocol waivers or exemptions, is not permitted.
5.1 Inclusion Criteria
A participant is eligible for inclusion in the study if the participant meets all of the following 
criteria :
Type of Participant and Disease Characteristics
1.Is infected with HIV and has a CD4+ T- cell count ≥50 cells/µL and plasma HIV RNA 
<50,000 copi[INVESTIGATOR_014]/mL tested at S creening (Visit 1).
2.Is receiving combination ART for ≥ 6 weeks before study entry with no intended changes 
to combination ART therapy for 3 months after randomization.
3.Is vaccine -naïve ( participant who has never received PCV13 andPPSV23), or 
vaccine -experienced ( participant who has received PCV13 ≥8 weeks, or PCV13 +
PPSV23 ≥4 years, or PPSV23 ≥4 years before Visit 2 [Day 1 ]).
Demographics
4.Ismale or female , ≥18years of age, at the time of informed consent.
Female Participants
5.A female participant is eligible to participate if she is not pregnant or breastfeeding, and 
at lea st one of the following conditions applies: 
•Not a WOCBP
OR
•A WOCBP and:
-Uses an acceptable contraceptive method, or be abstinent from heterosexual 
intercourse as their preferred and usual lifestyle (abstinent on a long -term and 
persistent basis), as descr ibed in Appendix [ADDRESS_368663] dose of study intervention. The investigator should 
evaluate the potential for contraceptive method failure (ie, noncompliance, recently 
initiated) in relationship to the first dose of study intervention. Contraceptive use by 
[CONTACT_301792] .Note : Use of an acceptable 
contraceptive method is required during the intervention period and for at least [ADDRESS_368664] (urine or serum as require d by [CONTACT_13125]) within [ADDRESS_368665]: V116  38
PROTOCOL/AMENDMENT NO.: 007-01
V116 -007-01 FINAL PROTOCOL 06-JUL-2022
cannot be confirmed as negative (eg, an ambiguous result), a serum pregnancy test is 
required. In such cases, the participant must be excluded from partici pation if the 
serum pregnancy result is positive. Additional requirements for pregnancy testing 
during and after study intervention are in Section 8.3. 2.
-Medical history, menstrual history, and recent sexual activity has been reviewed by 
[CONTACT_093] t o decrease the risk for inclusion of a woman with an early undetected 
pregnancy.
Informed Consent
6.The participant (or legally acceptable representative) has provide ddocumented informed 
consent for the study. The participant may also provide documented inf ormed consent for 
FBR and/or assay development sample collection . However, the participant may be 
enrolled in the study without providing consent forFBR or assay development sample 
collection.
Additional Categories
7.The participant has the ability to complete eVRC data collection without assistance based 
on judgment of the investigator .
5.[ADDRESS_368666] be excluded from the study if the participant meets any of the following 
criteria :
Medical Conditions
1.Has a h istory of opportunistic infections ≤ [ADDRESS_368667] vaccination at Visit 2 
(Day 1)(applicable to Part A) and before vaccination at Visit 9 (Day 1B ) (applicable to
Part B) .
2.Has a h istory of noninfectious acquired immune deficiency syndrome -related illness such 
as Kaposi's sarcoma, wasting syndrome, or HIV -associated nephropathy.
3. *H as a h istory of active hepatitis with elevation in pretreatment aspartate transaminase or 
alanine transaminase values >5 ×the upper limit of normal ≤[ADDRESS_368668] 
vaccination at Visit 2 (Day 1) (applicable to Part A) and before vaccination at Visit 9 
(Day 1B ) (applicable to Part B) .
4.Has a h istory of IPD (positive blood culture, positive CSF culture, or positive c ulture at 
another sterile site) or known history of other culture -positive pneumococcal disease 
≤3years before Visit 2 (Day 1) (applicable to Part A) and before vaccination at Visit 9 
(Day 1B ) (applicable to Part B) .
5.Has a known hypersensitivity to any component of V116, PCV15, or PPSV23 , including 
diphtheria toxoid .
08LGKL
PRODUCT: V116  39
PROTOCOL/AMENDMENT NO.: 007-01
V116 -007-01 FINAL PROTOCOL 06-JUL-2022
6.Has a known or suspected congenital immunodeficiency, functional or anatomic asplenia, 
or history of autoimmune disease ( including but not limited to the autoimmune conditions 
outlined in the Investigator Trial File Binder for this study ).
7.Has a c oagulation disorder contraindicating intramuscular vaccinations.
8.*Has a r ecent febrile illness (defined as oral or tympanic temperature ≥100.4°F 
[≥38.0°C]; axillary or temporal temperature ≥99.4°F [≥37.4°C]; or rectal temperature 
≥101.4°F [≥38.6°C]) or received antibiotic therapy for any acute illness occurring 
<72hours before receipt of any study vaccine.
9.Has a known malignancy that is progressing or has required active treatment <3 years 
before enrol lment . Note : Participants with basal cell and/or squamous cell carcinoma of 
the skin, or carcinoma in situ (eg, breast carcinoma, cervical cancer in situ ) that have 
undergone potentially curative therapy are not excluded .
Prior/Concomitant Therapy
10.Had prior administration of PCV15 or PCV20.
11.Isexpected to receive any pneumococcal vaccine during the study outside the protocol.
12.*Received systemic corticosteroids (prednisone equivalent of ≥20 mg/day) for 
≥14consecutive days and has not completed treatment ≥14 days before receipt of study 
vaccine at Visit 2 (Day 1) (applicable to Part A) and before receipt of study vaccine at 
Visit 9 (Day 1B ) (applicable to Part B) .Note : Physiologic replacement doses (prednisone 
equivalent of approximately 5 mg/day), t opi[INVESTIGATOR_2855], ophthalmic, intraarticular or soft -tissue 
(eg, bursa, tendon steroid injections) , and inhaled/nebulized steroids are permitted.
13.Is currently r eceiving immunosuppressive therapy, including chemotherapeutic agents or 
other immunotherapi[INVESTIGATOR_014]/immunomodulators used to treat cancer or other conditions, and 
interventions associated with organ or bone marrow transplantation, or autoimmune 
disease.
14.*Receiv ed any nonlive vaccine ≤ 14 days before receipt of any study vaccine or is 
scheduled to receive any nonlive vaccine ≤ 30 days after receipt of any study vaccine. 
Exception : Inactivated influenza vaccine and SARS- CoV -[ADDRESS_368669] be given ≥7 days before or 
≥15days after receipt of any study vaccine.
15.*Received any live virus vaccine ≤ 30 days before receipt of any study vaccine or is 
scheduled to receive any live virus vaccine ≤ 30 days after receipt of any study vaccine.
16.Received a blood transfusion or blood products, including immunoglobulins ≤[ADDRESS_368670] ≤[ADDRESS_368671]: V116  40
PROTOCOL/AMENDMENT NO.: 007-01
V116 -007-01 FINAL PROTOCOL 06-JUL-2022
Prior/Concurrent Clinical Study Experience
17.Is currently participating in or has participated in an interventional clinical study with an 
investigational compound or device within 2 months of parti cipating in this current study.
Diagnostic Assessments
Not applicable
Other Exclusions
18.In the opi[INVESTIGATOR_871], has a history of clinically relevant drug or alcohol use 
that would interfere with participation in protocol -specified activities.
19.Has history or current evidence of any condition, therapy, lab oratory abnormality, or 
other circumstance that might expose the participant to risk by [CONTACT_6231], 
confound the results of the study, or interfere with the participant’s participation for the 
full duration of the study.
20.Is or has an immediate family member (eg, spouse, parent/legal guardian, sibling, or 
child) who is investigational site or Sponsor staff directly involved with this study.
For items with an asterisk (*), if the participant meets these exclusion criteria, the 
Day 1 Visit (Visit 2) and Day 1B Visit (Visit 9) may be rescheduled for a time when 
these criteria are not met.
Country -specific criteria are included in Appendix 7.
5.[ADDRESS_368672]: V116  41
PROTOCOL/AMENDMENT NO.: 007-01
V116 -007-01 FINAL PROTOCOL 06-JUL-2022
6 STUDY INTERVENTION
Study intervention is defined as any investigational intervention(s), marketed product(s), 
placebo, or me dical device(s) inten ded to be administered to a study participant according to 
the study protoco l.
Clinical supplie s (V116, PCV15, PPSV23, placebo) will be packaged to support enrollment . 
Clinical supplies will be affixed with a clinical label in accordance with regulatory 
requirement s.
6.1 Study Intervention(s) Administered
The study interventions to be used in this study are outlined inTable [ADDRESS_368673]: V116  42
PROTOCOL/AMENDMENT NO.: 007-01
V116 -007-01 FINAL PROTOCOL 06-JUL-2022
Table 1 Study Intervention s
Arm 
Name [CONTACT_123682](s)Dosage 
Level(s)Route 
of 
Admin .Vaccination 
Regimen UseIMP or 
NIMP /
AxMP Sourcing
V116 Experimental Pneumococcal 
21-valent 
conjugate 
vaccineBiological/
VaccineSterile 
Solution 
(Prefilled 
Syringe)4 µg of each PnPs 
antigen (3, 6A, 7F, 
8, 9N, 10A, 11A, 
12F, 15A, 15C, 
16F, 17F, 19A, 20, 
22F, 23A, 23B, 
24F, 31, 33F, and 
35B)0.5 mL IM Single dose 
at Visit 2
(Day 1)Test 
ProductIMP Central
V116 Experimental Placebo (sterile 
saline)Biological/
VaccineSterile 
SolutionN/A 0.5 mL IM Single d ose 
at Visit 5 
(Week 8)Placebo IMP Central 
or local
V116 Experimental Pneumococcal 
15-valent 
conjugate 
vaccineBiological/
VaccineSterile 
Suspension 
(Prefilled 
Syringe)2 µg of each PnPs
antigen (1, 3, 4, 5, 
6A, 7F, 9V, 14, 
18C, 19A, 19F, 
22F, 23F, and 33F) 
and 4 µg of PnPs
antigen 6B0.5 mL IM Single dose 
at Visit 9 
(Day 1B)Test 
ProductIMP Central 
or local
PCV1 5 +
PPSV23Active 
ComparatorPneumococcal 
15-valent 
conjugate 
vaccineBiological/
VaccineSterile 
Suspension 
(Prefilled 
Syringe)2 µg of each PnPs 
antigen (1, 3, 4, 5, 
6A, 7F, 9V, 14, 
18C, 19A, 19F, 
22F, 23F, and 33F) 
and 4 µg of PnPs 
antigen 6B0.5 mL IM Single d ose 
at Visit 2
(Day 1)Comparator IMP Central 
or local
PCV15 + 
PPSV23Active 
ComparatorPneumococcal 
vaccine, 
polyvalent 
(23-valent)Biological/
VaccineSterile 
Solution 
(Prefilled 
Syringe)25 µg of each PnPs 
antigen (1, 2, 3, 4, 
5, 6B, 7F, 8, 9N, 
9V, 10A, 11A, 12F, 
14, 15B, 17F, 18C, 
19A, 19F, 20, 22F, 
23F, and 33F)0.5 mL IM Single dose 
at Visit 5 
(Week 8)Comparator IMP Central
or local
08LGKL
PRODUCT: V116  43
PROTOCOL/AMENDMENT NO.: 007-01
V116 -007-01 FINAL PROTOCOL 06-JUL-2022
Arm 
Name [CONTACT_123682](s)Dosage 
Level(s)Route 
of 
Admin .Vaccination 
Regimen UseIMP or 
NIMP /
AxMP Sourcing
Admin.=administration; IM=intramuscular; IMP=investigational medicinal product; NIMP /AxMP =noninvestigation al/auxiliary medicinal product; N/A=not applicable; 
PCV15= pneumococcal 15 -valent conjugate vaccine ( VAXNEUVANCE™ ); PnPs=pneumococcal polysaccharide; PPSV23= pneumococcal vaccine, polyvalent (23 -valent) 
(PNEUMOVAX™23 ); V116=pneumococcal 21 -valent conjugate vaccine
The classification of IMP and N IMP/AxMP in this table is based on guidance issued by [CONTACT_301793] 
(EEA).Country differences with respect to the definition /classification of IMP and NIMP /AxMP may exist. In these circumstances, local legislation is followed.
08LGKL
PRODUCT:   V116  44
PROTOCOL/AMENDMENT NO.:   007 -01  
V116 -007-01FINAL PROTOCOL 06-JUL-2022
All supplies indicated in Table 1 will be provided per the “Sourcing” column depending on 
local country operational requirements. If local sourcing, e very attempt should be made to 
source these supplies from a single lot/batch number where possible (eg, not applicable in the 
case where multiple lots or batches may be required due to the length of the study, etc).
Refer to Section 8.1.[ADDRESS_368674](s), which is legally marketed, provided for use in this 
study are: VAXNEUVANCE™ prefilled syringes and PNEUMOVAX™23 prefilled 
syringes . Refer to Section 8.4.8 and Appendix 4 for reporting events associated with these 
devices.
6.2 Preparation /Handling/Storage/Accountability
6.2.[ADDRESS_368675] be stored 
in a secure, environmentally controlled, and monitored (manual or automated) area in 
accordance with the labeled storage conditions with access limited to the investigator and 
authorized site staff.
The investigator, institution, or the head of the medical institution (where applicable) is 
responsible for study intervention accountability, rec onciliation, and record maintenance (ie, 
receipt, reconciliation, and final disposition records).
For all study sites, the local country Sponsor personnel or designee will provide appropriate 
documentation that must be completed for drug accountability and return, or local discard 
and destruction if appropriate. Where local discard and destruction is appropriate, the 
08LGKL
PRODUCT:   V116  45
PROTOCOL/AMENDMENT NO.:   [ADDRESS_368676]/destruction procedure is 
documented.
The study site is responsible for recording the lot number, manufacturer, and expi[INVESTIGATOR_19333] (if applicable) as per local guidelines unless otherwise 
instructed by [CONTACT_1034].
The investigator shall take responsibility for and shall take all steps to maintain appropriate 
records and ensure appropriate supply, storage, handling, distribution, and usage of study 
interventions in accordance with the protocol and any applicable laws and regulations.
6.3 Measures to Minimize Bias: Randomization and Blinding
6.3.1 Intervention Assignment
Intervention randomization will occur centrally using an IRT system. There are 2study 
intervention arms. Participants will be assigned randomly in a 1:1ratio to receive either 
V116 +placebo or PCV15 +PPSV23 in Part A .Participants who received V116 in Part A
will receive PCV15 in Part B.
6.3.2 Stratification
Intervention allocation/randomization will be stratified according to the following factors:
•Prior p neumococcal vaccination status:
-PCV1 3 and PPSV23 naïve
-Prior PCV13 only
-Prior PPSV23 only or prior PCV13 and PPSV23
Approximately 50% of participants will be naïve to PCV13 and PPSV23 .
•CD4+ T- cell count at Screening:
-≥50 to <500 cells/μL
-≥500 cells/μL
Pneumococcal vaccine -naïve participants are defined as individuals ≥18 years of age without 
prior receipt of PCV13 and PPSV23. Pneumococcal vaccine -experienced participants are 
defined as individuals ≥18 years of age with prior receipt of ≥1 dose of either PCV13 and/or 
PPSV23.
08LGKL
PRODUCT:   V116  46
PROTOCOL/AMENDMENT NO.:   007 -01  
V116 -007-01FINAL PROTOCOL 06-JUL-2022
Participants with prior receipt of pneumococcal vaccines during childhood will be handled as 
follows:
•Individuals who received PCV7 alone as part of their routine pediatric vaccination 
schedule will be eligible for enrolment and categorized as vaccine -naïve in this study.
•Individuals who received PCV13 as part of their routine pediatric schedule will not be 
eligible for this study as these individuals will be <18 ye ars of age in 2022 (PCV13 was 
approved first in the US in 2010). Individuals with a history of receipt of PCV13 alone , 
PPSV23 alone, or PCV13 and PPSV23 as part of the sequential regimen during later 
childhood or adolescence due to an increased risk of pne umococcal disease and who are 
≥18 years at the time of the study will be eligible and will be categorized as 
pneumococcal vaccine -experienced.
•Individuals who received PCV10 as part of their pediatric vaccination schedule will not 
be eligible for this study as these individuals will be <18 years of age at the time of study 
initiation.
6.3.3 Blinding
Part A
A double -blinding technique with in- house blinding will be used. V116, PCV15, PPSV23, 
and placebo will be prepared and/or dispensed in a blinded fashion by [CONTACT_301794]- site personnel .The participant, the investigator, and Sponsor 
personnel or delegate(s) w ho are involved in theclinical evaluation of the participants are 
unaware of the intervention assignments. 
Because V116, PCV15, PPSV23, and placebo have different appearances, the unblinded 
pharmacist (or qualified study -site personnel) will be responsible for receiving, main taining, 
preparing and/or dispensing, and administering these study vaccines (Section 8.1.8).
To avoid bias, contact [CONTACT_301795] -site personnel and study participants is 
strictly prohibited for any study -related procedures/assessments other than administration of 
study vaccines. Blinded site personnel will be responsible for all other study 
procedures/assessments specified in Section 1.3.1.
An unblinded Clinical Research Associate will monitor vaccine accountability at the study 
site. All ot her Sponsor personnel or delegate(s) directly involved with the conduct of this 
study will remain blinded to the participant- level intervention assignment.
See Section 8.1.13 for a description of the method of unblinding a participant during the 
study should such action be warranted.
Part B
Part B of the study is open -label; therefore, the Sponsor, investigator, and participant will be 
aware that PCV15 is administered.
08LGKL
PRODUCT:   V116  47
PROTOCOL/AMENDMENT NO.:   007 -01  
V116 -007-01FINAL PROTOCOL 06-JUL-2022
6.4 Study Intervention Compliance
Interruptions from the protocol -specified vaccination plan require consultation between the 
investigator and the Sponsor and written documentation of the collaborative decision on 
participant management.
6.5 Concomitant Therapy
Medications or vaccinations specifically prohibited in the exclusion criteria are not allowed
during the ongoing study (Section 5.2) . If there is a clinical indication for any m edications or 
vaccinatio nsspecifically prohibited, di scontinuation from study intervention may be 
required. The investigator should discuss any questions regarding this with the Sponsor
Clinical Director . The final decision on any supportive therapy or vaccination rests with the 
investigator and/or the participant ’s primary physician. However, the decision to continue the 
participant on study intervention requires the mutual agreement of the investigator, the 
Sponsor, and the participant.
It is important to record the use of any analgesic or antipyretic medication that occurs on the 
day of vaccination on the eVRC and appropriate eCRF.
Listed below are specific restric tions for concomitant therapy or vaccination:
•Administration of a nonstudy pneumococcal vaccine is prohibited during the study.
•Nonstudy vaccines may only be administered before or after the receipt of study vaccines 
according to the time frames specified in the Exclusion Criteria (Section 5.2).
•Receipt of systemic corticosteroids (prednisone equivalent ≥20 mg/day ) for 
≥14consecutive days is prohibited from 14 days before each vaccination through 30 days 
following each vaccination. Note : Physiologic replac ement doses (prednisone equivalent 
of approximately 5 mg/day), topi[INVESTIGATOR_2855] , ophthalmic, intraarticular or soft -tissue (eg, bursa, 
tendon steroid injections), and inhaled/nebulized steroids are permitted.
Any deviation from the above requires consultation between the investigator and the Sponsor 
and written documentation of the collaborative decision on participant management.
Use of prior and concomitant medications/vaccinations should be recorded as described in
Section 8.1.5.
Country -specific requirements for concomitant therapy are included in Appendix 7.
6.5.[ADDRESS_368677]:   V116  48
PROTOCOL/AMENDMENT NO.:   007 -01  
V116 -007-01FINAL PROTOCOL 06-JUL-2022
6.7 Intervention After the End of the Study
There is no study -specified intervention after the end of the study.
6.8 Clinical Supplies Disclosure
Part A
Part A of the study is blinded but supplies are provided as open label ; therefore, an unblinded 
pharmacist or qualified study- site personnel will be used to blind supplies. Study intervention
identity (name, strength, or potency) is included in the label text; random code/disclosure 
envelopes or lists are not provided.
The emergency unblinding call c enter will use the intervention/randomization schedule for 
the study to unblind participants and to unmask study intervention identity. The emergency 
unblinding call center should only be used in cases of emergency (see Section 8.1.13 ). Ifthe 
emergency un blinding call center is not available for a given site in this study, the central 
electronic intervention randomization system (IRT) should be used to unblind participants 
and to unmask study intervention identity. The Sponsor will not provide random 
code/ disclosure envelopes or lists with the clinical supplies.
See Section 8.1.13 for a description of the method of unblinding a participant during the 
study, should such action be warranted.
Part B
Part B of the study is open -label; therefore, the participant , the study -site personnel, the 
Sponsor, and/or designee are not blinded. Study intervention (name, strength, or potency) is 
included in the label text ;random code/disclosure envelopes or lists are not provided .
6.[ADDRESS_368678] be collected through the participant’s last scheduled follow -
up, even if the participant has discontinued study intervention. Therefore, a ll participants 
who discontinue study intervention before completion of the protocol -specified vaccination 
regimen will still continue to participate in the study as specified in Section s1.3.[ADDRESS_368679]:   V116  49
PROTOCOL/AMENDMENT NO.:   [ADDRESS_368680] 
occur. In addition, a participant may be discontinued from study intervention by [CONTACT_19419], the study plan is violated, or 
for administrative and/or other safety reasons. Specific details regarding procedures to be 
performed at study intervention discontinuation are provided in Section 8.1. 12and 
Section 8.12.3.
A participant must be discontinued from study intervention ,but continue to be monitored in 
the study, for any of the following reasons:
•The participant or participant’s legally acceptable representative requests to discontinue 
study interve ntion.
•The participant has a medical condition or personal circumstance which, in the opi[INVESTIGATOR_19348]/or Sponsor, placed the participant at unnecessary risk from continued 
administration of study intervention.
•The participant has a confirme d positive urine or serum pregnancy test before vaccination 
at Visit 5 (Week 8) in Part A and/or before vaccination at Visit 9 (Day 1B) in Part B .
7.[ADDRESS_368681] be withdrawn from the study if the participant or pa rticipant’s legally 
acceptable representative withdraws consent from the study.
If a participant withdraws from the study, they will no longer receive study intervention or be 
followed at scheduled protocol visits.
Specific details regarding procedures to be performed at the time of withdrawal from the 
study, as well as specific det ails regarding withdrawal from FBR ,are outlined in 
Section 8.1.12 . The procedures to be performed should a participant repeatedly fail to return 
for scheduled visits and/or if the study site is unable to contact [CONTACT_88683] 7.3.
7.[ADDRESS_368682] t o Follow -up
If a participant fails to return to the clinic for a required study visit and/or if the site is unable 
to contact [CONTACT_2299], the following pr ocedures are to be performed:
•The site must attempt to contact [CONTACT_19423]. If the 
participant is contact[INVESTIGATOR_530], the participant should be counseled on the importance of 
maintaining the protocol -specified visit schedule.
•Theinvestigator or designee must make every effort to regain contact [CONTACT_19424] (eg, telephone calls and/or a certified letter to the participant’s last 
known mailing address or locally equivalent methods). These contact [CONTACT_301796]’s medical record.
08LGKL
PRODUCT:   V116  50
PROTOCOL/AMENDMENT NO.:   007 -01  
V116 -007-01FINAL PROTOCOL 06-JUL-2022
•Note: A participant is not considered lost to follow -up until the last scheduled visit for the 
individual participant. The missing data for the participant will be managed via the 
prespecified st atistical data handling and analysis guidelines .
8 STUDY ASSESSMENTS AND PROCEDURES
•Study procedures and their timing are summarized in the SoA.
•Adherence to the study design requirements, including those specified in the SoA, is 
essential and required for study conduct.
•The investigator is responsible for ensuring that procedures are conducted by 
[CONTACT_19426] (by [CONTACT_8640], training, and experience) staff. Delegation of 
study- site personnel responsibilities will be docu mented in the Investigator Trial File 
Binder (or equivalent).
•All study- related medica l decisions must be made by [CONTACT_19427] a qualified 
physician.
•All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility criteria. The investigator will maintain a screening log to 
record details of all participants screened and to confirm eligibility or record reasons for 
screening failure, as applicable.
•Procedures conducted as part of the participant’s routine clinical management (eg, blood 
count) and obtained before signing of ICF may be u sed for screening or baseline purposes 
provided the procedure met the protocol -specified criteria and were performed within the 
time frame defined in the SoA.
•Additional eval uations/testing may be deemed necessary by [CONTACT_88686]. In some cases, such evaluation/testing 
may be potentially sensitive in nature (eg, HIV, hepatitis C), and thus local regulations 
may r equire that additional informed consent be obtained from the participant. In these 
cases, such evaluations/testing will be performed in accordance with those regulations.
In Part A, t he maximum amount of blood collected from each participant at each visit will 
not exceed 78.5 mL, and the total amount of blood collected over the duration of Part A will 
not exceed 246.5 mL(Table 2).For participants who enter Part B, a max imum of additional 
196mL blood will be collected ( Table 3).
Repeat or unscheduled samples may be taken for safety reasons or for technical issues with 
the samples.
08LGKL
PRODUCT:   V116  51
PROTOCOL/AMENDMENT NO.:   007 -01  
V116 -007-01FINAL PROTOCOL 06-JUL-2022
Table 2 Approximate Blood Volumes Drawn by [CONTACT_301797] 1
(Screening)Visit 2
(Day 1)Visit 4
(Day 30)Visit 7
(Week 12)
Parameter Approximate Blood Volume (mL)
Blood sample for HIV serology 4 mL N/A N/A N/A
Blood sample for CD4+ T -cell 
count2 mL N/A 2 mL 2 mL
Blood sample for plasma HIV 
RNA testing6 mL N/A 6 mL 6 mL
Immunogenicity assessment N/A 30 mL 30 mL 30 mL
DNA for FBRaN/A 8.5 mL N/A N/A
Assay developmentaN/A 40 mL 40 mL 40 mL
Expected total (mL) 12 mL 78.5 mL 78 mL 78 mL
DNA=deoxyribonucleic acid; FBR=future biomedical research; HIV=human immunodeficiency virus; 
N/A=not applicable; RNA=ribonucleic acid
aSamples for FBR and assay development will only be obtained from participants who provide separate 
consent for collection of these optional samples.
Table 3 Approximate Blood Volumes Drawn by [CONTACT_301798] 9
(Day 1B )Visit 11
(Day 30B )
Parameter Approximate Blood Volume (mL)
Blood sample for CD4+ T -cell count 2 mL 2 mL
Blood sample for plasma HIV RNA testing 6 mL 6 mL
Immunogenicity assessmenta50mL 50mL
Assay developmentb40mL 40mL
Expected total (mL) 98 mL 98 mL
HIV=human immunodeficiency virus; MOPA=Multiplexed Opsonophagocytic Assay; Pn 
ECL= pneumococcal electrochemiluminescence ; RNA= ribonucleic acid
a30 mL blood for V116 MOPA and Pn ECL assay; [ADDRESS_368683]:   V116  52
PROTOCOL/AMENDMENT NO.:   007 -01  
V116 -007-01FINAL PROTOCOL 06-JUL-2022
8.1 Administrative and General Procedures
8.1.1 Informed Consent
The investigator or medically qualified designee (consistent with local requirements) must 
obtain documented informed consent from each potential participant (or their legally 
acceptable representative ) prior to participating in thisclinical study or FBR .If there are 
changes to the participant’s status during the study (eg, health or age of majority 
requirements), the investigator or medically qualified designee must ensure the appropriate 
documented informed consent is in place.
[IP_ADDRESS] General Informed Consent
Informed c onsent given by [CONTACT_19429] a consent form . The form must include the study protocol number, study 
protocol title, dated signature , and agreement of the participant ( orhis/her leg ally acceptable 
representative ) and of the person conducting the consent discussion.
A copy of the signed and dated informed consent form should be given to the participant (or 
their legally acceptable representative) before participation in the study.
The initial ICF, any subsequent revised ICF, and any written information provided to the 
participant must receive the IRB /IEC’s approval/favorable opi[INVESTIGATOR_19349]. The 
participant or his/her legally acceptable representative should be informed in a timely manner 
if new information becomes available that may be relevant to the participant’s willingness to 
continue p articipation in the study. The communication of this information will be provided 
and documented via a revised consent form or addendum to the original consent form that 
captures the participant’s or the participant’s legally acceptable representative’s da ted 
signature.
Specifics about the study and the study population are to be included in thestudy informed
consent form.
Informed consent will adhere to IRB/IEC requirements, applicable laws and regulations, and 
Sponsor requirements .
[IP_ADDRESS] Consent and Collection of Specimens for Future Biomedical Research
The investigator or medically quali fied designee will explain the FBR consent to the 
participant, or the participant’s legally acceptable representative, answer all of his/her 
questions, and obtain documented informed consent before performin g any procedure related 
to FBR. A copy of the informed consent will be given to the participant before performing 
any procedure related to FBR .
[IP_ADDRESS] Consent and Collection of Specimens for Optional Assay Development
The investigat or or medically qualified designee will explain the consent for the optional 
assay development blood samples to the participant, answer all of their questions, and obtain 
08LGKL
PRODUCT:   V116  53
PROTOCOL/AMENDMENT NO.:   007 -01  
V116 -007-01FINAL PROTOCOL 06-JUL-2022
documented informed consent before performing any procedure related to the optional a ssay 
development blood samples collection. A copy of the informed consent will be given to the 
participant.
8.1.2 Inclusion/Exclusion Criteria
All inclusion and exclusion criteria will be reviewed by [CONTACT_093] ,who is a qualified 
physician, to ensure that the participant qualifies for the study.
8.1.[ADDRESS_368684] information (including direct 
telephone numbers) to be used in the event of an emergency. The investigator or qualified 
designee will provide the participant with a participant identification card immediately after 
the participant provides documented informed consent . At the time of intervention
randomization, site personnel will add the treatment /randomization number to the participant 
identification card.
The participant IDcard also contains contact [CONTACT_93307] a hea lthcare provider can obtain information about study intervention in 
emergency situations where the investigator is not available.
8.1.4 Medical History
A medical history will be obtained by [CONTACT_27404]. The participant’s 
relevant medi cal history for the 5 years before Day 1 will be obtained to ensure that the 
participant satisfies the inclusion and exclusion criteria of the study. History of tobacco use 
will be collected for all participants .
8.1.5 Prior and Concomitant Medications Revi ew
[IP_ADDRESS] Prior Medications
The investigator or qualified designee will review prior medications and vaccinations taken 
by [CONTACT_301799] 1 (Screening) ,Visit 2 (Day 1) ,and Visit 9 (Day 1B) to ensure 
the participant satisfies the inclusion and exclusion criteria.
The following must be recorded in the participant’s source documents and on the appropriate 
eCRF before the first vaccination in Part A and before vaccination in Part B:
Prior medications and vaccinations taken by [CONTACT_78772] 30 days before study 
vaccination at Visit 2and Visit 9
Receipt of any pneumococcal vaccine and current ART regardless of timing prior to
Visit 2and Visit [ADDRESS_368685]:   V116  54
PROTOCOL/AMENDMENT NO.:   007 -01  
V116 -007-01FINAL PROTOCOL 06-JUL-2022
Any analgesic or antipyretic medication taken on the day of vaccination before 
vaccination at Vis it 2 and Visit 9
[IP_ADDRESS] Concomitant Medications
The investigator or qualified designee will record vaccinations and medication s, if any, taken 
by [CONTACT_93308].
Any analgesic or antipyretic medication taken must be recorded on the eVRC and 
appropriate eCRF.
The participant will use their eVRC (Section 8.1.9) to record new and/or concomitant 
medications taken and nonstudy vaccines received from the day of each vaccination through 
[ADDRESS_368686] not be re used for 
different participants.
Any participant who is screened multiple times will retain the original screening number 
assigned at the initial Screening V isit. Specific details on the screening/rescreening visit 
requirements are in Section 8.12.1.
8.1.7 Assignment of Treatment/Randomization Number
All eligible participants will be randomly allocated and will receive a 
treatment /randomization number. The treatment/randomization number identifies the 
participant for all procedures occurring after treatment rando mization . Once a 
treatment /randomization number is assigned to a participant, it can never be reassigned to 
another participant.
A single participant cannot be assigned more than 1 treatment /randomization number.
8.1.8 Study Intervention Administrati on
For Part A only: Unblinded study personnel will prepare and administer study vaccines 
(Section 6.3.3). The unblinded study personnel who administer study vaccines should not 
have contact [CONTACT_301800] -related procedures/assessments.
Blinded site personnel will not be present in the examination room when study vaccines are 
administered.
Study vaccines should be prepared and administered by [CONTACT_93310] (eg, physician, nurse, physician’s assistant, nurs e practitioner, 
pharmacist, or medical assistant) as allowed by [CONTACT_5737]/state, country, and institutional 
08LGKL
PRODUCT:   V116  55
PROTOCOL/AMENDMENT NO.:   007 -01  
V116 -007-01FINAL PROTOCOL 06-JUL-2022
guidance. Procedures for handling, preparing, and administering study vaccines are provided 
in the Investigator Trial File Binder.
Study vaccine will be administered as a single IM injection, preferably in the deltoid region 
of the participant’s arm, according to the schedule specified in Section s1.3.[ADDRESS_368687] ,should be ava ilable for immediate use should an anaphylactic or anaphylactoid 
reaction occur [Centers for Disease Control and Prevention 2015] .
[IP_ADDRESS] Timing of Dose Administration
Study vaccines will be administered as indicated i n Sections 1.3.[ADDRESS_368688] 30 minutes after vaccination for any immediate 
reactions (Section 8.3. 5). This observation must be performed by [CONTACT_301801] A (Section 6.3.3).
Participants must not have a fever reported within 72 hours before vaccination 
(Section s1.3.1, 1.3.2, and 8.3. 4).
Administration of pregnancy tests (if applicable) must be performed before vaccine 
administration.
The collection of blood samples should be performed before vaccine administration.
8.1.[ADDRESS_368689]
The eVRC is structured as recommended in the final FDA Patient -reported Outcome 
Guidance [U.S. Food and Drug Administration 2009] .
The participant will use the eVRC to record body temperature (Section 8.3. 4), solicited 
injection- site AEs, and solicited systemic AEs (Section [IP_ADDRESS]). Unsolicited AEs 
(Section [IP_ADDRESS]), concomitant medications (including use of any analgesic or antipyretic 
medication), and nonstudy vaccinations (Section [IP_ADDRESS]) will also be reported. Participants 
will be provided an electronic device or have their own electronic device configur ed, if 
compatible, to complete the eVRC.
The investigator or delegate will review the data captured on the eVRC with the participant 
as indicated in Sections 1.3.[ADDRESS_368690] be clearly explained 
in the participant’s source document s.
8.1.[ADDRESS_368691] the participant (or the participant’s legally acceptable 
representative, as applicable ) as indicated in Section 1.3.[ADDRESS_368692]:   V116  56
PROTOCOL/AMENDMENT NO.:   007 -01  
V116 -007-01FINAL PROTOCOL 06-JUL-2022
from this discussion will include SAEs and/or any updates to previously reported safety 
information.
8.1.11 Confirmation of Eligibility in Part B
Upon database lock and unblinding of Part A, site personnel and participants will be notified 
of intervention assignment received in Part A.
Participants who received V116 alone or V116 + placebo in Part A (regardless of 
intervention group assigned) are eligible to return to the site for participation in Part B.
All e xclusion criteria in Section 5.2 will be reviewed by [CONTACT_301802] 9 (Day 1B)
before receipt of study vaccine to ensure that the participant qualifies for Part B of the study.
8.1.12 Discontinuation and Withdrawal
Participants who discontinue study intervention before completion of the vaccination 
regimen should be encouraged to continue to be followed for all remaining study visits as 
outlined in the SoA and Section 8.1 2.3.
Participants who withdraw from the study should be encouraged to complete all applicable 
activities scheduled for the laststudy visit in Part A or the final study visit in Part B as 
applicable at the time of withdrawal. Any AEs that are present at the time of withdrawal 
should be followed in accordance with the safety requirements outlined in Section 8.4.
[IP_ADDRESS] Withdrawal From Future Biomedical Resear ch
Participants may withdraw their consent for FBR . Participants may withdraw consent at any 
time by [CONTACT_88690]. If medical records for the study are still available, 
the investigator will contact [CONTACT_75355] 
(clinical.specimen.management@ MSD .com). Subse quently, the participant’s consent for 
FBR will be withdrawn. A letter will be sent from the Sponsor to the investigator confirming 
the withdrawal. It is the responsibility of the investigator to inform the participant of 
completion of withdrawal. Any anal yses in progress at the time of request for withdrawal or 
already performed before the request being received by [CONTACT_88691]. No new analyses would be generated 
after the reque st is received.
If the medical records for the study are no longer available (eg, if the investigator is no longer 
required by [CONTACT_88692]) or the specimens have been 
completely anonymized, there will no longer be a l ink between the participant’s personal 
information and their specimens. In this situation, the request for specimen withdrawal 
cannot be processed .
08LGKL
PRODUCT:   V116  57
PROTOCOL/AMENDMENT NO.:   007 -01  
V116 -007-01FINAL PROTOCOL 06-JUL-2022
8.1.13 Participant Blinding/Unblindi ng
Part A
STUDY INTERVENTION IDENTIFICATION INFORMATION IS TO BE UNMASKED 
ONLY IF NECESSARY FOR THE WELFARE OF THE PARTICIPANT. EVERY 
EFFORT SHOULD BE MADE NOT TO UNBLIND.
For emergency situations where the investigator or medically qualified designee (consistent 
with local requirements) needs to identify the interventi on used by a participant and/or the 
dosage administered , he/she will contact [CONTACT_88693] a request for emergency unblinding. As requested by [CONTACT_19445], the emergency unbl inding call center will provide the information to 
him/her promptly and report unblinding to the Sponsor. Before contact[CONTACT_88694] a participant’s intervention assignment, the 
investigator who is a qua lified physician should make reasonable attempts to enter the
intensity grade of the AEs observed, the relation to study intervention, the reason thereof , etc, 
in the medical record. If it is not possible to record this assessment in the medical record 
before the unblinding, the unblinding should not be delayed.
If unblinding has occurred, the circumstances around the unblinding (eg, date, reason, and 
person performing the unblinding) must be documented promptly, and the Sponsor Clinical 
Director notified a s soon as possible.
Once an emergency unblinding has taken place, the investigator, site personnel, and Sponsor 
personnel may be unblinded so that the appropriate follow -up medical care can be provided 
to the participant.
Participants whose treatment assignment has been unblinded by [CONTACT_93311]/or nonstudy treating physician should continue to be monitored in the 
study. Participants may receive study intervention at Visit 5(Week 8) after a benefit/risk 
assessment an d consultation between the investigator/delegate and Sponsor.
Additionally, the investigator or medically qualified designee must go into the IRT system 
and perform the unblind in the IRT system to update drug disposition. I fthe emergency 
unblinding call center is not available for a given site in this study, the IRT system should be 
used for emergency unblinding i fthis is required for participant safety.
Part B
Part B of the study is open -label; there is no blinding. The emergency unblinding call center 
will be available so that a health care provider can obtain information about study 
intervention in emergency situations where the investigator is not available.
08LGKL
PRODUCT:   V116  58
PROTOCOL/AMENDMENT NO.:   007 -01  
V116 -007-01FINAL PROTOCOL 06-JUL-2022
8.1.14 Calibration of Equipme nt
The investigator or qualified designee has the responsibility to ensure that any device or 
instrument used for a clinical evaluation/test during a clinica l study that provides information 
about inclusion/exclusion criteria and/or safety or efficacy parameters shall be suitably 
calibrated and/or maintained to ensure t hat the data obtained are reliable and/or reproducible. 
Documentation of equipment calibration must be retained as source documentation at the 
study sit e.
8.2 Immunogenicity Assessmen ts
Sera from participants will be used to measure vaccine -induced OPA and IgG responses. 
These endpoints will be tested for all immunogenicity blood draws specified in 
Sections 1.3.1 and 1.3.2 . Blood collection, storage, and shipment instructions for serum 
samples will be provided in the operations/laboratory manual.
The MOPA will be used for measuring OPA responses. Opsonization of pneumococci for 
phagocytosis is an important mechanism by [CONTACT_301803]. The OPA assay is a useful tool for assessing the protective function 
of sero type-specific antibodies and, therefore, the immunogenicity of pneumococcal vaccine 
formulations.
Serotype -specific IgG will be measured using the Pn ECL assay to assess the concentration 
of binding antibodies to capsular polysaccharide of S pneumoniae .
After completion of immunogenicity testing to evaluate the study objectives, serum samples 
will be stored to conduct any additional study -related testing as requested by [CONTACT_63503]. For participants who provide optional consent for FBR, leftover sera 
from the study may be used for other purposes, such as the development and/or validation of 
pneumococcal assays after completion of all study- related immunogenicity testing.
8.2.1 Multiplex Opsonophagocytic Assay
The MOPA is an antibody- mediated killing assay that measures the ability of human serum 
to kill S pneumoniae serotypes with the help of complement and phagocytic effector cells 
[Burton, Robert L. and Nahm, Moon H. 2006] . The ability of the assay to simultaneously test 
[ADDRESS_368693] dilution that gives ≥50% 
bacterial killing, as determined by [CONTACT_93313]. The MOPA for 
V116 and PCV15 have been validated for various performance parameters of the assay 
including precision, ruggedness, relative accuracy/dilutional linearity, and the limit of 
detection of the assay.
MOPA for V116
The Sponsor has developed and optimized the MOPA in a high -throughput microcolony 
platform, which not only covers all [ADDRESS_368694]:   V116  59
PROTOCOL/AMENDMENT NO.:   007 -01  
V116 -007-01FINAL PROTOCOL 06-JUL-2022
15B so that antibodies induced by [CONTACT_93314] 6A and 15C but cross -reactive to 
serotypes 6C and 15B, respectively, can be measured.
MOPA for PCV15
The Sponsor has also developed and optimized the MOPA in a high -throughput microcolony 
platform, which covers all 15 serotypes in PCV15.
8.2.2 Pneumococcal Electroc hemiluminescence Assay
The Sponsor has developed, optimized, and validated a multiplex, ECL-based detection 
method for the quantitation of IgG serotype -specific antibodies. The ECL assay is based on 
the Meso -Scale Discovery technology, which employs dispos able multispot microtiter plates. 
Briefly, PnPs are bound to the surface of 96 -well 10 plex carbon microplates, and serum 
containing purported anti -PnPs antibodies is added. The anti -PnPs antibodies bind to the 
coated plates and form an antibody -antigen complex. The bound antibody -antigen complex 
can be detected using a ruthenium labeled anti- human IgG. Plates are read by [CONTACT_301804] s of the microplates.  
 
Assay validation studies showed excellent 
performance opera ting characteristics for precision (intra -and interassay), dilutability, 
ruggedness (to different plate lots and analysts), relative accuracy, and specificity.
ECL for V116
This multiplexed ECL assay not only detects all 21 serotypes contained in V116 but also 
detects serotypes 6C and 15B so that antibodies induced by [CONTACT_93314] 6A and 15C
but cross -reactive to serotypes 6C and 15B, respectively, can be measured.
ECL for PCV15
The ECL assay for PCV15 detects all 15 serotypes contained in PCV15.
8.3 Safety Assessments
Details regarding specific safety procedures/assessments to be performed in this study are 
provided below .
Planned time points for all safety assessments are provided in the SoA.
8.3.1 Physical Examinations
A complete physical examination and a brief directed physical examination will be 
conducted by [CONTACT_19444] (consistent with local 
requirements) per institutional standard before vaccination as indicated in Sections 1.3.[ADDRESS_368695]:   V116  60
PROTOCOL/AMENDMENT NO.:   [ADDRESS_368696] consistent with local requirements (sensitive to at l east 25 IU hCG) must be 
performed before vaccination in WOCBP as indicated in Sections 1.3.[ADDRESS_368697] be negative before vaccination can occur. 
A detailed definition of WOCBP is provided in Appendix 5.
•Pregnancy testing:
-Pregnancy testing requirements for study inclusion are described in Section 5.1.
-Additional serum or urine pregnancy tests may be performed, as determined 
necessary by [CONTACT_31837], to establish the ab sence 
of pregnancy at any time during the subject's participation in the study.
8.3.3 HIV Serology, CD4+ T -cell C ount, and Plasma HIV RNA Testing
Serum for assessment of HIV serology and a blood sample for CD4+ T -cell count and 
plasma HIV RNA testing will be col lected at Visit 1 (Screening) to confirm inclusion criteria 
related to HIV infection. Additionally, blood sample sfor CD4+ T- cell count and plasma HIV 
RNA testing will be collected as indicated in Sections 1.3.1 and 1.3.2.
8.3.4 Body Temperature Measurement
Each participant’s body temperature must be taken by [CONTACT_3449] -site staff before vaccination as 
described in Sections 1.3.1 and 1.3.2. The prevaccination temperature should be documented 
in the participant’s source documents. Participants who have febrile illness (defined as oral or 
tympanic temperature ≥100.4°F [≥38.0°C]; axillary or temporal temperature ≥99.4°F 
[≥37.4°C]) <[ADDRESS_368698] oral body temperature measurements using the eVRC 
(Sect ion8.1.9) from Day [ADDRESS_368699]:   V116  61
PROTOCOL/AMENDMENT NO.:   [ADDRESS_368700] of clinical laboratory tests to be performed and to the SoA for 
the timing and frequency.
•The investigator or medically qualified designee (consistent with local requirements) 
must review the laboratory report, document this review , and record any clinically 
relevant changes occurring during the study in the AE section of the CRF. The laboratory 
reports must be filed with the source documents. Clinically significant abnormal 
laboratory findings are those which are not associated wit h the underlying disease, unless 
judged by [CONTACT_19448] ’s condition.
•All protocol -required laboratory assessments, as defined in Appendix [ADDRESS_368701] be 
conducted in accordance with the laboratory manual and the SoA .
•If laboratory values from nonprotocol -specified laboratory assessments performed at the 
institution’s local laboratory require a change in study participant management or are 
considered clinically significant by [CONTACT_093] (eg, SAE or AE or dose 
modification), then the results must be recorded in the appropriate CRF (eg, SLAB).
•For any laboratory tests with values considered clinically significantly abnormal during 
participation in the study or within [ADDRESS_368702] dose of study intervention, 
every attempt should be made to perform repeat assessments until the values return to 
normal or baseline or if a new baseline is established as determined by [CONTACT_093] .
8.4 Adverse Events , Serious Adverse Events ,and Other Reportable Safety Events
The definitions of an AE or SAE, as well as the method of recording, evaluating, and 
assessing causality of AE and SAE and the procedures for completing and transmitting AE, 
SAE, and other reportable safety event reports can be found in Appe ndix 3.
Adverse events, SAEs, and other reportable safety events will be reported by [CONTACT_2299] 
(or, when appropriate, by a caregiver, surrogate, or the participant's legally authorized 
representative).
The investigator and any designees are responsible for detecting, documenting, and reporting 
events that meet the definition of an AE or SAE as well as other reportable safety events . 
Investigators need to document if an SAE was associated with a medication error, misuse, or 
abuse. Investigators remain responsible for following up AEs , SAEs, and other reportable 
safety events for outcome according to Section 8.4.3.
The investigator, who is a qualified physician, will assess events that meet the definition of 
an AE o r SAE as well as other reportable safety events with respect to seriousness, 
intensity/toxicity and causality .
08LGKL
PRODUCT:   V116  62
PROTOCOL/AMENDMENT NO.:   [ADDRESS_368703] be reported by [CONTACT_93316], or are the result of a 
protocol -specified intervention, including, but not limited to washout or discontinuation of 
usual therapy, diet, placebo, or a procedure.
All nonserious AEs and other reportable safety events (excluding pregnancy and lactation 
exposure) must be reported by [CONTACT_301805] [ADDRESS_368704] be reported by [CONTACT_1275] 1) from the day of ra ndomization through 6 weeks after the final vaccination in 
Part A, and 2) from the day of vaccination through [ADDRESS_368705] be reported by [CONTACT_301806] 6 months of initial vaccination (Day 1) in Part A and through [ADDRESS_368706] be reported immediately to the Sponsor if 
the event is either:
•A death that occurs before the participant completes the study.
OR
•An SAE that is considered by [CONTACT_2413] ,who is a qualified physician ,to be vaccine 
related.
Investigators are not obligat ed to actively seek AE sor SAEs or other reportable safety events 
in former study participants. However, if the investigator learns of any SAE, including a 
death, at any time after a participant has been discharged from the study, and the investigator 
considers the event to be reasonabl y related to the study intervention or study participation, 
the investigator must promptly notify the Sponsor.
All initial and follow -up AEs, SAEs, and other reportable safety events will be recorded and 
reported to the Sponsor or designee within the time frames as indicated in Table 4 .
Exception: A positive pregnancy test at the time of initial screening is not a reportable event 
unless the participant has received st udy intervention.
08LGKL
PRODUCT:   V116  63
PROTOCOL/AMENDMENT NO.:   007 -01  
V116 -007-01FINAL PROTOCOL 06-JUL-2022
Table 4 Reporting Time Periods and Time Frames for A dverse Events and Other 
Reportable Safety Events
Type of EventReporting Time Period:
Consent to 
Randomization/ 
AllocationReporting Time 
Period:
Randomization/ 
Allocation through 
Protocol -specified 
Follow -up PeriodReporting Time 
Period:
After the 
Protocol -
specified Follow -
up PeriodTime Frame to 
Report Event 
and Follow- up 
Information to 
Sponsor:
NSAE Report if:
-due to protocol -
specified interve ntion
-causes exclusion
-participant is receiving 
placebo run -in or other 
run-in treatmentReport all Not required Per data entry 
guidelines
SAE Report if:
-due to protocol -
specified intervention
-causes exclusion
-participant is receiving 
placebo run -in or other 
run-in treatmentReport all Report if:
-drug/vaccine 
related.
-any death until 
participant 
completion of 
study
(Follow ongoing 
to outcome)Within 24 hours 
of learning of 
event
Pregnancy/
Lactation 
ExposureReport if:
-participan t has been 
exposed to any protocol -
specified intervention 
(eg, procedure, washout 
or run -in treatment 
including placebo run -in)
Exception: A positive 
pregnancy test at the time 
of initial screening is not 
a reportable event.Report all Previously 
reported – Follow 
to completion/
termination; report 
outcomeWithin 24 hours 
of learning of 
event
ECI (require 
regulatory 
reporting)Report if:
-due to intervention
-causes exclusionReport
-Potential DILI
-Require regulatory 
reportingNot required Within 24 hours 
of learning of 
event
ECI (do not 
require 
regulatory 
reporting)Report if:
-due to intervention
-causes exclusionReport
-non-DILI ECIs and 
those not requiring 
regulatory reportingNot required Within 5 
calendar days of 
learning of event
Cancer Report if:
-due to intervention
-causes exclusionReport all Not required Within 5 
calendar days of 
learning of event
(unless serious)
Overdose Report if:
-receiving placebo run -in 
or other run -in 
medication Report all Not required Within 5 
calendar days of 
learning of event
DILI=drug -induced liver injury; ECI=event of clinical interest; NSAE=nonserious adverse event; SAE=serious adverse 
even t.
08LGKL
PRODUCT:   V116  64
PROTOCOL/AMENDMENT NO.:   007 -01  
V116 -007-01FINAL PROTOCOL 06-JUL-2022
8.4.2 Method of Detecting AE s, SAE s,and Other Reportable Safety Events
Care will be taken not to introduce bias when detecting AE sand/or SAEs and other 
reportable safety events. Open- ended and nonleading verbal questioning of the participant is 
the preferred m ethod to inquire about AE occurrence.
8.4.3 Follow -up of AE, SAE ,and Other Reportable Safety Event Information
After the initial AE/SAE report, the investigator is required to proactively follow each 
participant at subsequent visits/contacts. All AE s, SAE s, and other reportable safety events,
including pregnancy and exposure during breastfeeding, ECI s, cancer, and overdose will be 
followed until resolution, stabilization, until the event is otherwise explained, or the 
participant is lost to follow -up (as defined in Section 7.3). In addition, the investigator will 
make every attempt to follow all nonserious AEs that occur in randomized participants for 
outcome. Further information on follow -up procedures is given in Appendix 3.
8.4.4 Regulatory Reporting Requirements for SAE
Prompt notification (within 24 hours) by [CONTACT_88701] a study intervention under clinical investigat ion are met.
The Sponsor has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about the safety of a study intervention under clinical investigation. The 
Sponsor will comply w ith country -specific regulatory requirements and global laws and 
regulations relating to safety reporting to regulatory authorities , IRB/IECs, and investigators.
Investigator safety reports must be prepared for S[LOCATION_003]R saccording to local regulatory 
requirements and Sponsor policy and forw arded to investigators as necessary.
An investigator who receives an investigator safety report describing an SAE or other 
specific safety information (eg, summary or listing of SAE) from the Sponsor will file it 
along with the I Band will notify the IRB/I EC, if appropriate according to local requirements .
8.4.5 Pregnancy and Exposure During Breastfeeding
Although pregnancy and infant exposure during breastfeeding are not considered AEs, any 
pregnancy or infant exposure during breastfeeding in a participant (spontaneously reported to 
the investigator or their designee) that occurs during the study are reportable to the Sponsor.
All reported pregnancies must be followed to the completion/termination of the pregnancy.
Any pregnancy complication will be reported as an AE or SAE.
The medical reason (example: maternal health or fetal disease) for an elective termination of 
a pregnancy will be reported as an AE or SAE. Prenatal testing showing fetus will be born 
with severe abnormalities/congenital anoma lies that leads to an elective termination of a 
pregnancy will be reported as an SAE for the fetus.
08LGKL
PRODUCT:   V116  65
PROTOCOL/AMENDMENT NO.:   [ADDRESS_368707] be reported as serious events (Important Medical Events). If the pregnancy continues to 
term, the outcome (health of infant) must also be reported.
8.4.6 Disease -related Events and/or Disease -related Outcomes Not Qualifying as 
AEs or SAEs
Not applicable for this study.
8.4.[ADDRESS_368708]
There are no ECIs for this study.
8.4.8 Medical Device and Drug- device Combination Products -PQCs/Malfunctions
The method of documenting and reporting of such events (Complaint s associated with 
medical devices including PQCs/malfunctions )will occur as below and in Appendix 4.
Tofulfill regulatory reporting obligations worldwide, medical device information associated 
with AEs will be collected and reported to the Sponsor in the same time frame as AEs per
Section 8.4.1 via CRF (paper or electronic) and as per data entry guidelines.
PQCs/malfunctions includi ng those that involve a participant or any user/associated person 
must be reported to the Sponsor. Sponsor shall review repor ted events by [CONTACT_301807]- device combination 
products being used in clinical s tudies.
The investigator is responsible for ensuring that follow- up includes any supplemental 
investigations as indicated to elucidate the nature and/or causality between the AE and the 
medical device or device constituent of combination product.
8.4.9 Adverse E vents on the VRC
Participants will use a n eVRC to report solicited and unsolicited AEs.
The definitions of solicited and unsolicited AEs can be found in Appendix 3.
[IP_ADDRESS] Solicited Adverse Event
Solicited AEs for this study are summarized in Table 5.
08LGKL
PRODUCT:   V116  66
PROTOCOL/AMENDMENT NO.:   007 -01  
V116 -007-01FINAL PROTOCOL 06-JUL-2022
Table 5 Solicited Adverse Events
Type of Solicited 
Adverse EventPredefined Solicited Adverse Events
(Preferred Term)Solicited Time 
Period
Injection site Injection -site pain/ tenderness (injection -site pain)
Injection -site redness (injection -site erythema )
Injection -site swelling (injection -site swelling )Day 1 through Day 5
postvaccination
Systemic Headache (headache)
Muscle aches all over body (myalgia )
Tiredness (fatigue )Day 1 through Day 5
postvaccination
[IP_ADDRESS] Unsolicited Adverse Events
Unsolicited AEs for this study are events that are 1) not predefined in Table 5, or 2) 
predefined in Table 5but reported at any time outside the solicited time period.
8.5 Treatment of Overdose
In this study, an overdose is the administration of more than 1 dose of any individual study 
vaccine in any 24- hour period.
No specific information is available on the treatment of overdose.
8.6 Pharmacokinetics
PK parameters will not be evaluated in this study.
8.7 Pharmacodynamics
Pharmacodynamic parameters will not be evaluated in this study.
8.8 Biomarkers
Biomarkers are not evaluated in this study.
8.9 Future Biomedical Research Sample Collection
If the participant provides documented informed consent for FBR , the following specime ns 
will be obtained as part of FBR :
•DNA for future research
•Leftover study serum after completion of immunogenicity testing stored for future 
research
08LGKL
PRODUCT:   V116  67
PROTOCOL/AMENDMENT NO.:   007 -01  
V116 -007-01FINAL PROTOCOL 06-JUL-2022
8.10 Optional Assay Development Blood Sample Collection
If the participant provides documented informed consent for the optional assay development 
blood samples, these additional blood samples will be obtained a s indicated in Section s1.3.1 
and 1.3.2 . These blood samples will be used to support future development work on 
improving bioanalytical measurements, which requires high -volume single -donor samples to 
monitor performance of the assay over time.
Sample collection, storage, and shipment instructions for the optional assay development 
blood samples will be provided in the operations/laboratory manual.
8.11 Medical Resource Utilization and Health Economics
Medical Resource Utilization and Health Economics are not evaluated in this study.
8.12 Visit Requirements
Visit requirements are outlined in Sections 1.3 .1 and 1.3.2 .Specific procedure -related details 
areprovided in Section 8.
8.12.1 Screening
Screening procedures will be conducted at Visit 1 as outlined in Section 1.3 .1. Potential
participants will be evaluated to determine that they fulfill the entry requirements as set forth 
in Section 5.
8.12.2 Treatment Period/Vaccination Visit
Requirements during the treatment period are outlined in Section s1.3.1 and 1.3.2 .
If Visit 2 ( Day 1 ) and/or Visit 9 ( Day 1 B) are rescheduled (see Section 5.2), a pregnancy test 
(if applicable), a body temperature measurement, and a review of inclusion/exclusion criteria, 
prior medications/vaccinations ,and medical history (if applicable ), must be repeated before 
vaccination.
8.12.[ADDRESS_368709]:   V116  68
PROTOCOL/AMENDMENT NO.:   [ADDRESS_368710] hoc exploratory 
analyse s will be clearly identified in the CSR.
9.1 Statistical Analysis Plan Summary
Key elements of the Statistical Analysis Plan are summarized below; the comprehensive plan 
is provided in Sections 9.2 through 9.12.
Study Design Overview A Phase 3, Multicenter, Randomized, Double- blind, Active Comparator -
Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of 
V116 in Adults Living With HIV
Treatment Assignment Participants will be randomly assigned in a 1:1 ratio to receive V116 +placebo or 
PCV15 +PPSV23 in Part A. Randomization will be stratified by [CONTACT_301808] (PCV13 and PPSV23 naïve; prior PCV13 only; 
prior PPSV23 only or prior PCV13 and PPSV23 ) and by [CONTACT_398]4+ T -cell count at 
Screening ( ≥50 to <500 cells/ µL;≥500 cells/ µL) as described in S ection 6.3.2 .
Participants who received V116 in Part A will receive PCV15 in Part B.
Analysis Populations Immunogenicity : PP population
Safety : APaT population
Primary Endpoint(s) Part A
Immunogenicity :
Serotype -specific OPA GMTs postvaccination with V116 (30days 
postvaccination [ Day 30 ]) or PCV15 +PPSV23 ( 30 days postvaccination 
with the final dose in the regimen [Week 12 ])
Safety :
Proportion of participants with solicited injection -site AEs (redness/erythema, 
swelling, tenderness/pain) from Day 1through Day 5postvaccination
Proportion of participants with solicited systemic AEs (muscle aches all over 
body/myalgia , headache, tiredness /fatigue) from Day 1 through Day 5
postvaccination
Proportion of participants with vaccine -related SAEs from Day 1 through the 
duration of participation in Part A
Key Secondary 
EndpointsPart A
Serotype -specific IgG GMCs postvaccination with V116 (Day 30) or PCV15 
+ PPSV23 (Week 12)
Statistical Methods for 
Key Immunogenicity 
AnalysesImmunogenicity analyses will be conducted separately for each serotype in 
V116 within each vaccination group .
To address the primary immunogenicity objective, evaluation of the OPA GMTs 
postvaccination wi th V116 (Day 30 )or PCV15 +PPSV23 (Week 12 )will 
include descriptive summaries and within -group 95% CIs for each vaccination 
group.
Statistical Methods for 
Key Safety AnalysesFor the overall safety evaluation, safety parameters will be summarized via 
descriptive statistics. For select safety parameters, point estimates and 
within -group 95% CIswill be provided.
08LGKL
PRODUCT:   V116  69
PROTOCOL/AMENDMENT NO.:   [ADDRESS_368711] 
to enable a benefit -risk assessment.
Multiplicity No multiplicity adjustment is planned as there is no hypothesis testing .
Sample Size and Power This study will randomize approximately 1 50 participants into the V116 +placebo 
group and 150 participants into the PCV15 +PPSV23 group . It is assumed that 
135 participants per vaccination group (90% evaluability rate) will be evaluable 
for PP immunogenicity analyses. There are no hypotheses to be evaluated , but 
Section 9.9.1 provides information about the expected variability of the OPA
GMT sgiven the sample size.
9.2 Responsibility for Analyses/In -house Blinding
The statistical analysis of the data obtained from this study will be the responsibility of the 
Clinical Biostatistics department of the Sponsor.
Part A of this study will be conducted as a double -blind study under in -house blinding 
procedures. The official, final database in Part A will not be unblinded until 
medical/scientific review has been performed, protocol deviations have been identified, and
data in Part A have been declared final and complete . Part B of the study will be open-label.
The Clinical Biostatistics department wil l generate the randomized allocation schedule(s) for 
study intervention assignment. Randomization will be implemented using an IRT system .
Blinding issues related to the planned interim analyses are described in Section 9.7.
9.3 Hypotheses/Estimation
Objective s of the study are stated in Section 3. This is an estimation study and no hypothesis 
testing will be performed .
9.4 Analysis Endpoints
Immunogenicity and safety analysis endpoints that will be summarized are listed below.
9.4.1 Immunogenicity Endpoints
In Part A and Part B, i mmune responses will be measured for each of the serotypes contained 
in V116: the 6 serotypes in common with PCV15 ( 3, 6A, 7F, 19A, 22F, and 33F);7 
additional serotypes in common with PPSV23 but not included in PCV15 (8, 9N, 10A, 11A, 
12F, 17F, and 20); 8 unique serotypes in V116 ( 15A, 15C, 16F, 23A, 23B, 24F, 31, and 
35B); and 2 cross -reactiv e serotypes (6C and 15B).
08LGKL
PRODUCT:   V116  70
PROTOCOL/AMENDMENT NO.:   007 -01  
V116 -007-01FINAL PROTOCOL 06-JUL-2022
In Part B, immune responses will also be measured for the 9 serotypes contained in PCV15
but not in V116 (1, 4, 5, 6B, 9V, 14, 18C, 19F, and 23F).
Part A
The primary immunogenicity endpoint include s:
Serotype- specific OPA GMTs postvaccination with V116 (Day 30 )orPCV15 +PPSV23 
(Week 12 )
o13 serotypes common between V116 and PCV15 +PPSV23
o8 serotypes unique to V116
The secondary immunogenicity endpoint s include:
Serotype -specific IgG GMCs postvaccination with V116 (Day 30) or PCV15 + PPSV23 
(Week 12)
o13 serotypes common between V116 and PCV15 + PPSV23
o8 serotypes unique to V116
Serotype -specific GMFR and proport ion of participants with a ≥4 -fold rise from baseline
(Day 1) to postvaccination with V116 (Day 30) or PCV15 +PPSV23 (Week 12) for both 
OPA and IgG responses
o13 serotypes common between V116 and PCV15 + PPSV23
o8 serotypes unique to V116
The exploratory im munogenicity endpoints include:
Serotype- specific OPA GMTs and IgG GMCs postvaccination with V116 (Day 30) or 
PCV15 + PPSV23 (Week 12)
o13 serotypes common between V116 and PCV15 + PPSV23
o8 serotypes unique to V116
Serotype- specific OPA GMTs and IgG GMCs postvaccination with V116 (Day 30) or 
PCV15 (Day 30)
o6 serotypes common between V116 and PCV15
o15 serotypes unique to V116
08LGKL
PRODUCT:   V116  71
PROTOCOL/AMENDMENT NO.:   007 -01  
V116 -007-01FINAL PROTOCOL 06-JUL-2022
Serotype -specific GMFR and proportion of participants with a ≥4 -fold rise from baseline
(Day 1) to postvaccination with V116 (Da y 30) or PCV15 (Day 30) for both OPA and 
IgG responses
o6 serotypes common between V116 and PCV15
o15 serotypes unique to V116
Summaries of the c ross- reactive immune responses to serotypes within a serogroup using 
serotype -specific OPA and IgG responses
Part B
The exploratory immunogenicity endpoints include:
Serotype- specific OPA GMTs and IgG GMCs postvaccination with PCV15 (Day 30 B)
for participants administered V116 in Part A
o6 serotypes common between V116 and PCV15
o15 serotypes unique to V116
o9 serotypes included in PCV15 but not in V116
GMFR and proportion of participants with a ≥4-fold rise from baseline (Day 1B) to 
postvaccination with PCV15 (Day 30 B) for participants administered V116 in Part A for 
both OPA and IgG responses
o6 serotypes common between V116 and PCV15
o15 serotypes unique to V116 
o9serotypes included in PCV15 but not in V116
9.4.2 Safety Endpoints
Part A
The safety endpoints for overall safety assessment that address the primary safety objective
include:
Proportion of participants with solicited injection -site AEs (redness/erythema, swelling, 
and tenderness/pain) from Day 1 through Day 5 postvaccination
Proportion of participants with solicited systemic AEs (muscle aches all over 
body/myalgia, headache, and tiredness /fatigue) from Day [ADDRESS_368712]:   V116  72
PROTOCOL/AMENDMENT NO.:   007 -01  
V116 -007-01FINAL PROTOCOL 06-JUL-2022
Proportion of participants with vaccine -related SAEs from Day 1 through the duration of 
participation in Part A
Additional safety endpoints for overall safety assessment include:
Proportion of participants with the b road AE categories consisting of any AE, any 
unsolicited AEs, and any vaccine -related AE from Day [ADDRESS_368713] vaccination
Proportion of participants with the b road AE categories consisting of any SAE, any 
vaccine -related SAE, discontinuation due to an AE, and death from Day 1 through the 
duration of participation in Part A
Proportion of participants with maximum temperature measurements meeting the 
Brighton Collaboration cut points from Day 1 through Day 5 postvaccination
Part B
The safety endpoints for overall safety assessment that address the secondary safety objective 
include:
Proportion of participants with solicited injection- site AEs (redness/erythema, swelling, 
and tenderness/pain) from Day 1 Bthrough Day 5 Bafter PCV15 vaccination
Proportion of participants with solicited systemic AEs (muscle aches all over 
body/myalgia, headache, and tiredness/fatigue) from Day 1B through Day 5 Bafter 
PCV15 vaccination
Proportion of participants with vaccine -related SAEs from Day 1 Bthrough the duration 
of participation in Part B
Additional safety endpoints for overall safety assessment include:
Proportion of participants with the broad AE categories consisting of any AE, any 
unsolicited AEs, and any vaccine -related AE from Day 1 Bthrough Day 30 Bafter PCV15 
vaccination
Proportion of participants with the broad AE categories consisting of any SAE, any 
vaccine -related SAE, discontinuation due to an AE, and death from Day 1 Bthrough the 
duration of participation in Part B
Proportion of participants with maximum temperature measurements meeting the 
Brighton Collaboration cut points from Day [ADDRESS_368714]:   V116  73
PROTOCOL/AMENDMENT NO.:   [ADDRESS_368715] the results of the immunogenicity endpoints. Potential 
deviations that may result in the exclusion of a participant from the PP population for all 
immunogenicity analyses include:
Failure to receive study vaccine at Visit 2 (Day 1)
Failure to receive correct clinical material as per randomization schedule
Receipt of a prohibited medication or prohibited vaccine prior to study vaccinat ion
Additional potential deviations that may result in the exclusion of a participant from the PP 
population for specific immunogenicity analyses (depending on the time point) include:
Failure to receive study vaccine at Visit 5 (Week 8)
Receipt of a prohi bited medication or prohibited vaccine prior to a blood sample 
collection
Collection of a blood sample outside the prespecified window
The final determination on protocol deviations, and thereby [CONTACT_176006], will be made prior to the final unblinding of the database . Participants will be 
included in the vaccination group to which they are randomized for the analysis of 
immunogenicity data using the PP population.
A supportive analysis using the FAS population will also be performed for the primary 
immunogenicity endpoint. The FAS population consists of all randomized participants who 
received at least [ADDRESS_368716]:   V116  74
PROTOCOL/AMENDMENT NO.:   [ADDRESS_368717] the results of the immunogenicity endpoints. 
Potential deviations that may result in the exclusion of a participant from the PP population 
for all immunogenicity analyses include:
Failure to receive PCV15 at Visit 9(Day 1 B)
Receipt of a prohibited medication or prohibited vaccine prior to PCV15 vaccination at 
Visit 9 (Day 1B)
Additional potential deviations that may result in the exclusion of a participant from the PP 
population for specific immuno genicity analyses include:
Receipt of a prohibited medication or prohibited vaccine prior to a blood sample 
collection
Collection of a blood sample outside the prespecified window
The final determination on protocol deviations, and thereby [CONTACT_176006], will be made prior to the planned Part B analysis .
9.5.[ADDRESS_368718] study vaccination ;such participants will be 
included in the group corresponding to the study vaccination actually received.
At least 1temperature measurement obtained after study intervention is required for 
inclusion in the analys is of temperature .
9.[ADDRESS_368719]:   V116  75
PROTOCOL/AMENDMENT NO.:   007 -01  
V116 -007-01FINAL PROTOCOL 06-JUL-2022
Part A
Immunogenicity analyses will be conducted for each of the 21 pneumococcal serotypes in 
V116 separately. To address the primary immunogenicity objective, evaluation of the OPA 
GMTs postvaccination with V116 ( Day 30 )orPCV15 +PPSV23 (Week 12) will include 
descriptive summaries and within -group 95% CIs for each vaccination group.
For the secondary immunogenicity objective s,to evaluate IgG GMCs postvaccination with 
V116 (Day 30) or PCV15 + PPSV23 (Week 12 ), asimilar statistical approach described in 
the primary objective will be used. Also, GMFR and proportions of participants with a 
≥4-fold rise for both OPA and IgG responses will be calculated forV116 (from Day 1 to 
Day 30) or PCV15 +PPSV23 ( from Day 1 to Week 12). Descriptiv e statistics with point 
estimates and within- group 95% CIs will be provided for these endpoints .
For the continuous endpoints, the point estimates will be calculated by [CONTACT_301809]- group CIs will be derived by 
[CONTACT_301810] 
t-distribution. For the dichotomous endpoints, the within- group CIs will be calculated based 
on the exact method proposed by [CONTACT_93325] [CLOPPER, C. J. and PEARSON, E. 
S. 1934] .
To address the exploratory immunogenicity objective that aims to evaluate the immune 
responses for V116 (Day 30 )compared with PCV15 +PPSV23 (Week 12 ), the 
serotype -specific OPA GMTs will be compared between intervention groups through the 
estimation of serotype -specific OPA GMT ratios. Estimation of the OPA GMT ratios and 
computation of the corresponding 95% CIs will be calculated using a cLDA method 
propose d by [CONTACT_165381] [Liang, K -Y and Zeger, S. L. 2000] . Details regarding the 
cLDA models will be included in the sSAP. A similar statistical approach will be used to 
analyze the IgG GMC sbetween the 2 intervention groups.
Reverse Cumulative Distribution Curves for OPA titers and IgG concentrations will be 
graphically displayed by [CONTACT_93326] .
Part B
For the exploratory immunogenicity objective, evaluation of the OPA GMTs andIgG GMCs
postvaccination with PCV15 (Day 30B) , GMFR and proportions of participants with a 
≥4-fold rise for both OPA and IgG responses from Day 1B to Day 30 Bwill be provided with 
within -group 95% C Is. A similar statistical approach described in the primary and secondary 
immunogenicity objectives in Part A will be applied.
Reverse Cumulative Distribution Curves for OPA titers and IgG concentrations will be 
graphically displayed by [CONTACT_93326] .
A detaile d analysis strategy for immunogenicity endpoints in Part A and Part B is listed in 
Table [ADDRESS_368720]:   V116  76
PROTOCOL/AMENDMENT NO.:   007 -01  
V116 -007-01FINAL PROTOCOL 06-JUL-2022
Table 6 Analysis Strategy for Immuno genicity Variables
Endpoint/Variable
(Description, Time Point)Primary vs. 
Supportive 
ApproachaStatistical 
MethodAnalysis 
PopulationMissing Data 
Approach
Primary Endpoint s
Part A: OPA GMTs postvaccination 
with V116 (Day 30) or PCV15 + 
PPSV23 (Week 12)PDescriptive 
Statistics
(estimate, 95%
CI)PP Missing data 
will not be 
imputed S FAS
Secondary Endpoints
Part A: IgG GMCs postvaccination 
with V116 (Day 30) or PCV15 + 
PPSV23 (Week 12)PDescriptive 
Statistics
(estimate, 95%
CI) PPMissing data 
will not be 
imputed
Part A: GMFR and % of participants 
who achieved a ≥4-fold rise from 
baseline (Day 1) to postvaccination 
with V116 (Day 30) or PCV15 + 
PPSV23 (Week 12) for both OPA and 
IgG responsesPDescriptive 
Statistics
(estimate, 95%
CI)PPMissing data 
will not be 
imputed
CI=confidence interval ; FAS= full analysis set; GMC= geometric mean concentration; GMFR= geometric 
mean fold rise; GMT= geometric mean titer; IgG=immunoglobulin G; OPA=opsonophagocytic activity; 
PP=per-protocol
a P=primary approach; S=supportive approach
9.6.2 Statistical Methods for Safety Analyses
Part A
Safety and tolerability will be assessed by [CONTACT_14339], 
including AEs and postvaccination temperature measurements. The safety profile will be 
assessed via point estimates and 95% CIs (for select safety endpoints) across vaccination 
groups . Summaries on safety parameters will be provided following any vaccination and 
following each vaccination.
Part B
Similar statistical method sfor safety assess ment used in Part A will be used in Part B . In 
addition, summaries on key safety parameters following V116 and following PCV15 will be 
provide d for participants who receive V116 and PCV15 on Day 1 and Day 1B , respectively.
[IP_ADDRESS] Overall Safety Assessment
The overall safety evaluation will include a summary (ie, number and percentage) of 
participants with any AEs , any unsolicited AEs, anyvaccine -related AEs, anySAEs , any
vaccine -related SAEs, discontinuation due to an AE, and an AE resulting in death. Point 
08LGKL
PRODUCT:   V116  77
PROTOCOL/AMENDMENT NO.:   007 -01  
V116 -007-01FINAL PROTOCOL 06-JUL-2022
estimates and within -group 95% CIs for the percentages of participants will be provided for 
these events.
The number and percentage of participants with specific AEs will also be provided. Point 
estimates and within -group 95% CIs for the perc entages of participants with specific AEs 
will be provided for solicited AEs and AEs that occur in ≥5% of participants. 
The number and percentage of participants with maximum temperature measurements 
categorized by [CONTACT_93327] [Marcy, S. M., et al 2004] will be provided 
along with point estimates and within -group 95% CIs to evaluate elevated temperatures .
Within -group CIs will be calculated using the Clopper Pearson method [CLOPPER, C. J. and 
PEARSON, E. S. 1934] . CIs should only be regarded as helpful descriptive measures for the 
review of the safety profile and not as a formal method for assessing statist ical significance.
The analysis strategy for safety endpoints is provided in Table 7 .
Table 7 Analysis Strategy for Safety Parameters –Part A and Part B
Analysis Part Safety EndpointDescriptive 
StatisticsWithin -group 
95% CI
Overall Safety 
AssessmentSolicited injection -site AE (Day 1 through Day 5
postvaccination )a X X
Solicited systemic AE (Day 1 through Day 5
postvaccination )a X X
Any AEbX X
Any unsolicited AEbX X
Any vaccine -related AEbX X
Any SAEbX X
Any vaccine -related SAEbX X
Discontinuation due to AEbX X
DeathbX X
Specific AEs by [CONTACT_93328] X
Maximu mtemperature (Day 1 through Day 5 
postvaccination)d X X
AE=adverse event; CI=confidence interval; PT=preferred term; SAE=serious adverse event; SOC=system organ class
aSolicited injection -site AEs include redness/erythema, swelling, and tenderness/pain; s olicited systemic AEs include 
muscle aches all over body/myalgia, headache, and tiredness/fatigue.
bThese endpoints are broad AE categories. For example, descriptive statistics for the safety endpoint of “Any AE” will 
provide the number and percentage of participants with at least 1 AE.
cDescriptive statistics will be provided for specific AEs with incidence >0% of participants in any vaccination group; 
additionally within -group 95% CIs will be provided for specific AEs within ≥5% of partici pants in any vaccination group.
dMaximum temperature measurements are categorized by [CONTACT_93327].
08LGKL
PRODUCT:   V116  78
PROTOCOL/AMENDMENT NO.:   007 -01  
V116 -007-01FINAL PROTOCOL 06-JUL-2022
9.6.3 Demographic and Baseline Characteristics
The comparability of the vaccination groups for each relevant demographic and baseline 
characteristic will be assessed by [CONTACT_93329]. No statistical hypothesis tests 
will be performed on these characteristics. The number and percentage of pa rticipants 
screened and randomized and the primary reasons for screening failure and discontinuation 
will be displayed. Demographic variables (eg, age, race, ethnicity, sex, and gender ), baseline 
characteristics, and prior and concomitant vaccinations and therapi[INVESTIGATOR_301774].
9.[ADDRESS_368721] to enable a benefit- risk assessment.
The DMC will serve as the primary reviewer of the results of the ongoing safety reviews and 
will make recommendations for discontinuation of the study or protocol modifications to an 
EOC of the Sponsor (see Appendix 1 for details on the Committees Structure for this study). 
If the DMC recommends modifications to the design of the protocol or discontinuation of the 
study, the EOC of the Sponsor (and potentially other limited Sponsor personnel) may be 
unblinded to results at the intervention level to act on these recommendations. The extent to 
which individuals are unblinded with respect to ongoing safety reviews will be documented 
by [CONTACT_301811]. Additional logistical details will be provided in the 
DMC charter.
Study enrollment may be ongoing at the time of external DMC review. Blinding to 
intervention assignment will be maintained at all investigational sites. Participant -level 
unblinding will be restricted to an external unblinded statistician performing ongoing safety 
reviews. Intervention -level ongoing sa fety reviews will be provided by [CONTACT_252344]. Prior to final study unblinding, the external unblinded 
statistician will not be involved in any discussions regarding modifications to the protocol, 
statistical methods, iden tification of protocol deviations, or data validation efforts after the 
safety reviews.
9.[ADDRESS_368722]:   V116  79
PROTOCOL/AMENDMENT NO.:   007 -01  
V116 -007-01FINAL PROTOCOL 06-JUL-2022
9.9 Sample Size and Power Calculations
9.9.1 Sample Size and Power for Immunogenicity Analys es
This is a descriptive study. This study will randomize approximately 1 50participants into the 
V116 + placebo group and 150participants into the P CV15 + PPSV23 group . It is assumed 
that 135 participants per vaccination group will be evaluable for PP immunogenicity analyses 
based on a 90% evaluability rate.
The width of the within- group 95% CIs for the serotype -specific OPA GMTs depend on the 
sample size, variability of the natural log titers, and the magnitude of the OPA GMTs . The 
95% CIs for various hypothetical OPA GM Tsand various hypothetical standard deviation 
estimates for the natural log titers are displayed in Table 8 .
Table 8 Within -group 95% CIs for Varying Hypothetical OPA GMTs and Varying 
Standard Deviations With [ADDRESS_368723] 
Deviation of 
Natural Log 
TitersaSerotype- specific OPA GMTa
500 1000 5000
1.0 (422, 593) (843, 1186) (4217, 5928)
1.5 (387, 645) (775, 1291) (3873, 6454)
2.0 (356, 703) (711, 1406) (3557, 7028)
2.5 (327, 765) (653, 1530) (3267, 7652)
CI=confidence interval; GMT= geometric mean titer; OPA=opsonophagocytic activity
aThe estimates of the standard deviation and OPA GMTs arerepresentative of those observed in V116 -001.
9.9.[ADDRESS_368724] 1 SAE in this study depends on the 
number of participants vaccinated and the underlying incidence of participants with a SAE in 
the study population. Calculations below assume that 100% of the randomized participants 
will be evaluable for safety analyses. There is an 80% chance of observing at least 1SAE 
among 150 participants in the V116 group if the underlying incidence of a SAE is 1.07% 
(1of every 93 participants receiving the vaccine). There is a 50% chance of observing at 
least 1 SAE among 150 participants in the V116 group if the underlying incidence of a SAE 
is 0.46% (1 of every 216 participants receiving the vaccine). If no SAEs are observed among 
the 150 participants in the V11 6group, this study will provide 97.5% confidence that the 
underlying percentage of participants with a SAE is < 2.44% ( 1in every 40 participants) in 
the V11 6group .
08LGKL
PRODUCT:   V116  80
PROTOCOL/AMENDMENT NO.:   007 -01  
V116 -007-01FINAL PROTOCOL 06-JUL-2022
9.10 Subgroup Analyses
Part A
Serotype -specific OPA GMTs and their corres ponding within- group 95% CIs for V116 (Day 
30)or PCV15 + PPSV 23(Week 12 )will be calculated within each vaccination group for 
each subgroup of the following classification variables:
•Age category (18 to <50 ;≥50 years of age )
•Sex
•Race
•Ethnicity
•Prior pneumococcal vaccination status (PCV13 andPPSV23 naïve ; prior PCV13 only, 
prior PPSV23 only, or prior PCV13 and PPSV23 )
•CD4+ T- cell count at Screening (≥50 to <500; ≥500 cells/μL )
•Time since receipt of last pneumococcal vaccination forPCV13 and/or PPSV23
experienced participants:
oPrior PCV13 only (≥8 weeks to <5 years ; ≥5 years)
oPrior PPSV23 only or prior PCV13 and PPSV23 (4to 9 years; ≥10 years )
In addition, a summary of AEs and a summary of solicited AEs will be provided for each of 
the subgroups listed above (point estimates only).
Further details of subgroup analyses will be documented in the sSAP.
9.11 Compliance (Medication Adherence)
Given that participants will receive a single dose of V11 6 or PCV15, followed by a single 
dose of placebo or PPSV23 in Part A, respectively, and the V116 recipi[INVESTIGATOR_301775] A will 
receive a single dose of PCV15 in Part B , compliance will not be calculated. However, the 
number and proportion of randomized participants receiving each vaccination will be 
summariz ed (Section 9.12) .
9.[ADDRESS_368725]:   V116  81
PROTOCOL/AMENDMENT NO.:   007 -01  
V116 -007-01FINAL PROTOCOL 06-JUL-2022
10 SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS
10.1 Appendix 1: Regulatory, Ethical, and Study Oversight Considerations
10.1.[ADDRESS_368726] for Clinical Trials
[COMPANY_006] Sharp & Dohme LLC, Rahway, NJ, [LOCATION_003] (MSD )
Code of Conduct for Interventional Clinical Trials
I. Introduction
A. Purpose
MSD, through its subsidiaries, conducts clinical trials worldwide to evaluate the safety and effectiveness of our 
products. As such, we are committed to designing, implementing, conducting, analyzing, and reporting these trials 
in compliance with the highest ethical and scientific standards. Protection of participants in clinical trials is the 
overriding concern in the design and conduct of clinical trials. In all ca ses, MSD clinical trials will be conducted 
in compliance with local and/or national regulations (including all applicable data protection laws and
regulations), and International Council for Harmonisation Good Clinical Practice (ICH- GCP), and also in 
accor dance with the ethical principles that have their origin in the Declaration of Helsinki.
B. Scope
Highest ethical and scientific standards shall be endorsed for all clinical interventional investigations sponsored by 
[CONTACT_19481] (parties) employed for their execution (e.g., contract research organizations, 
collaborative research efforts). This Code is not intended to apply to trials that are observational in nature, or 
which are retrospective. Further, this Code does not apply to investiga tor-initiated trials, which are not under the 
full control of MSD.
II. Scientific Issues
A. Trial Conduct
1. Trial Design
Except for pi[INVESTIGATOR_19354], clinical trial protocols will be hypothesis -driven to assess safety, efficacy 
and/or pharmacoki netic or pharmacodynamic indices of MSD or comparator products. Alternatively, MSD 
may conduct outcomes research trials, trials to assess or validate various endpoint measures, or trials to 
determine patient preferences, etc.
The design (i.e., participant population, duration, statistical power) must be adequate to address the specific 
purpose of the trial and shall respect the data protection rights of all participants, trial site staff and, where 
applicable, third parties . All trial protocols are and will be assessed for the need and capability to enroll 
underrepresented groups. Participants must meet protocol entry criteria to be enrolled in the trial. 
2. Site Selection
MSD ’s clinical trials are conducted globally in many different countries and in diver se populations, including 
people of varying age, race, ethnicity, gender, and accounting for other potential disease related factors. MSD 
selects investigative sites based on medical expert[INVESTIGATOR_18700], access to appropriate participants, adequacy of facilities 
andstaff, previous performance in clinical trials, as well as budgetary considerations. Prior to trial initiation, 
sites are evaluated by [CONTACT_26397] (or individuals acting on behalf of MSD) to assess the ability to 
successfully conduct the trial.
08LGKL
PRODUCT:   V116  82
PROTOCOL/AMENDMENT NO.:   007 -01  
V116 -007-01FINAL PROTOCOL 06-JUL-2022
Where ap propriate, and in accordance with regulatory authority guidance, MSD will make concerted efforts 
to raise awareness of clinical trial opportunities in various communities. MSD will seek to engage 
underrepresented groups and those disproportionately impacted by [CONTACT_26398]. MSD will support 
clinical trial investigators to enroll underrepresented groups and expand access to those who will ultimately 
use the products under investigation.
3. Site Monitoring/Scientific Integrity
Investigative trial s ites are monitored to assess compliance with the trial protocol and Good Clinical Practice 
(GCP). MSD reviews clinical data for accuracy, completeness, and consistency. Data are verified versus 
source documentation according to standard operating procedure s. Per MSD policies and procedures, if
potential fraud, scientific/research misconduct, privacy incidents/breaches orClinical Trial -related 
Significant Quality Issues are reported, such matters are investigated . When necessary, appropriate corrective 
and/or preventative actions are defined and regulatory authorities and /orethics review committees are 
notified.
B. Publi cation and Authorship
Regardless of trial outcome, MSD commits to publish the primary and secondary results of its registered trials of 
marketed products in which treatment is assigned, according to the pre -specified plans for data analysis. To the 
extent scientifically appropriate, MSD seeks to publish the results of other analyses it conducts that are important 
to patients, physicians, and payers. Some early phase or pi[INVESTIGATOR_26346] -generating rather 
than hypothesis testing; in such cases, publication of results may not be appropriate since the trial may be 
underpowered and the analyses complicated by [CONTACT_19482].
MSD’s policy on authorship is consistent with the recommendations published by [CONTACT_126558] (ICMJE). In summary, authorship should reflect significant contribution to the design and 
conduct of the trial, performance or interpretation of the analysis, and/or writing of the manuscript. All named 
authors must be able to defend the trial results and conclusions. MSD funding of a trial will be acknowledged in 
publications.
III. Participant Protection
A. Regulatory Authority and Ethics Committee Review (Institutional Review Board [IRB]/Independent Ethics 
Comm ittee [IEC])
All protocols and protocol amendments will be submitted by [CONTACT_88708]/authorization prior to implementation of the trial or amendment, in compliance with local and/or 
national regulations.
The protocol, protocol am endment(s), informed consent form, investigator’s brochure, and other relevant trial 
documents must be reviewed and approved by [CONTACT_2717]/IEC before being implemented at each site, in compliance 
with local and/or national regulations. Changes to the protocol that are required urgently to eliminate an 
immediate hazard and to protect participant safety may be enacted in anticipation of ethics committee approval. 
MSD will inform regulatory authorities of such new measures to protect participant safety, in complia nce with 
local and/or national regulations.
B. Safety
The guiding principle in decision -making in clinical trials is that participant welfare is of primary importance. 
Potential participants will be informed of the risks and benefits of, as well as alternatives to, trial participation. At 
a minimum, trial designs will take into account the local standard of care.
All participation in MSD clinical trials is voluntary. Participants enter the trial only after informed consent is 
obtained. Participants m ay withdraw from an MSD trial at any time, without any influence on their access to, or 
receipt of, medical care that may otherwise be available to them.
08LGKL
PRODUCT:   V116  83
PROTOCOL/AMENDMENT NO.:   [ADDRESS_368727] ext ent possible , as well as all 
applicable data protection rights . Unless required by [CONTACT_2371], only the investigator, Sponsor (or individuals acting on 
behalf of MSD), ethics committee, and/or regulatory authorities will have access to confidential medical record s 
that might identify the participant by [CONTACT_2300].
D. Genomic Research
Genomic research will only be conducted in accordance with a protocol and informed consent authorized by [CONTACT_88709].
IV. Financial Considerations
A. Payments to Investigators
Clini cal trials are time -and labor -intensive. It is MSD’s policy to compensate investigators (or the sponsoring 
institution) in a fair manner for the work performed in support of MSD trials. MSD does not pay incentives to 
enroll participants in its trials. However, when enrollment is particularly challenging, additional payments may be 
made to compensate for the time spent in extra recruiting efforts.
MSD does not pay for participant referrals. However, MSD may compensate referring physicians for time spent 
on chart review and medical evaluation to identify potentially eligible participants.
B. Clinical Research Funding
Informed consent forms will disclose that the trial is sponsored by [CONTACT_19487], and that the investigator or sponsoring 
institution is being paid or pr ovided a grant for performing the trial. However, the local ethics committee may 
wish to alter the wording of the disclosure statement to be consistent with financial practices at that institution. As 
noted above, all publications resulting from MSD trials will indicate MSD as a source of funding.
C. Funding for Travel and Other Requests
Funding of travel by [CONTACT_19488] (e.g., to scientific meetings, investigator meetings, etc.) will be 
consistent with local guidelines and practices.
V. Investigator Commitment
Investigators will be expected to review MSD’s Code of Conduct as an appendix to the trial protocol, and in signing the 
protocol, agree to support these ethical and scientific standards.
10.1.2 Financial Disclosure
Financial d isclosure requirements are outlined in the US Food and Drug Administration 
Regulations, Financial Disclosure by [CONTACT_6230] (21 CFR Part 54). It is the 
Sponsor ’s responsibility to determine, based on these regulations, whether a request for 
financial d isclosure information is required. It is the investigator ’s/subinvestigator ’s 
responsibility to comply with any such request.
The investigator/subinvestigator(s) agree, if requested by [CONTACT_19489] 21 
CFR Part 54, to provide his/her financial interests in and/or arrangements with the Sponsor to 
allow for the submission of complete and accurate certification and disclosure statements. 
The investigator/subinvestigator(s) further agree to provide this information on a 
Certification/Dis closure Form, frequent ly known as a financial disclosure form, provided by 
[CONTACT_1034]. The investigator/subinvestigator(s) also consent to the transmission of this 
08LGKL
PRODUCT:   V116  84
PROTOCOL/AMENDMENT NO.:   [ADDRESS_368728] this study in compliance with all applicable data protection 
regulations.
Participants will be assigned a unique identifier by [CONTACT_1034]. Any participant records or 
datasets that are transferred to the Sponsor will contain the identifier only; participant names 
or any information that would make the participant identifiable will not be transferred.
The participant must be informed that his/her personal study- related data will be used by [CONTACT_19490]. The level of disclosure must also be 
explained to the participant. 
The participant must be informed that his/her medical re cords may be examined by [CONTACT_88710] S ponsor, by 
[CONTACT_6667]/IEC members, and by [CONTACT_6668].
[IP_ADDRESS] Confidentiality of Data
By [CONTACT_12570], the investigator affirms to the Sponsor that information furnished to 
the investigator by [CONTACT_19492], and such information will 
be divulged to the IRB , IEC ,or similar or expert committee; affiliated institution and 
employees, only under an appropriate understanding of confidentiality with such board or 
committee, affiliated institution and employees. Data generated by [CONTACT_19493], except to the extent that it is included in a 
public ation as provided in the Publications section of this protocol.
[IP_ADDRESS] Confidentiality of Participant Records
By [CONTACT_12570], the investigator agrees that the Sponsor (or Sponsor representative), 
IRB/IEC, or regulatory authority representatives may cons ult and/or copy study documents to 
verify worksheet/ CRF data. By [CONTACT_17317], the participant agrees to this 
process. If study documents will be photocopi[INVESTIGATOR_88648]/ CRF information, the participant will be ide ntified by [CONTACT_19494]; full 
names/initials will be masked before transmission to the Sponsor.
By [CONTACT_12570], the investigator agrees to treat all participant data used and 
disclosed in connection with this study in accordance with all appl icable privacy laws, rules 
and regulations.
[IP_ADDRESS] Confidentiality of IRB/IEC Information
The Sponsor is required to record the name [CONTACT_19525]/IEC that reviews and 
approves this study. The Sponsor is also required to document that each IRB/IEC meets
regulatory and ICH GCP requirements by [CONTACT_88711] 
08LGKL
PRODUCT:   V116  85
PROTOCOL/AMENDMENT NO.:   007 -01  
V116 -007-01FINAL PROTOCOL 06-JUL-2022
and qualifications of the IRB/IEC members and to make these records available for 
regulatory agency review upon request by [CONTACT_19496] .
10.1.4 Committees Structure
[IP_ADDRESS] Executive Oversight Committee
The EOC is comprise d of members of Sponsor Senior Management. The EOC will receive 
and decide on any recommendations made by [CONTACT_113836].
[IP_ADDRESS] External D ata Monitoring Committee
To supplement the routine study monitoring outlined in this protocol, an external DMC will 
monitor the interim data from this study. The voting members of the committee are external 
to the Sponsor. The members of the DMC must not be involved with the study in any other 
way (eg, they cann ot be study investigators) and must have no competing interests that could 
affect their roles with respect to the study.
The DMC will make recommendations to the EOC regarding steps to ensure both participant 
safety and the continued ethical integrity of t he study. Also, the DMC will review interim 
study results, consider the overall risk and benefit to study participants ( Section 9.7) and 
recommend to the EOC whether the study should continue in accordance with the protocol.
Specific details regarding comp osition, responsibilities, and governance, including the roles 
and responsibilities of the various members and the Sponsor protocol team ; meeting 
facilitation; the study governance structure; and requirements for and proper documentation 
of DMC reports, mi nutes, and recommendations will be described in the DMC charter that is 
reviewed and approved by [CONTACT_63548].
[IP_ADDRESS] Scientific Advisory Committee (SAC)
This study was developed in collaboration with a SAC. The SAC is comprised of both 
Sponsor and non -Sponsor scientific experts who provide scientific and strategic guidance on 
various aspects of the clinical trial and/or development, which may include study design, 
interpretation of study results, and subsequent peer -reviewed scientific publications .
10.1.[ADDRESS_368729]:   V116  86
PROTOCOL/AMENDMENT NO.:   007 -01  
V116 -007-01FINAL PROTOCOL 06-JUL-2022
Authorship will be determined by [CONTACT_11403] I CMJE authorship 
requirement s.
10.1.6 Compliance with Study Registration and Results Posting Requirements
Under the terms of the FDAAA of 2007 and the EMA clinical trial Directive 2001/20/EC, the 
Sponsor of the study is solely responsible for determining whether the study and its results 
are subject to the requirements for submission to http://www.clinicaltrials.gov, 
www.clinicaltrialsregister.eu or other local registries. MSD, as Sponsor of this study, will 
review this protocol and submit the information necessary to f ulfill these requirements. MSD 
entries are not limited to FDAAA or the EMA clinical trials directive mandated trials . 
Information posted will allow participants to identify potentially appropriate studies for their 
disease conditions and pursue participation by [CONTACT_3379] a central contact [CONTACT_88712] -site contact [CONTACT_3031].
By [CONTACT_12570], the investigator acknowledges that the statutory obligations under 
FDAAA, the EMA clinical trials directive ,or other locally mandated registries are that of the 
Sponsor and agrees not to submit any information about this study or i ts results to those 
registries.
10.1.[ADDRESS_368730] the study in an efficient and 
diligent manner and in conformance with this protocol; generally accepted standards of G CP
(eg, I CH GCP: Consolidated Guideline and other generally accepted standards of GCP ); and 
all applicable federal, state and local laws, rules and regulations relating to the conduct of the 
clinical study.
The Code of Conduct, a collection of goals and considerations th at govern the ethical and 
scientific conduct of clinical investigations sponsored by [CONTACT_19487], is provided i n this appendix 
under the Code of Conduct for Clinical Trials.
The investigator agrees not to seek reimbursement from participants, their insurance 
provi ders, or from government programs for procedures included as part of the study 
reimbursed to the investigator by [CONTACT_1034].
The investigator will promptly inform the Sponsor of any regulatory authority inspection 
conducted for this study.
The investigator agrees to provide the Sponsor with relevant information from inspection 
observations/findings to allow the Sponsor to assist in responding to any citations resulting 
from regulatory authority inspection and will provide the Sponsor with a copy of the 
proposed response for consultation before submission to the regulatory authority. 
Persons debarred from conducting or working on clinical studies by [CONTACT_19500]’s studies. The inves tigator 
will immediately disclose in writing to the Sponsor if any person who is involved in 
08LGKL
PRODUCT:   V116  87
PROTOCOL/AMENDMENT NO.:   [ADDRESS_368731] 
of the investigator’s knowledge, threatened .
10.1.8 Data Quality Assurance
All participant data relating to the study will be recorded on printed or electronic CRF unless 
transmitted to the Sponsor or designee electronically (eg, laboratory data). The investigator 
or qualified designee is responsible for verifying that data entri es are accurate and correct by 
[CONTACT_1189].
Detailed information regarding Data Management procedures for this protocol will be 
provided separately.
The investigator must maintain accurate documentation (source data) that s upports the 
information entered in the CRF.
The investigator must permit study- related monitoring, audits, IRB/IEC review, and 
regulatory agency inspections and provide direct access to source data documents.
Study documentation will be promptly and fully disclosed to the Sponsor by [CONTACT_63551], 
copying, review, and audit at reasonable times by [CONTACT_111969] e Sponsor or any 
regulatory authorities. The investigator agrees to promptly take any reasonable steps that are 
requested by [CONTACT_88713] a result of an audit or inspection to 
cure deficiencies in the study documentation and worksheets/CRFs .
The Sponsor or designee is responsible for the data management of this study including 
quality checking of the data.
Study monitors will perform ongoing source data review and verification to confirm that data 
entered into the CRF by [CONTACT_1191], complete, and verifiable from 
source documents; that the safety and rights of participants are being protected; and that the 
study is being conducted in accordance with the currently approved protocol and any other 
study agreements, ICH GCP, and all applicable regulatory requirements.
Records and documents, including participants’ documented informed consent , pertaining to 
the conduct of this study must be retained by [CONTACT_1732] 15 years after study 
completion unless local regulations or institutional policies require a longer retention period. 
No records may be destroyed during the retention period without the written approval of the 
Sponsor. No records may be transferred to another location or party without wri tten 
notification to the Sponsor .
10.1.9 Source Documents
Source documents provide evidence for the existence of the participant and substantiate the 
integrity of the data collected. The investigator/institution should maintain adequate and 
accurate source docume nts and study records that include al lpertinent observations on each 
08LGKL
PRODUCT:   V116  88
PROTOCOL/AMENDMENT NO.:   007 -01  
V116 -007-01FINAL PROTOCOL 06-JUL-2022
of the site’s participants. Source documents and data should be attributable, legible, 
contemporaneous, original, accurate, and complete. Changes to source data should be 
traceable, shou ld not obscure the original entry, and should be explained if necessary (eg, via 
an audit trail). Source documents are filed at the investigator’s site.
Data reported on the CRF or entered in the eCRF that are transcribed from source documents 
must be consistent with the source documents or the discrepancies must be explained. The 
investigator /institution may need to request previous medical records or transfer records, 
depending on the study. Also, current medical records must be available .
10.1.10 Study and Site Closure
The Sponsor or its designee may stop the study or study -site participation in the study for 
medical, safety, regulatory, administrative, or other reasons consistent with applicable laws, 
regulations, and GCP.
In the event the Sponsor prematurely terminates a particular study site, the Sponsor or 
designee will promptly notify that study site’s IRB/IEC as specified by [CONTACT_88714](s).
08LGKL
PRODUCT:   V116  89
PROTOCOL/AMENDMENT NO.:   007 -01  
V116 -007-01FINAL PROTOCOL 06-JUL-2022
10.2 Appendix 2: Clinical Laboratory Tests
•The pregnancy testing (Table 9)will be performed by [CONTACT_301812], CD4+ T- cell count, and plasma HIV RNA testing will be performed by [CONTACT_19979] .
•Protoc ol-specific requirements for inclusion or exclusion of participants are detailed in 
Section 5 of the protocol.
•Additional tests may be performed at any time during the study as determined necessary 
by [CONTACT_11006].
Table 9 Protocol -require d Safety Laboratory Assessments
Laboratory 
Assessments Parameters
Pregnancy 
Testing•Highly sensitive serum or urine hCG pregnancy test (as needed for WOCBP)
Other Screening 
Tests•Serum for HIV Serology
•Blood sample for CD4+ T -cell count and plasma HIV RNA testing
hCG=human chorionic gonadotropin; HIV=human immunodeficiency virus; RNA=ribonucleic acid;
WOCBP=women of childbearing potential
The i nvestigator (or medically qualified designee) must document their review of each 
laboratory safety report.
08LGKL
PRODUCT:   V116  90
PROTOCOL/AMENDMENT NO.:   007 -01  
V116 -007-01FINAL PROTOCOL 06-JUL-2022
10.3 Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting
10.3.[ADDRESS_368732].
10.3.2 Definition of AE
AE definition
•An AE is any untoward medical occurrence in a clinical study participant, temporally 
associated with the use of study intervention, whether or not considered related to the 
study intervention.
•Note: An AE can therefore be any unfavorable and unintended sign (including an 
abnor mal laboratory finding), symptom, or disease (new or exacerbated) temporally 
associated with the use of a study intervention.
•Note: For purposes of AE definition, study intervention (also referred to as Sponsor’s 
product) includes any pharmaceutical produc t, biological product, vaccine, diagnostic 
agent, medical device, combination product, or protocol specified procedure whether 
investigational or marketed (including placebo, active comparator product, or run- in 
intervention), manufactured by, licensed by, provided by, or distributed by [CONTACT_88715].
Events meeting the AE definition
•Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or 
other safety assessments (eg, ECG, radiological scans, vital signs measurements), 
including those that worsen from baseline, considered clinically significant in the medical 
and scientific judgment of the investigator.
08LGKL
PRODUCT:   V116  91
PROTOCOL/AMENDMENT NO.:   007 -01  
V116 -007-01FINAL PROTOCOL 06-JUL-2022
•Exacerbation of a chronic or intermittent preexisting condition including either an 
increase in frequency and/or intensity of the condition.
•New conditions detected or diagnosed after study intervention administration even 
though it may have been present before the start of the study.
•Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction.
•Signs, symptoms, or the clinical sequelae of a suspected overdose of either study 
intervention or a concomitant medication.
•For all reports of overdose (whether accidental or intentional) with an associated AE, the 
AE term should reflect the clinical symptoms or abnormal test result. An overdose 
without any associated clinical symptoms or abnormal laboratory results is reported using 
the terminology “accidental or intentional overdose without adverse effect.”
•Any new cancer or progression of existing cancer.
Events NOT meeting the AE d efinition
•Medical or surgical procedure (eg, endoscopy, appendectomy): the condition that leads to 
the procedure is the AE.
•Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).
•Anticipated day -to-day fluctuations of preexisting disease(s) or condition(s) present or 
detected at the start of the study that do not worsen.
•Surgical procedure(s) planned prior to informed consent to treat a preexis ting condition 
that has not worsened.
•Refe r to Section 8.4.6 for protocol -specific exceptions.
Definition of Unsolicited and Solicited AE
•An unsolicited AE is an AE that was not solicited using a VRC and that is communicated 
by a participant/participant’s legally authorized representative who has signed the 
informed consent. Unsolicited AEs include serious and nonserious AEs.
•Solicited AEs are predefined local (at the injection/administration site) and systemic 
events for which the participant/participant’s legally authorized representative is 
specifically questioned, and which are noted by [CONTACT_2299]/participant’s legally 
authorized representative in their VRC.
08LGKL
PRODUCT:   V116  92
PROTOCOL/AMENDMENT NO.:   [ADDRESS_368733] medical occurrence that, at any dose:
a.Results in death
b.Is life -threatening
•The term “ life-threatening ”in the definition of “serious” refers to an event in which 
the participant was at risk of death at the time of the event. It does not refer to an 
event, which hypothetically might have caused death, if it were more severe.
c.Requires inpatient hospi[INVESTIGATOR_1081]
•Hospi[INVESTIGATOR_5186] n is defined as an inpatient admission, regardless of length of stay, even 
if the hospi[INVESTIGATOR_2138] a precautionary measure for continued observation. (Note: 
Hospi[INVESTIGATOR_19358] a preexisting condition that has not 
worsened is not an SAE.) A preexisting condition is a clinical condition that is 
diagnosed prior to the use of an MSD product and is documented in the participant’s 
medical history.
d.Results in persistent or significant disability/incapacity
•The term disability mean s a substantial disruption of a person’s ability to conduct 
normal life functions.
•This definition is not intended to include experiences of relatively minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, 
and ac cidental trauma (eg, sprained ankle) that may interfere with or prevent 
everyday life functions but do not constitute a substantial disruption.
e.Is a congenital anomaly/birth defect
•In offspring of participant taking the product regardless of time to diagno sis.
f.Other important medical events
•Medical or scientific judgment should be exercised in deciding whether SAE 
reporting is appropriate in other situations such as important medical events that may 
not be immediately life -threatening or result in death or hospi[INVESTIGATOR_63474] [ADDRESS_368734]:   V116  93
PROTOCOL/AMENDMENT NO.:   007 -01  
V116 -007-01FINAL PROTOCOL 06-JUL-2022
•Examples of such events include invasive or malignant cancers, intensive treatment in 
an emergency room or at home for allergic bronchospasm, blood dyscrasias or 
convulsions that do not result in hospi[INVESTIGATOR_059], or development of drug dependency 
or drug abuse.
10.3.4 Additional Events Report ed
Additional events that require r eporting
In addition to the above criteria, AEs meeting either of the below criteria, although not 
serious per ICH definition, are reportable to the Sponsor.
•Is a cancer
•Is associated with an overdose
10.3.5 Recording AE and SAE
AE and SAE r ecording
•When an AE/SAE occurs, it is the responsibility of the investigator to review all 
documentation (eg, hospi[INVESTIGATOR_1088], laboratory, and diagnostics reports) related to 
the event.
•The investigator will record all rele vant AE/SAE information on the AE 
CRFs /worksheets at each examination.
•It is not acceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s medical 
records to the Sponsor in lieu of completion of the AE CRF page.
•There may be instances when copi[INVESTIGATOR_88650]. In this case, all participant identifiers, with the exception of the participant 
number, will be blinded on the copi[INVESTIGATOR_19361].
•The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. In such cases, the diagnosis (not the 
individual signs/symptoms) will be documented as the AE/SAE.
Assessment of i ntensity
•An event is defined as “serious” when it meets at least 1 of the predefined outcomes as 
described in the definition of an SAE, not when it is rated as severe.
•The investigator will make an assessment of overall intensity grade for each AE and SAE 
(and other report able event) reported during the study. An overall intensity grade will be 
assigned to injection- site AEs, specific systemic AEs, other systemic AEs, and vital sign 
(temperature) AEs as shown in the following tables. The overall intensity grading scales 
08LGKL
PRODUCT:   V116  94
PROTOCOL/AMENDMENT NO.:   007 -01  
V116 -007-01FINAL PROTOCOL 06-JUL-2022
used in this study are adapted from the “FDA Guidance for Industry: Toxicity Grading 
Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine 
Clinical Trials, September 2007” [Food and Drug Adm inistration 2007] .
Injection -site AE Overall Intensity Grading Scale
Injection -site 
Reaction to Study 
Vaccine/PlaceboMild
(Grade 1)Moderate
(Grade 2)Severe
(Grade 3)Potentially Life 
Threatening
(Grade 4)
Injection -site AEs occurring Day 1 through Day 5following receipt of study vaccine/placebo
Pain/Tenderness Does not 
interfere with 
activityRepeated use of 
non-narcotic pain 
reliever >24 hours 
or interferes with 
activityAny use of narcotic 
pain reliever or 
prevents daily 
activityER visit or 
hospi[INVESTIGATOR_2666]/Redness Size measured 
as
≤5cmSize measured as
5.1to 10 cmSize measured as
>10cmNecrosis or 
exfoliative 
dermatitis or 
results in ER visit 
or hospi[INVESTIGATOR_301776] 
≤5cmSize measured as
5.1to 10 cmSize measured as
>10cmNecrosis or ER 
visit or 
hospi[INVESTIGATOR_301777]-narcotic pain 
reliever >24 hours 
or interferes with 
activityAny use of narco tic 
pain reliever or 
prevents daily 
activityER visit or 
hospi[INVESTIGATOR_63479] -site reaction that begins ≥6 days after receipt of study vaccine/placebo
Pain/Tenderness
Erythema/Redness
Swelling
OtherDoes not 
interfere with 
activityRepeated use of 
non-narcotic pain 
reliever >24 hours 
or interferes with 
activityAny use of narcotic 
pain reliever or 
prevents daily 
activityER visit or 
hospi[INVESTIGATOR_93275]=adverse event; ER=emergency room
Theoverall intensity grading scales used in this study are adapted from the “FDA Guidance for Industry: Toxicity Grading 
Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September 2007” [Food 
and Drug Administration 2007].
08LGKL
PRODUCT:   V116  95
PROTOCOL/AMENDMENT NO.:   007 -01  
V116 -007-01FINAL PROTOCOL 06-JUL-2022
Specific Systemic AE Overall Intensity Grading Scale
Systemic (General)Mild 
(Grade 1)Moderate 
(Grade 2)Severe 
(Grade 3)Potentially Life 
Threatening
(Grade 4)
Headache No interference 
with activityRepeated use of non-
narcotic pain reliever 
>24hours or some 
interference with 
activitySignificant; any use 
of narcotic pain 
reliever or prevents 
daily activityER visit or 
hospi[INVESTIGATOR_93276]; 
prevents daily 
activityER visit or 
hospi[INVESTIGATOR_93277]; 
prevents daily 
activityER visit or 
hospi[INVESTIGATOR_93278]=emergency room
The overall intensity grading scales used in this study are adapted from the “FDA Guidance for Industry: Toxicity Grading 
Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September 2007” [Food 
and Drug Administration 2007].
Other Systemic AE Overall Intensity Grading Scale
Systemic IllnessaMild 
(Grade 1)Moderate 
(Grade 2)Severe 
(Grade 3)Potentially Life 
Threatening
(Grade 4)b
Illness or clinical AE 
(as defined 
according to 
applicable 
regulations)No interference 
with activitySome interference 
with activity not 
requiring medical 
interventionPrevents daily 
activity and 
required medical 
interventionER visit or 
hospi[INVESTIGATOR_93275]=adverse event; ER=emergency room; eVRC=electronic Vaccine Report Card; SAE=serious adverse event
The overall intensity grading scales used in this study are adapted from the “FDA Guidance for Industry: Toxicity Grading 
Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventiv e Vaccine Clinical Trials, September 2007” [Food 
and Drug Administration 2007] .
aBased upon information provided by [CONTACT_301813] -up period. For SAEs reported beyond the primary safety follow -up period, grading will be based upon the 
initial report and/or follow -up of the event.
bAEs resulting in death will be assessed as Grade 4.
08LGKL
PRODUCT:   V116  96
PROTOCOL/AMENDMENT NO.:   007 -01  
V116 -007-01FINAL PROTOCOL 06-JUL-2022
Vital Sign (Temperature) Overall Intensity Grading Scale
Vital SignsaMild 
(Grade 1)Moderate 
(Grade 2)Severe 
(Grade 3)Potentially Life 
Threatening
(Grade 4)
Fever (°C)b
(°F)b38.0 to 38.4
100.4 to 101.138.5 to 38.9
101.2 to 102.039.0 to 40.0
102.1 to 104.0>40.0
>104.0
The overall intensity grading scales used in this study are adapted from the “FDA Guidance for Industry: Toxicity Grading 
Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September 2007” [Food 
and Drug Administration 2007] .
aParticipant should be at rest for all vital sign requirements.
bOral temperature; no recent hot or cold beverages or smoking.
Assessment of c ausality
•Did the Sponsor’s product cause the AE?
•The determination of the likelihood that the Sponsor’s product caused the AE will be 
provided by [CONTACT_19427] a qualified physician. The investigator’s signed/dated 
initials on the source document or worksheet that supports the causality note d on the AE 
form, ensures that a medically qualified assessment of causality was done. This initialled 
document must be retained for the required regulatory time frame. The criteria below are 
intended as reference guidelines to assist the investigator in a ssessing the likelihood of a 
relationship between the test product and the AE based upon the available information.
•The following components are to be used to assess the relationship between the 
Sponsor’s product and the AE ; the greater the correlation wit h the components and 
their respective elements (in number and/or intensity), the more likely the Sponsor’s 
product caused the AE:
-Exposure: Is there evidence that the participant was actually exposed to the 
Sponsor’s product such as: reliable history, acce ptable compliance assessment 
(diary, etc.), seroconversion or identification of vaccine virus in bodily specimen?
-Time Course: Did the AE follow in a reasonable temporal sequence from 
administration of the Sponsor’s product? Is the time of onset of the AE compatible 
with a vaccine -induced effect?
-Likely Cause: Is the AE not reasonably explained by [CONTACT_19511], other drug(s)/vaccine(s), or other host or environmental factors?
-Rechallenge: Was the participant re -exposed to the Sponsor’s product in the study?
◦If yes, did the AE recur or worsen?
◦If yes, this is a positive rechallenge.
◦If no, this is a negative rechallenge.
08LGKL
PRODUCT:   V116  97
PROTOCOL/AMENDMENT NO.:   007 -01  
V116 -007-01FINAL PROTOCOL 06-JUL-2022
(Note: This criterion is not applicable if: (1) the initial AE resulted in death or 
permanent disability, or (2) the study is a single -dose vaccine study; or (3) 
Sponsor’s product(s) is/are used only 1 time.)
NOTE: IF A RECHALLENGE IS PLANNED FOR AN AE THAT WAS SERIOUS AND 
MAY HAVE BEEN CAUSED BY [CONTACT_26370]’S PRODUCT, OR IF RE -EXPOSURE 
TO THE SPON SOR’S PRODUCT POSES ADDITIONAL POTENTIAL SIGNIFICANT 
RISK TO THE PARTICIPANT THEN THE RECHALLENGE MUST BE APPROVED IN 
ADVANCE BY [CONTACT_93333], AND IF REQUIRED, THE 
IRB/IEC.
•Consistency with study intervention profile: Is the clinical/pathological presentation of 
the AE consistent with previous knowledge regarding the Sponsor’s product or drug class 
pharmacology or toxicology?
•The assessment of relationship will be reported on the CRFs/worksheets by [CONTACT_26368] a qualified physician according to their best clinical judgment, 
including consideration of the above elements.
•Use the following scale of criteria as guidance (not all criteria must be present to be 
indicative of a Sponsor’s product relationship).
-Yes, there is a reasonable possibility of Sponsor’s product relationship:
◦There is evidence of exposure to the Sponsor’s product. The temporal sequence 
of the AE onset relative to the administration of the Sponsor’s product is 
reasonable. The AE is more likely explained by [CONTACT_19457]’s product than by 
[CONTACT_5748].
-No, there is not a reasonable possibility of Sponsor’s product relationship:
◦Participant did not receive the Sponsor’s product OR temporal sequence of the 
AE onset relative to administration of the Sponsor’s product is not reasonable 
OR the AE is more likely explained by [CONTACT_26372]’s 
product. (Also entered for a participant with overdose without an associated 
AE.)
•The investigator must review and provide an assessment of causality for each AE/SAE 
and document this in the medical notes.
•There may be situations in which an SAE has occurred and the investigator has minimal 
information to include in the initial report to the Sponsor. However, it is very important 
that the investigator always make an assess ment of causality for every event before the 
initial transmission of the SAE data to the Sponsor.
•The investigator may change their opi[INVESTIGATOR_9242]- up information 
and send an SAE follow- up report with the updated causality assessmen t.
08LGKL
PRODUCT:   V116  98
PROTOCOL/AMENDMENT NO.:   007 -01  
V116 -007-01FINAL PROTOCOL 06-JUL-2022
•The causality assessment is 1 of the criteria used when determining regulatory reporting 
requirements.
Follow -up of AE and SAE
•The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medical ly indicated or as requested by [CONTACT_19514]/or causality of the AE or SAE as fully as possible. This may 
include additional laboratory tests or investigations, histopathological examinations, or 
consultation with other health care p rofessionals.
•New or updated information will be recorded in the CRF.
•The investigator will submit any updated SAE data to the Sponsor within 24 hours of 
receipt of the information.
10.3.6 Reporting of AE s, SAE s, and Other Reportable Safety Events to the Sponso r
AE, SAE, and o ther reportable safety event reporting to Sponsor via electronic d ata 
collection t ool
•The primary mechanism for reporting to the Sponsor will be the EDC tool.
-Electronic reporting procedures can be found in the EDC data entry guidelines (or 
equivalent).
-If the electronic system is unavailable for more than 24 hours, then the site will use 
the paper AE Reporting form.
◦Reference Section 8.4.1 for reporting time requirements.
•The site will enter the SAE data into the electronic sy stem as soon as it becomes 
available.
•After the study is completed at a given site, the EDC tool will be taken off -line to prevent 
the entry of new data or changes to existing data.
•If a site receives a report of a new SAE from a study participant or recei ves updated data 
on a previously reported SAE after the EDC tool has been taken off -line, then the site can 
report this information on a paper SAE form or by [CONTACT_756] (see next section).
•Contacts for SAE reporting can be found in the Investigator Study File Binder (or 
equivalent).
08LGKL
PRODUCT:   V116  99
PROTOCOL/AMENDMENT NO.:   007 -01  
V116 -007-01FINAL PROTOCOL 06-JUL-2022
SAE reporting to the Sponsor via paper CRF
•If the EDC tool is not operational, facsimile transmission or secure e -mail of the SAE 
paper CRF is the preferred method to transmit this information to the Sponsor.
•In rare circumstances and in the absence of facsimile equipment, notification by 
[CONTACT_9337] a copy of the SAE data collection tool sent by [CONTACT_19515].
•Initial notification via telephone does not replace the need for the investigator to 
complete and sign the SAE CRF pages within the designated reporting time frames.
•Contacts and instructions for SAE reporting and paper reporting procedures can be found 
in the Investigator Study File Binder (or equivalent) .
08LGKL
PRODUCT:   V116  100
PROTOCOL/AMENDMENT NO.:   007 -01  
V116 -007-01FINAL PROTOCOL 06-JUL-2022
10.4 Appendix 4: Medical Device and Drug- device Combination Products : Product 
Quality Complaints/Malfunction s: Definition s, Recording, and Follow -up
The recording and follow -up procedures described in this protocol apply to all medical 
devices as described below. For purposes of this section, medical devices in scope for device 
information collection include devices intended to be used by a study parti cipant according to 
the study protocol, that are manufactured by [CONTACT_88716] a third party, 
licensed by [CONTACT_88717]/or drug -device combination products as listed in 
Section 6.1.1. Product Quality Complaints/Malfuncti ons must be reported to the Sponsor .
10.4.[ADDRESS_368735] comprised of two or more regulated components (ie, a 
drug and a device; a biologic and device; a biologic and a drug; or a drug, a device, and a 
biologic ). Combination product s can be single entity, copackaged, or colabeled.
Complaint -Any written, electronic, or oral communication that alleges deficiencies related 
to the identity, quality, durability, reliability, safety, effectiveness, or performance of a device 
after it is released for distribution. This would include PQC, AE, and customer feedback.
A complaint does not necessarily need to involve a user or any other person. 
Constituent Part -A drug, device, or biological product that is part of a combination 
product.
Customer Feedback - Areport that does not allege a PQC or defect and has no relevant 
safety information/untoward event associated with it (eg, goodwill or courtesy replacement, 
consumer preference or suggestion, remark which may suggest an improvement in the 
functionality or quality of a medical device or device -like features of a drug delivery system).
Malfunction -The failure of a device to meet its performance specifications or otherwise 
perform as intended.
Medical Device - Any instrument, apparatus, appliance, material or other article, whether 
used alone or in combination, including the software necessary for its proper application 
intended by [CONTACT_88718]: 
•diagnosis, prevention, monitoring, treatme nt or alleviation of disease, 
•diagnosis, monitoring, treatment, alleviation of or compensation for an injury or 
handicap, 
•investigation, replacement or modification of the anatomy or of a physiological process,
•control of conception, 
08LGKL
PRODUCT:   V116  101
PROTOCOL/AMENDMENT NO.:   [ADDRESS_368736] identified by [CONTACT_88721]. This includes 
potential device or device component malfunctions. Note: Areport of Lack or Limited 
Efficacy is considered an AE rather than a PQC .
Serious Injury -An injury or illness that: 
1.Is life -threatening, 
2.Results in permanent impairment of a body function or permanent damage to a body 
structure, or 
3.Necessitates medical or surgical intervention to preclude permanent impairment of a 
body function or permane nt damage to a body structure.
Permanent means irreversible impairment or damage to a body structure or function, 
excluding trivial impairment or damage.
10.4.2 Recording, Assessing Causality, and Follow -up of PQC s/Malfunctions
Recording
•When a Complaint includin g PQC/malfunction occurs it is the responsibility of the 
investigator to review all documentation (eg, hospi[INVESTIGATOR_1088], laboratory reports, 
and diagnostic reports) related to the event .
•Events occurring during the study will be recorded in the part icipant’s medical records, in 
accordance with the investigator’s normal clinical practice, and on the appropriate CRF 
(paper or electronic) as per instructions provided in the data entry guidelines . Medical 
device/device constituent part of drug device com bination product information will be 
collected and reported to the Sponsor in the same time frame as SAEs as per 
Section 8.4.1 via CRF (paper or electronic) . PQCs/malfunctions must be reported to the 
Sponsor .
Assessing Causality
•A“reasonable possibility” of a relationship conveys that there are facts, evidence, and/or 
arguments to suggest a causal relationship.
•The investigator will use clinical judgement to determine the relationship.
•Alternative causes such as underlying disease(s), concomitant ther apy, and other risk 
factors, as well as the temporal relationship of the event to study intervention 
administration should be considered and investigated.
08LGKL
PRODUCT:   V116  102
PROTOCOL/AMENDMENT NO.:   007 -01  
V116 -007-01FINAL PROTOCOL 06-JUL-2022
Follow -up
•The investigator will perform or arrange for the conduct of supplemental measurements 
and/or evaluations as medically indicated or as requested by [CONTACT_88722]/or causality of the event as complete as possible.
08LGKL
PRODUCT:   V116  103
PROTOCOL/AMENDMENT NO.:   007 -01  
V116 -007-01FINAL PROTOCOL 06-JUL-2022
10.5 Appendix 5: Contraceptiv e Guidance
10.5.1 Definitions
Women of Childbearing Potential (WOCBP)
A woman is considered fertile following menarche and until becoming postmenopausal 
unless permanently sterile (see below):
If fertility is unclear (eg, amenorrhea in adolescents or athletes) and a menstrual cycle cannot 
be confirmed before first dose of study intervention, additional evaluation should be 
considered.
Women in the following categories are not considered WOCBP:
•Premenarchal
•Premenopausal female with 1 of the following:
-Documented hysterectomy
-Documented bilateral salpi[INVESTIGATOR_1656]
-Documented bilateral oophorectomy
For individuals with permanent infertility due to an alternate medical cause other than the 
above (eg, Mullerian agenesis, androgen insensitivity), investigator d iscretion should be 
applied to determining study entry.
Note: Documentation can come from the site personnel’s review of the participant’s medical 
records, medical examination, or medical history interview.
•Postmenopausal female
-A postmenopausal state is defined as no menses for 12 months without an alternative 
medical cause.
◦A high FSH level in the postmenopausal range may be used to confirm a 
postmenopausal state in women not using hormonal contraception or HRT. 
However, in the absence of [ADDRESS_368737]:   V116  104
PROTOCOL/AMENDMENT NO.:   007 -01  
V116 -007-01FINAL PROTOCOL 06-JUL-2022
10.5.2 Contraception Requirements
Contraceptives allowed during the study includea:
Highly Effective Contraceptive Methods That Have Low User Dependencyb
Failure rate of <1% per year when used consistently and correctl y.
•Progestogen -only contraceptive implantc
•IUSd
•Non-hormonal IUD
•Bilateral tubal occlusion
•Azoospermic partner (vasectomized or secondary to medical cause)
This is a highly effective contraception method provided that the partner is the sole male sexual partner of 
the WOCBP and the absence of sperm has been confirmed. If not, an additional highly effective method of 
contraception should be used. A spermatogenesis cycle is approximately 90 days.
Note: Documentation of azoospermia for a male participant can come from the site personnel’s review of 
the participant’s medical records, medical examination, or medical history interview.
Highly Effective Contraceptive Methods That Are User Dependentb
Failure rate of <1% per year when used consistently and correctly.
•Combined (estrogen -and progestogen -containing) hormonal contraceptionc
-Oral
-Intravaginal
-Transdermal
-Injectable
•Progestogen -only hormonal contraceptionc
-Oral
-Injectable
Sexual Abstinence
•Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual 
intercourse during the entire period of risk associated with the study int ervention. The reliability of sexual 
abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle 
of the participant.
Methods That Are Not Considered Highly Effective
Failure rate of >1% per year when used consistently and correctly.
•Progesterone- only hormonal contraception where inhibition of ovulation is not the primary mode of action
•Male or female condom with or without spermicide
•Cervical cap, diaphragm, or sponge with spermicide
•A combination of male condom with either cervical cap, diaphragm, or sponge with spermicide (double 
barrier methods) .
a   Contraceptive use by [CONTACT_93339].
b   Typi[INVESTIGATOR_63485] -use failure rates (ie, when used consistently and correctly).
c   If locally required, in accordance with CTFG guidelines, acceptable hormonal contraceptives are limited to 
those which inhibit ovulation.
d   IUS is a progestin releasing IUD.
Note: The following are not acceptable methods of contraception:
-  Periodic abstinence (calendar, symptothermal, post -ovulation methods), withdrawal (coitus 
interruptus), spermicides only, and LAM.
-  Male and female condom should not be used together (due to risk of failure with friction ).
Country -specific contraception requirements are included in Appendix 7.
08LGKL
PRODUCT:   V116  105
PROTOCOL/AMENDMENT NO.:   007 -01  
V116 -007-01FINAL PROTOCOL 06-JUL-2022
10.6 Appendix 6: Collection and Management of Specimens for Future Biomedical 
Research
1.   Definitions
a.   Biomarker: A biological molecule found in blood, other body fluids, or tissues that is
a sign of a normal or abnormal process or of a condition or disease. A biomarker may
be used to see how well the body responds to a treatment for a disease or condition.1
b.   Pharmacogenomics: The investigation of variations of DNA and RNA characteristics 
as related to drug/vaccine response.2
c.   Pharmacogenetics: A subset of pharmacogenomics, pharmacogenetics is the influence 
of variations in DNA sequence on drug/vaccine response.2
d.   DNA: Deoxyribonucleic acid.
e.   RNA: Ribonucleic acid.
2.   Scope of Future Biomedical Research3, 4
The specimens consented and/or collected in this study as outlined in Section 8. 9will be 
used in various experiments to understand:
a.The biology of how drugs/vaccines work
b.Biomarkers responsible for how a drug/vaccine enters and is removed by [CONTACT_10489]
c.Other pathways with which drugs/vaccines may interact
d.The biology of disease
The specimen(s) may be used for f uture assay development and/or drug/vaccine 
development.
It is now well recognized that information obtained from studying and testing clinical 
specimens offers unique opportunities to enhance our understanding of how individuals 
respond to drugs/vaccines, enhance our understanding of human disease and ultimately 
improve public health through development of novel treatments targeted to populations 
with the greatest need. All specimens will be used by [CONTACT_63558].
3.  Summary of Procedures for Future Biomedical Researc h3, [ADDRESS_368738]:   V116  106
PROTOCOL/AMENDMENT NO.:   007 -01  
V116 -007-01FINAL PROTOCOL 06-JUL-2022
b.   In formed Consent
Informed consent for specimen s (ie, DNA, RNA, protein, etc) will be obtained during 
screening for protocol enrollment from all participants or legal guardians, at a study 
visit by [CONTACT_63559] d esignate. Informed consent for future 
biomedical research should be prese nted to the participants on the visit designated in 
the SoA. If delayed, present consent at next possible Participant Visit. Consent forms 
signed by [CONTACT_88723].
A template of each study site’s approved informed consent will be stored in the 
Sponsor’s clinical document repository.
c.   eCRF Documentation for Future Biomedical Research Specimens
Documentat ion of participant consent for future biomedical research will be captured 
in the eCRFs . Any specimens for which such an informed consent cannot be verified 
will be destroyed.
d.   Future Biomedical Research Specimen(s)
Collection of specimens for future biomedical research will be performed as outlined 
in the SoA. In general, if additional blood specimens ar e being collected for future 
biomedical research, these will usually be obtained at a time when the participant is 
having blood drawn for other study purposes.
4.   Confidential Participant Information for Future Bi omedical Research3, 4
In order t o optimize the resea rch that can be conducted with future biomedical research
specimens, it is critical to link participant s' clinical information with future test results. In 
fact,little or no research can be conducted wit hout connecting the clinical study data to 
the specimen. The clinical data allow specific analyses to be conducted. Knowing 
participant characteristics like sex, ag e, medical history and intervention outcomes are 
critical to understanding clinical context of analytical results.
To maintain privacy of information collected from specimens obtained for future 
biomedical research, the Sponsor has developed secure policies and procedures. All 
specimens will be single -coded per ICH E15 guidelines as described bel ow.
At the clinical study site, unique codes will be placed on the future biomedical research
specimens. This code is a random number which does not contain any personally 
identifying information embedded within it. The link (or key) between participant 
identifiers and this unique code will be held at the study site. No personal identifiers will 
appear on the specimen tube.
08LGKL
PRODUCT:   V116  107
PROTOCOL/AMENDMENT NO.:   [ADDRESS_368739] party (eg, a university investigator) designated by [CONTACT_429]. The investigator conducting the analysis will follow the Sponsor’s privacy and 
confidentiality requirements. Any contracted third party analyses will conform to the 
specific scope o f analysis outlined in future biomedical research protocol and consent . 
Future biomedical research specimens remaining with the third party af ter specific 
analysis is performed will be reported to the Sponsor.
6.   Withdrawal From Future Biomedical Research3, [ADDRESS_368740] the Sponsor using the designated mailbox 
(clinical.specimen.management@ MSD .com). Subsequently, the participant's specimens 
will be flagged in the biorepository and restricted to study use only. If specimens were 
collected from study participants specifically for FBR, these specimens will be removed 
from the biorepository and destroyed. Documentation will be sent to the investigator 
confirming withdrawal and/or destruction, if applicable. It is the responsibility of the 
investigator to inform the participant of completion of the withdrawal and/or destruction, 
if applicable. Any analyses in progress at the time of request for wit hdrawal/destruction 
or already performed before the request being received by [CONTACT_93336]. No new analyses would be 
generated after the request is received.
If the medical reco rds for the study are no longer available (eg, if the investigator is no 
longer required by [CONTACT_88692]) or the specimens 
have been completely anonymized, there will no longer be a link between the 
participant’s perso nal information and their specimens. In this situation, the request for 
withdrawal of consent and/or destruction cannot be processed.
7.   Retention of Specimens3, [ADDRESS_368741]:   V116  108
PROTOCOL/AMENDMENT NO.:   [ADDRESS_368742] results are accessible only to the 
authorized Sponsor representatives and the designated study administrator researc h 
personnel and/or collaborators. Database user authentication is highly secure, and is 
accomplished using network security policies and practices based on international 
standards to protect against unauthorized access.
9.   Reporting of Future Biomedical Research Data to Participants3, 4
No information obtained from exploratory laboratory studies will be reported to the 
participant, family, or physicians. Principle reasons not to inform or return results to the 
participant include: lack of relev ance to participant health, limitations of predictive 
capability, and concerns regarding misinterpretation.
If important research findings are discovered, the Sponsor may publish results, present 
results in national meetings, and make results accessible on a public website in order to
rapi[INVESTIGATOR_88651]. Participants will not be 
identified by [CONTACT_88726].
10.Future Biomedical R esearch Study Population3, [ADDRESS_368743] security, policies, and procedures to address participant 
data privacy concerns. Data privacy risk s are largely limited to rare situations involving 
possible breach of confidentiality. In this highly unlikely situation, there is risk that the 
information, like all medical information, may be misused.
12.Questions
Any questions related to the future bi omedical research should be e mailed directly to 
clinical.specimen.management@ MSD .com.
08LGKL
PRODUCT:   V116  109
PROTOCOL/AMENDMENT NO.:   007 -01  
V116 -007-01FINAL PROTOCOL 06-JUL-2022
13.References
1.   National Cancer Institute [Internet]: Available from 
https://www.cancer.gov/publications/dictionaries/cancer -terms?cdrid=[ZIP_CODE]
2.   International Council on Harmoni sation [Internet] : E15: Definitions for Genomic 
Biomarkers, Pharmacogenomics, Pharmacogenetics, Genomic Data and Sample 
Coding Categories. Available from 
http://www.ich.org/products/guidelines/efficacy/efficacy -single/articl e/definitions-
for-genomic -biomarkers- pharmacogenomics -pharmacogenetics -genomic -data-and-
sample -cod.html 
3.   Industry Pharmacogenomics Working Group [Internet]: Understanding the Intent, 
Scope and Public Health Benefits of Exploratory Biomarker Research: A Guide for 
IRBs/IECs and Investigational Site Staff. Available at http://i- pwg.org/ 
4.   Industry Pharmacogenomics Working Group [Internet]: Pharmacogenomics 
Informational Brochure for IRBs/IECs and Investigational Site Staff. Available at 
http://i- pwg.o rg/
08LGKL
PRODUCT:   V116  110
PROTOCOL/AMENDMENT NO.:   007 -01  
V116 -007-01FINAL PROTOCOL 06-JUL-2022
10.7 Appendix 7: Country -specific Requirements
10.7.[ADDRESS_368744] Exclusion Criteri a13and 1 4in 
Section 5.2:
13. R eceiv edimmunosuppressive therapy within 6 months before vaccination , including 
chemotherapeutic agents or other immunotherapi[INVESTIGATOR_014]/immunomodulators used to treat cancer 
or other conditions, and interventions associated with organ or bone marrow transplantation, 
or autoimmune disease.
14. * Received any nonlive vaccine ≤15days before receipt of study vaccine or is scheduled 
to receive any nonlive vaccine 
≤30 days after receipt of any study vaccine. Exce ption : 
inactivated influenza vaccine andSARS -CoV -[ADDRESS_368745] be given ≥15 days before or after receipt of study vaccine .
To clarify the exclusion criteria for protected populations, the following criterion is 
added to Section 5.2:
21.Adults protected by [CONTACT_2371], persons deprived of their liberty by a judicial or administrative 
decision, those hospi[INVESTIGATOR_301778], and persons admitted to a health or social institution for 
purposes other than research.
Section 6.5 Concomitant Therapy
For study sites in [LOCATION_009], to clarify and align with the [LOCATION_009] -specific exclusion criteri a
above, the following concomitant therapy replaces the original one in Section 6.5:
Medications or vaccinations specifically prohibited in the exclusion criteria are not allowed
during the ongoing study (Section 10.7.1) . If there is a clinical indication for any medications 
or vaccinations specifically prohibited, discontinuation from study intervention may be 
required. The investigator should discuss any questions regarding this with the Sponsor
Clinical Director . The final decision on any supportive therapy or vaccination rests with the 
investigator and/or the participant ’s primary physician. However, the decision to continue the 
participant on study intervention requires the mu tual agreement of the investigator, the 
Sponsor, and the participant.
It is important to record the use of any analgesic or antipyretic medication that occurs on the 
day of vaccination on the eVRC and appropriate eCRF.
08LGKL
PRODUCT:   V116  111
PROTOCOL/AMENDMENT NO.:   007 -01  
V116 -007-01FINAL PROTOCOL 06-JUL-2022
Listed below are specific restricti ons for concomitant therapy or vaccination:
•Administration of a nonstudy pneumococcal vaccine is prohibited during the study.
•Nonstudy vaccines may only be administered before or after the receipt of study vaccines 
according to the time frames specified in the Exclusion Criteria (Section 5.2).
•Receipt of systemic corticosteroids (prednisone equivalent ≥20 mg/day) for ≥14 
consecutive days is prohibited from 14 days before vaccination through 30 days 
following vaccination. Note : physiologic replacement doses (prednisone equivalent of 
approximately 5 mg/day), topi[INVESTIGATOR_2855], ophthalmic, intraarticular or soft -tissue (eg, bursa, 
tendon steroid injections), and inhaled/nebulized steroids are permitted.
•Receipt of immunosuppressive therapy within 6 months before vaccinat ion, including 
chemotherapeutic agents or other immunotherapi[INVESTIGATOR_014]/immunomodulators used to treat 
cancer or other conditions, and interventions associated with organ or bone marrow 
transplantation, or autoimmune disease.
•Receipt of a blood transfusion or bloo d products, including immunoglobulin ≤[ADDRESS_368746] until the Day 30 postvaccination blood draw is complete. Autologous blood 
transfusions are not considered an excl usion criterion.
•Receipt of any nonlive vaccine ≤ 15days before receipt of study vaccine or is scheduled 
to receive any nonlive vaccine ≤30 days after receipt of any study vaccine. Exception: 
inactivated influenza vaccine and SARS -CoV -[ADDRESS_368747] be given ≥15 days before and after receipt of study vaccine.
•Receipt of any live virus vaccine ≤30 days before receipt of study vaccine or is scheduled 
to receive any live virus vaccine ≤30 days after receipt of study vaccine.
Any deviation from the above requires consultation between the investigator and the Sponsor 
and written documentation of the collaborative decision on participant management.
Use of prior and concomitant medications/vaccinations s hould be recorded as described in
Section 8.1.5.
08LGKL
PRODUCT:   V116  112
PROTOCOL/AMENDMENT NO.:   007 -01  
V116 -007-01FINAL PROTOCOL 06-JUL-2022
Section 10.5.2 Contraception Requirements
For study sites in [LOCATION_009], to clarify the contraception methods allowed during the 
study, the following table replaces Contraception Requirements in Section 10.5.2 :
Contraceptives allowed during the study includea:
Highly Effective Contraceptive Methods That Have Low User Dependencyb
Failure rate of <1% per year when used consistently and correctl y.
•Progestogen -only subdermal contraceptive implantc
•IUSd
•Non-hormonal IUD
•Bilateral tubal occlusion
•Azoospermic partner (vasectomized or secondary to medical cause)
This is a highly effective contraception method provided that the partner is the sole male sexual partner of 
the WOCBP and the absence of sperm has bee n confirmed. If not, an additional highly effective method of 
contraception should be used. A spermatogenesis cycle is approximately 90 day s.
Note: Documentation of azoospermia for a male participant can come from the site personnel’s review of 
the partic ipant’s medical records, medical examination, or medical history interview. 
Highly Effective Contraceptive Methods That Are User Dependentb
Failure rate of <1% per year when used consistently and correctly .
•Combined (estrogen -and progestogen -containing) hormonal contraceptionc
-Oral
-Intravaginal
-Transdermal
-Injectable
•Progestogen -only hormonal contraceptionc
-Oral
-Injectable
Sexual Abstinence
•Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual 
intercourse during the entire period of risk associated with the study intervention. The reliability of sexual 
abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle 
of the participant.
a   Contraceptive use by [CONTACT_93339].
b   Typi[INVESTIGATOR_63485] -use failure rates (ie, when used consistently and correctly).
c   If locally required, in accordance with CTFG guidelines , acceptable hormonal contraceptives are limited to 
those which inhibit ovulation.
d   IUS is a progestin releasing IUD.
Note: The following are not acceptable methods of contraception:
-  Periodic abstinence (calendar, symptothermal, post -ovulation methods), withdrawal (coitus 
interruptus), spermicides only, and LAM.
-  Male and female condom should not be used together (due to risk of failure with fr iction ).
08LGKL
PRODUCT:   V116  113
PROTOCOL/AMENDMENT NO.:   007 -01  
V116 -007-01FINAL PROTOCOL 06-JUL-2022
10.8 Appendix 8: Abbreviations
Abbreviation Expanded Term
ABCs Active Bacterial Core Surveillance
ACIP Advisory Committee on Immunization Practices
AE adverse event 
APaT All-Participants -as-Treated
ART antiretroviral therapy
CDC Centers for Disease Control and Prevention
CFR Code of Federal Regulations
CI confidence interval
cLDA constrained Longitudinal Data Analysis
CONSORT Consolidated Standards of Reporting Trials
CRF case report form
CSF cerebrospi[INVESTIGATOR_301779]15B de-O-acylated serotype 15B
DMC Data Monitoring Committee
DNA deoxyribonucleic acid
ECI event of clinical interest
eCRF electronic Case Report Form
EDC electronic data collection
EEA European Economic Area
EMA European Medicines Agency
EOC Executive Oversight Committee
EU European Union
eVRC electronic Vaccination Report Card
FAS Full Analysis Set
FBR Future Biomedical Research
FDA Food and Drug Administration
FDAAA Food and Drug Administration Amendments Act
FSH follicle stimulating hormone
FSR first site ready
GCP Good Clinical Practice
GMC geometric mean concentration
GMFR geometric mean fold rise
GMT geometric mean titer
hCG human chorionic gonadotropin
HIV human immunodeficiency virus
HRT hormone replacement therapy
IB Investigator’s Brochure
ICF Informed Consent Form
ICH International Council for Harmonisation of Technical Requirements for 
Pharmaceuticals for Human Use
ICMJE International Committee of Medical Journal Editors
IEC Independent Ethics Committee
IgG Immunoglobulin G
08LGKL
PRODUCT:   V116  114
PROTOCOL/AMENDMENT NO.:   [ADDRESS_368748]
NSAE nonserious adverse event
OPA opsonophagocytic activity
PCV pneumococcal conjugate vaccine
PCV7 Prevnar™ (Serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F)
PCV10 Synflorix™ (Serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F)
PCV13 Prevnar 13™ (Serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 
23F)
PCV15 VAXNEUVANCE™ (Serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 
19F, 22F, 23F, and 33F)
PCV20 Prevnar 20™ / Apexxnar™
Pn ECL pneumococcal electrochemiluminescence
PnPs pneumococcal polysaccharide
PP per-protocol
PPSV23 PNEUMOVAX™23 (Serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 
12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F)
PQC product quality complaint
PT preferred term
RNA ribonucleic acid
SAC Scientific Adv isory Committee
SAE serious adverse event
SARS -CoV -[ADDRESS_368749](s)
SoA Schedule of Activities
SOC system organ class
sSAP supplemental Statistical Analysis Plan
S[LOCATION_003]R suspected unexpected serious adverse reaction
US [LOCATION_002]
VRC Vaccination Report Card
WOCBP woman (or women) of childbearing potential
08LGKL
PRODUCT:   V116  115
PROTOCOL/AMENDMENT NO.:   007 -01  
V116 -007-01FINAL PROTOCOL 06-JUL-2022
11 REFERENCES
[Anttila, M., et al 
1999]Anttila M, Voutilainen M, Jäntti V, Eskola J, 
Käyhty H. Contribution of serotype -specific IgG 
concentration, IgG subclasses and relative 
antibody avidity to opsonophagocytic activity 
against Streptococcus pneumoniae. Clin Exp 
Immunol 1999;118(3):402- 7.[03QY70]
[Bonnave, C., et al 
2019]Bonnave C, Mertens D, Peetermans W, Cobbaert 
K, Ghesquiere B, Deschodt M, et al. Adult 
vaccination for pneumococcal disease: a 
comparison of the national guidelines in Europe. 
Eur J Clin Microbiol Infect Dis. 2019;38:785 -91.[05CZ9M]
[Burton, Robert L. and 
Nahm, Moon H. 2006]Burton RL, Nahm MH. Development and 
validation of a fourfold multiplexed opsonization 
assay (MOPA4) for pneumococcal antibodies. 
Clin Vaccine Immunol 2006;13(9):1004- 9.[03QT2R]
[Castiglia P. 2014] Castiglia P. Recommendations for pneumococcal 
immunization outside routine childhood 
immunization programs in Western Europe. Adv 
Ther. 2014Oct;31(10):1011- 44.[04P7LW]
[Centers for Disease 
Control and 
Prevention 2010]Centers for Disease Control and Prevention. 
Prevention of Pneumococcal Disease Amo ng 
Infants and Children - Use of 13- Valent 
Pneumococcal Conjugate Vaccine and 23- Valent 
Pneumococcal Polysaccharide Vaccine; 
Recommendations of the Advisory Committee on 
Immunization Practices (ACIP). MMWR 
2010;59(RR -11):1- 19.[03RSB6]
[Centers for Diseas e 
Control and 
Prevention 2015]Centers for Disease Control and Prevention. 
Epi[INVESTIGATOR_301780] -
preventable diseases. 13th ed. Hamborsky J, 
Kroger A, Wolfe S, editors. Washington (DC): 
Department of Health and Human Services 
(HHS); c2015. Chapter 6, Vaccine 
administration; p. 79 -106.[0508PV]
08LGKL
PRODUCT:   V116  116
PROTOCOL/AMENDMENT NO.:   007 -01  
V116 -007-01FINAL PROTOCOL 06-JUL-2022
[Centers for Disease 
Control and 
Prevention 2019]Centers for Disease Control and Prevention. 
Advisory Committee on Immunization Practices 
(ACIP), summary report, October 24 -25, 2018. 
Washington (DC): Department of Health and 
Human Services (HHS); 2019. 190 p.[057YZL]
[Centre for Disease 
Control and 
Prevention 2016]Centre for Disease Control and Prevention. 
Active Bacterial Core surveillance (ABCs) report 
emerging infections program network 
Streptococcus pneumoniae, 2016. Atlanta (GA): 
Department of Health and Human Services 
(HHS); 2016. 1 p.[052RDB]
[Centre for Disease 
Control and 
Prevention 2018]Centers for Disease Control and Prevention. 
Active Bacterial Core surveillance (ABCs) report: 
emerging infections program network: 
Streptococcus pneumoniae, 2018. Washington 
(DC): Department of Health and Human Services 
(HHS); 2018.[05J8JP]
[CLOPPER, C. J. and 
PEARSON, E. S. 
1934]Clopper CJ, Pearson ES. The use of confidence of 
fiducial limits illustrated in the case of the 
binomial. Biometrika 1934;26(4):404- 13.[03RRVC]
[Demczuk, W. H. B., 
et al 2013]Demczuk WHB, Martin I, Griffith A, Lefebvre B, 
McGeer A, Lovgren M, et al. Serotype 
distribution of invasive Streptococcus 
pneumoniae i n Canada after the introduction of 
the 13 -valent pneumococcal conjugate vaccine, 
2010- 2012. Can J Microbiol 2013;59:778- 88.[03XKZ6]
[European Center for 
Disease Prevention 
and Control 2018]European Center for Disease Prevention and 
Control. Surveillance report: annual 
epi[INVESTIGATOR_93282] 2016: invasive 
pneumococcal disease. Stockholm (Sweden): 
European Center for Disease Prevention and 
Control (ECDC) 2018 Aug. 12 p.[052RH8]
[Food and Drug 
Administration 2007]Food and Drug Administra tion. Guidance for 
industry: toxicity grading scale for healthy adult 
and adolescent volunteers enrolled in preventive 
vaccine clinical trials. Rockville, MD. Sep 2007.[05B4S4]
08LGKL
PRODUCT:   V116  117
PROTOCOL/AMENDMENT NO.:   007 -01  
V116 -007-01FINAL PROTOCOL 06-JUL-2022
[Garcia Garrido, H. 
M., et al 2020]Garcia Garrido HM, Mak AMR, Wit FWNM, 
Won g GWM, Knol MJ, Vollaard A, et al. 
Incidence and risk factors for invasive 
pneumococcal disease and community -acquired 
pneumonia in human immunodeficiency virus -
infected individuals in a high -income setting. Clin 
Infect Dis. 2020 July 1;71(1):41 -50.[06CWP T]
[Golden, A. R., et al 
2016]Golden AR, Adam HJ, Zhanel GG. Invasive 
Streptococcus pneumoniae in Canada, 2011 -
2014: Characterization of new candidate 15 -
valent pneumococcal conjugate vaccine serotypes 
22F and 33F. Vaccine. 2016 May 
17;34(23):2527- 30.[04KWF0]
[Hicks, L. A., et al 
2007]Hicks LA, Harrison LH, Flannery B, Hadler JL, 
Schaffner W, Craig AS, et al. Incidence of 
Pneumococcal Disease Due to Non -
Pneumococcal Conjugate Vaccine (PCV7) 
Serotypes in the [LOCATION_002] during the Era of 
Widespread PC V7 Vaccination, [ADDRESS_368750] Dis 2007;196:1346- 54.[03QT0G]
[Kobayashi, M. 2021] Kobayashi M. Considerations for age -based and 
risk-based use of PCV15 and PCV20 among U.S. 
adults and proposed policy options. Slides 
presented at: Advisory Committee on 
Immunization Practices (ACIP) meeting; [ADDRESS_368751] 20- 21; Atlanta, GA.[07XY2V]
[Kobayashi, M., et al 
2022]Kobayashi M, Farrar JL, Gierke R, Britton A, 
Childs L, Leidner AJ, et al. Use of 15- valent 
pneumococcal conjugate vaccine and 20- valent 
pneumococcal conjugate vaccine among U.S. 
adults: updated recommendations of the Advisory 
Committee on Immunization Practices - United 
States, 2022. MMWR Morb Mortal Wkly Rep. 
2022 Jan 28;71(4):109 -17.[07YPRJ]
[Liang, K- Y and 
Zeger, S. L. 2000]Liang K -Y,Zeger SL. Longitudinal data analysis 
of continuous and discrete responses for pre -post 
designs. Sankyha: The Indian Journal of Statistics 
2000;62(Series B, Part 1):134- 48.[00V5V6]
08LGKL
PRODUCT:   V116  118
PROTOCOL/AMENDMENT NO.:   007 -01  
V116 -007-01FINAL PROTOCOL 06-JUL-2022
[Marcy, S. M., et al 
2004]Marcy SM, Kohl KS, Dagan R, Nalin D, Blum 
M, C onnell Jones M, et al. Fever as an adverse 
event following immunization:  case definition 
and guidelines of data collection, analysis, and 
presentation. Vaccine 2004;22:551 -6.[03PVW0]
[Matanock, A. 2018] Matanock A. Estimating pneumococcal 
pneumonia burden among U.S. adults and 
progress on the research agenda for potential 
policy change. Slides presented at: Advisory 
Committee on Immunization Practices (ACIP) 
Meeting; 2018 Feb 21 -22; Atlanta, GA.[05B5W5]
[Matanock, A., et al 
2019]Matanock A, Lee G, Gierke R, Kobayashi M, 
Leidner A, Pi[INVESTIGATOR_63466] T. Use of 13 -valent 
pneumococcal conjugate vaccine and 23- valent 
pneumococcal polysaccharide vaccine among 
adults aged greater than or equal to 65 years: 
updated recommendations of the Advisory 
Commit tee on Immunization Practices. MMWR 
Morb Mortal Wkly Rep. 2019 Nov 
22;68(46):1069- 75.[05D5ST]
[Miller, Elizabeth, et 
al 2011]Miller E, Andrews NJ, Waight PA, Slack MP, 
George RC. Herd immunity and serotype 
replacement 4 years after seven- valent 
pneumoco ccal conjugate vaccination in England 
and Wales: an observational cohort study. Lancet 
Infect Dis 2011;11(10):760 -8.[03RKY7]
[Mohapi, L., et al 
2021]Mohapi L, Pi[INVESTIGATOR_210533] Y, Osiyemi O, Supparatpi[INVESTIGATOR_301781] 
K, Ratanasuwan W, Molina JM, et al. Safety and 
immunogenici ty of V114, a 15 -valent 
pneumococcal conjugate vaccine, in adults living 
with HIV: a randomized phase 3 study. AIDS. In 
press 2021.[07Y6B9]
[Moore, M. R., et al 
2015]Moore MR, Link- Gelles R, Schaffner W, 
Lynfield R, Lexau C, Bennett NM, et al. Effect of
use of 13- valent pneumococcal conjugate vaccine 
in children on invasive pneumococcal disease in 
children and adults in the [LOCATION_003]: analysis of 
multisite, population -based surveillance. Lancet 
Infect Dis. 2015 Feb 3. [Epub ahead of print].[043MRP]
08LGKL
PRODUCT:   V116  119
PROTOCOL/AMENDMENT NO.:   007 -01  
V116 -007-01FINAL PROTOCOL 06-JUL-2022
[Nuorti, J. P. and 
Whitney, C. G. 2010]Nuorti JP, Whitney CG. Prevention of 
pneumococcal disease among infants and children  
use of 13- valent pneumococcal conjugate vaccine 
and 23- valent pneumococcal polysaccharide 
vaccine -recommedations of the advisory
committee on immunization practices (ACIP). 
MMWR 2010;59(R11):1- 19.[03RSLZ]
[Pi[INVESTIGATOR_63466], T. 2015] Pi[INVESTIGATOR_63466] T, Bennett NM. Pneumococcal disease 
prevention among adults: strategies for the use of 
pneumococcal vaccines. Am J Prev Med. 2015 
Dec;49([ADDRESS_368752] 4):S383- 90.[04WP9S]
[Pi[INVESTIGATOR_63466], Tamara, et 
al 2010]Pi[INVESTIGATOR_63466] T, Lexau C, Farley MM, Hadler J, 
Harrison LH, Bennett NM, et al. Sustained 
reductions in invasive pneumococcal disease in 
the era of conjugate vaccine. J Infect Dis 
2010;201(1):32- 41.[03R5S4]
[Robert Koch Institut 
2017]Robert Koch Institut. Statement of the German 
Standing Committee on Vaccination at the RKI: 
recommendations of the Standing Committee on 
Vaccination (STIKO) at the Robert Koch Institute 
-2017/2018. Epid Bull. 2017 Aug 24;( 34):333-
76.[05MFT7]
[Romero -Steiner, S., 
et al 1997]Romero- Steiner S, Libutti D, Pais LB, Dykes J, 
Anderson P, Whitin JC, et al. Standardization of 
an opsonophagocytic assay for the measurement 
of functional antibody activity against 
streptococcus pneum oniae using differentiated 
HL-60 cells. Clin Diagn Lab Immunol 
1997;4(4):415- 22.[03NWQ5]
[Simonsen, L., et al 
2014]Simonsen L, Taylor RJ, Schuck- Paim C, Lustig 
R, Haber M, Klugman KP. Effect of 13 -valent 
pneumococcal conjugate vaccine on admissions 
to hospi[INVESTIGATOR_307] 2 years after its introduction in the 
[LOCATION_003]: a time series analysis. Lancet Respir Med. 
2014 May;2(5):387 -94.[04KVRV]
08LGKL
PRODUCT:   V116  120
PROTOCOL/AMENDMENT NO.:   007 -01  
V116 -007-01FINAL PROTOCOL 06-JUL-2022
[Troeger, C., et al 
2018]Troeger C, Blacker BF, Khalil IA, Rao PC, Cao 
S, Zimsen SRM, et al. Estimates of the glob al, 
regional, and national morbidity, mortality, and 
aetiologies of lower respi[INVESTIGATOR_93283] 195 
countries, 1990 -2016: a systematic analysis for 
the Global Burden of Disease Study 2016. Lancet 
Infect Dis. 2018 Nov;18:1191 -210.[07XTBZ]
[U.S. Food a nd Drug 
Administration 2009]U.S. Food and Drug Administration (CDER, 
CBER, CDRH). Guidance for industry patient -
reported outcome measures: use in medical 
product development to support labeling claims 
[Internet]. Washington: U.S. Department of 
Health and Human Services; 2009. Available 
from: 
https://www.fda.gov/downloads/drugs/guidances/
ucm193282.pdf[04MG9J]
[van der Linden, M., 
et al 2015]van der Linden M, Falkenhorst G, Perniciaro S, 
Imohl M. Effects of infant pneumococcal 
conjugate vaccination on ser otype distribution in 
invasive pneumococcal disease among children 
and adults in [LOCATION_013]. PLoS One. 2015 Jul 
1;10(7):e0131494.[04KVRY]
[Waight, P. A., et al 
2015]Waight PA, Andrews NJ, Ladhani SN, Sheppard 
CL, Slack MP, Miller E. Effect of the 13- valent
pneumococcal conjugate vaccine on invasive 
pneumococcal disease in England and Wales 4 
years after its introduction: an observational 
cohort study. Lancet Infect Dis. 2015 
May;15(5):535 -43.[04KTF2]
08LGKL